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Preface
The preface is written somewhat informally, in a non-technical language. It is 
here to help the reader place this thesis in context. It is about me and how I got 
here. I didn’t always follow a straight line, but I am pleased with the place where 
this journey led me.
The path to a PhD
Curiosity about the world and the way it works has always been present. I have a 
hard time accepting something without understanding it, questioning its assump-
tions and seeing its effects.
During my last year in medical school I had the opportunity to do a small re-
search project during the family medicine rotation. The question was simple: do 
patients take their prescribed medicines? It arose when my tutor was renewing 
prescriptions for patients who had left a request at the clinic, but had not come to 
a face-to-face visit. Why did some have such long gaps in between prescription 
renewals? It was the first time I did something that felt like real research, not just 
an exercise to turn in and get approval in a class.
After that, questions kept coming up and the need to answer them grew. I was a 
family medicine resident by then. I had the support of my tutor and worked with 
other residents doing small research projects. However, at some point, I began to 
feel like an amateur. I had the will, but lacked knowledge about research methods 
and statistics, a larger team to criticize my ideas and funding to make projects 
happen.
One day my tutor asked me if I had ever considered doing a PhD. I wasn’t expect-
ing such a question. No, PhDs were for experienced and really good clinicians. I 
was just a resident! But he had planted a seed. A PhD wasn’t an award for being a 
good clinician, it was a way to learn to be a better researcher. By then I had tasted 
research, amateurish as it may have been, and I liked it. Maybe it could become a 
greater part of what I did, even a part of my job. And I needed to learn more about 
how to become a better researcher, just like I was learning to become a better 
clinician with the residency program.
After a few months, the idea settled in: I was going to apply for a PhD, but only 
after I had finished my residency training in 2010.
Choosing a subject
Before enrolling in the PhD program, I needed a subject. I had an interest in the 
International Classification of Primary Care, but not a very good idea on how to 
build a thesis on the subject. Another area of affinity was evidence based medi-
cine, namely rational use of medicines and tests. I was in contact with the head 
of the family medicine department at NOVA Medical School, Professor Isabel 
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Santos, and had discussed some ideas with her. An opportunity came when a new 
researcher joined the faculty at the pharmacology department - Professor Pedro 
Caetano. He had experience in epidemiological research abroad and was keen on 
improving care in Portugal. He had been in contact with a group from Harvard 
Medical School led by Jerry Avorn doing academic detailing (or educational out-
reach visits) in the United States. We talked and an idea started to develop into a 
project: to bring educational outreach visits to Portugal. We would try to demon-
strate its feasibility and effectiveness, hoping to convince the Ministry of Health 
to implement this technique nationwide if we were successful. It was in one of my 
areas of interest, innovative and it could matter in improving the quality of health-
care being delivered. I had a subject and was ready to enroll in the PhD program.
Laying the foundation
To do educational outreach visits you need a subject and a message to com-
municate. Luckily, around that time, the Portuguese National Health Directorate 
was looking for academics to develop guidelines for primary care and other phy-
sicians. It was an opportunity we could not waste. This was not something that 
could be done by a single person, so we gathered a team and the family medicine 
and pharmacology departments of NOVA Medical School were commissioned to 
produce four guidelines on subjects chosen by the National Health Directorate: 
non-steroidal anti-inflammatory drugs (with a focus on COX-2 inhibitors), acid 
secretion modifiers (with a focus on proton pump inhibitors), antiplatelets (with 
a focus on clopidogrel) and antibiotics in pneumonia.
We began to work by the end of 2010. For the first three subjects, the American 
group had already done literature reviews and produced brochures and other ma-
terials for educational outreach. Instead of starting from scratch, we entered an 
agreement with them to adapt their materials. Adapting involved updating the 
literature review, understanding what made sense in the Portuguese health sys-
tem, translating, and validating our work with focus groups composed of primary 
care clinicians. For pneumonia, we started in the previous step, conducting the 
literature review. We also had to consider differences in drug resistance patterns 
from were research had been conducted to what was documented in Portugal.
While we were working, the country was in turmoil. A financial crisis had struck, 
the Prime-Minister had resigned in March 2011 and in May the country signed 
a memorandum of understanding with European Financial Stabilization Mech-
anism, the European Financial Stability Facility, and the International Monetary 
Fund to a €78 billion financial assistance package. The memorandum of under-
standing had one very relevant item that would affect our work: “3.59. Establish 
clear rules for the prescription of drugs and the realization of complementary 
diagnostic exams (prescription guidelines for physicians) on the basis of interna-
tional prescription guidelines.” This brought about changes in the way the National 
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Health Directorate was producing guidelines. There would be many more groups 
making guidelines on other subjects and all had to follow a similar template. We 
had to change structure and formatting, guidelines would first be published as 
drafts for public comment, a reply to those comments had to be prepared and 
latter be sent for approval by an expert Committee. We became convinced that 
these changes would make guidelines less user friendly and would decrease their 
effectiveness. Instructions from the National Health Directorate changed often, 
prompting us to review much of the work that had been submitted before. Trying 
to reach a final version of each guideline would take over three years.
Getting funded
Producing guidelines was only about laying a foundation to do research and not 
the research project itself. The best way to prove the efficacy of an intervention is 
through a randomized controlled trial. But to conduct a randomized controlled 
trial you need money. Getting funded was one of the hardest parts of the job. In 
2011 the Ministry of Health had a call for research projects in primary care. The 
available funding was relatively small and the call had been designed with less 
lengthy projects in mind. Yet, it was an opportunity and it gave us the change to 
prepare a protocol for the trial. We submitted and waited for a decision.
In 2012 we applied for a research grant from the Foundation for Science and 
Technology (the Portuguese national funding agency for science, research and 
technology). It would be a larger grant and allow for more time to finish the 
project. We made major improvements to the research protocol during this stage. 
We had collected pilot data, could accurately calculate a sample size, decided on 
the outcomes and on several other details, registered the trial and applied for a 
study seal from the European Network of Centers for Pharmacoepidemiology and 
Pharmacovigilance. We had done so much work, the group decided to submit the 
protocol for publication. The grant decision came a few months later. Although 
our project was rated as excellent on all criteria, it was not chosen for funding due 
to budget limitations.
This was a major blow, as it would be impossible to complete the project without 
funding. A glimmer of hope arrived in December 2012, when we were informed 
that the Ministry of Health had decided to fund our project. We wouldn’t get all 
the money we had applied to and we had little time to finish, but believed we 
could make it work with some adjustments and a lot of cost saving.
Sidetracked
Since enrolling in the PhD program, I had reduced my working ours as a cli-
nician, but never stopped seeing patients. I didn’t want to study something very 
distant from clinical practice, and what I saw with patients motivated me to pose 
research questions. In 2011 I received a letter from a drug company and the Por-
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tuguese Medicines Authority. It was about the non-steroidal anti-inflammatory 
drug nimesulide; the European Medicines Agency had recommended several re-
strictions on its use due to safety concerns. I didn’t prescribe the drug very often, 
so it was easy to stop. However, in the following weeks I noticed some of my 
patients still came to a visit telling me that had seen another doctor, usually in the 
hospital, and had been prescribed nimesulide. I wondered how effective were the 
recommendations from a regulatory authority on physicians actual practice and 
if primary care and hospital physicians reacted differently. I would need to gather 
data on nimesulide use over time, see if any change had happened and make sure 
it wasn’t due to chance or other factors. This was something I could add to my 
thesis, as I would be observing the effects of an intervention on physician pre-
scribing behavior. It wasn’t an intervention I could control, like in the randomized 
controlled trial, but an intervention nonetheless.
As a family physician, patients often asked me to renew prescriptions that had 
been initiated by other physicians, at a hospital visit or in private practices. For 
some drugs, I was glad to do it, but not for others. Sometimes I would not agree 
with the prescription because I believed it was not the right treatment for that 
patient, but more often because I believed the drug had not demonstrated a good 
benefit-risk or benefit-cost profile. One of those drugs was trimetazidine and, 
when in 2012, recommendations for restricted used were made by the European 
Medicines Agency, I seized the opportunity to stop prescribing it. As with nime-
sulide, some of my patients kept asking me for it because another doctor had told 
them to keep taking it. I decided to study the effects of the recommendations for 
restricted trimetazidine use and include it in my thesis.
However, it isn’t easy to change a drug being prescribed by another physician 
when you don’t have a strong authoritative statement to back you up. More often 
than not, it comes down to the way different physicians interpret current medi-
cal knowledge and their personal values. I would sometimes prefer that a patient 
was being treated differently, but other physicians also treating them may hold a 
different opinion. This is normal and a problem only arises when the patient asks 
me to prescribe a drug that was decided by someone else and with which I do not 
agree. Many family physicians complain about this problem and feel it difficult to 
change the patient’s treatment. They feel a part of their prescription is not their 
own direct responsibility. The prescribing behavior of family doctors was being 
changed by other physicians that shared their patients.
I considered this was a real problem, but I could not say how large it was. I then 
began to think of a way to measure it. Looking at newly diagnosed patients would 
be a more reliable way, as it would be difficult to gather from a database who first 
prescribed a drug, even with reliable individual patient data. The Sentinel Practice 
Network would be a good way to prospectively collect data. To measure prescrip-
tions made by other physicians I would have to choose a chronic problem, so that 
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patients would come to their family doctor and share what had been prescribed 
by other physicians. Diabetes and hypertension were the obvious choices, as they 
were two of the major drivers of drug expenditures in Portugal.
Setbacks
A major hurdle that had to be tackled throughout the PhD’s research projects was 
how to access prescribing data. The Portuguese National Health Service, being a 
single payer system with centralized records, was ideal for studying prescriptions 
of reimbursed drugs. However, not much research had been allowed with the 
Ministry of Health’s databases. Getting through authorizations and bureaucra-
cy was very time consuming. There were also validation issues, as the database 
structure is complex and sparsely documented, there are no dedicated researchers 
in the Ministry of Health and some of what we did had never been tried before. 
Often there were problems with the first data extraction attempts. Fortunately, 
these could be corrected, as the database did hold the necessary records.
The PhD led me and other members of the research team to learn new skills. This 
was both challenging and gratifying, as we were all eager to learn. None of us had 
ever done randomization by minimization, managed a randomized control trial 
or used time-series methods. We tried to cooperate with other research units in 
NOVA University, with people that had the needed research knowledge. However, 
for one reason or another, most of them did no go through. This caused delays, 
but did not prevent us from achieving our goals and the team is now empowered 
to do more in the future.
Putting it all together
As described above, the thesis was constructed around three research projects: a 
randomized controlled trial to test the effectiveness of educational outreach visits; 
two interrupted time-series observational studies to evaluate the effectiveness of 
regulatory measures on drug use; and two observational studies on how patients 
with diabetes and hypertension are first treated, highlighting differences between 
primary care clinicians and other physicians. Each study has been planned, con-
ducted and reported both to stand individually and to be part of a larger view on 
the thesis’ subject: understanding what influences prescription behavior with an 
emphasis in primary care.
Naturally, the thesis could not encompass all questions that still remain to be an-
swered in this field. Instead, it gives context to the subject of influencing prescrip-
tion behavior, addresses some of the unanswered questions and draws conclusions 
about what was found. To achieve this goal, the thesis is divided in six parts. Part 
one will discuss what is known about factors that influence prescription behavior 
and gaps in current knowledge. It also provides some context on the work done in 
the thesis, covering scientific aspects not intended for this preface. Part two out-
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lines the aims and objectives for the thesis. Parts three to five present each of the 
studies done. They are grouped and ordered according the questions they try to 
answer. Part three begins with the two studies conducted in the Sentinel Practice 
Network, documenting how physicians behave when they have an opportunity to 
decide on a treatment and how physicians may influence each other when they 
share patients. Part four describes the influence of drug regulatory agencies when 
they interact with physicians, but also how other factors occurring at the same 
time may play a role. Part five describes how an educational outreach program 
could be implemented, the views or participants (both those receiving and those 
doing the visits) and their effectiveness in changing prescribing behaviors. Finally, 
part six draws global conclusions from the studies that were presented and high-
lights their implication for practice and future research.
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Medical science can provide evidence on what high quality care should look 
like. However, there is a gap between research findings and routine clinical prac-
tice. Physicians do not always act like what the best scientific evidence would 
recommend, but aiming for high-quality, high-value care is important as it ben-
efits patients. Clinical practice guidelines aim to assist clinicians in this task by 
providing critically appraised summaries of the best current medical knowledge 
and recommending how to proceed. However, often, clinicians will fail to fol-
low guideline recommendations. Medical prescribing is not only determined by 
knowledge, competence, benefit-risk and cost-effectiveness. Other factors such as 
personal values, beliefs, attitudes and experiences, health services organization, 
the availability of information, patient characteristics and requests, peer interac-
tions, marketing techniques, reciprocity, authority, social validation and personal 
relationships are also decisive. To some extent, primary care physicians may be in-
fluenced by specialists to prescribe drugs they would have otherwise not choose.
Many interventions have been studied with the purpose of improving clinical 
practice. Most interventions show small to moderate effects on prescription im-
provement. However, there is considerable heterogeneity in results, which proba-
bly reflects lack of standardization and the interference of setting specific factors. 
Two specific interventions are educational outreach visits, aimed at changing 
healthcare professionals’ behavior by delivering educational content in face-to-
face visits; and regulation authorities’ risk minimization measures, meant to im-
prove the benefit-risk balance of drugs after they have been approved.
The general aim of this thesis is to contribute to the understanding of how pri-
mary care physicians decide to prescribe drug treatments and how they can be 
influenced. Specific objectives are to describe how physicians initiate treatment 
in hypertension and type 2 diabetes and if there are differences between family 
physicians and other specialists; to assess the effect of regulatory actions taken by 
the European Medicines Agency to restrict the utilization of trimetazidine and 
nimesulide; and to determine the efficacy and cost-effectiveness of educational 
outreach visits to improve compliance with guideline recommendations.
Methods
The thesis contains seven research manuscripts, divided in three parts. The first 
two studies were cohort-nested cross-sectional studies done within the Portu-
guese Sentinel Practice Network. Family physicians notified incident cases of ar-
terial hypertension and type 2 diabetes, reporting treatment, who made the initial 
prescription and if they had changed treatments initiated by other physicians.
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The second group contains two interrupted time-series analysis of ambulatory 
pharmacy reimbursement records for the Portuguese National Health Service. Ef-
fects of the European Medicines Agency risk minimization measures on prescrip-
tion of trimetazidine and nimesulide were measured. Regulatory actions were 
identified by searching the European Medicines Agency, Portuguese Medicines 
Authority and European Commission’s websites. Confounding factors in the same 
period were also identified. Segmented regression models were built assessing the 
effects on dispensing of trimetazidine and nimesulide, both globally and for phy-
sicians in National Health Service primary care, National Health Service hospitals 
and other settings. For nimesulide, adverse drug reactions were also measured.
The third group contains a parallel, open, superiority, randomized trial directed 
to primary care physicians. Physicians were recruited in clusters of primary care 
practices and randomly allocated to receive educational outreach visits at their 
workplace or usual guideline dissemination. Primary outcomes were the propor-
tion of cyclooxygenase-2 (COX-2) inhibitors prescribed in the anti-inflammatory 
(NSAID) class, and the proportion of omeprazole in the proton pump inhibitors 
class at 18 months post-intervention. Secondary outcomes were the proportion of 
COX-2 inhibitors within the NSAID class at one and six months; the proportion 
of omeprazole within the proton pump inhibitors class at one and six months; and 
the number of defined daily doses of clopidogrel prescribed per 1,000 registered 
patients at 1, 6 and 18 months. Prescription data was collected from the regional 
pharmacy claims database. Costs were also measured to perform a cost-benefit 
analysis. The trial was also subjected to a process evaluation by gathering data on 
recruitment of physicians and detailers, recording a post-visit questionnaire, con-
ducting a focus group with detailers, interviewing participating physicians and 
send a questionnaire to physicians in the intervention arm.
Results
The studies on initial treatment for hypertension and diabetes showed that fam-
ily physicians made the majority of diagnosis and there was very high compliance 
with guideline recommendations in both conditions. Angiotensin converting en-
zyme inhibitors were the most used drugs to initiate anti-hypertensive treatment 
and metformin was most used for type 2 diabetes. Some differences were observed 
between family physicians and other doctors, with the former prescribing less 
beta-blockers and loop diuretics in hypertension and less dipeptidyl peptidase-4 
inhibitors and insulin in type 2 diabetes. In both cases, prescriptions initiated by 
other specialists were rarely altered by family physicians.
The studies on trimetazidine and nimesulide showed significant decreases in use 
of these drugs associated with complex interventions consisting of regulatory risk 
minimization measures and other concurrent factors. However, not all actions by 
regulatory authorities led to changes in drug use and concurrent factors such as 
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media coverage may have played an important role. Family physicians were more 
compliant with recommendations to restrict nimesulide use than hospital or 
private based physicians, while for trimetazidine they were less compliant (after 
adjusting for differences in global market share). There were no changes in clinical 
adverse events for nimesulide.
The randomized controlled trial of educational outreach visits was successfully 
implemented, visits occurred as planned, and were acceptable to participating 
physicians. Yet, the intervention was not effective in improving primary or sec-
ondary outcomes or reducing costs.
Conclusions
The two studies in the Portuguese Sentinel Practice Network showed that phy-
sicians mostly follow recommended guidelines, but there are some differences 
between family physicians and other specialists in the drugs chosen for first-line 
treatment. Family physicians usually kept prescriptions initiated by others, indi-
cating that prescription induction is likely to occur.
Regulatory risk minimization measures were effective in reducing drug use, but 
there was no decrease in reported adverse drug reactions to nimesulide.
The educational outreach visits trial was implemented with reasonable reach, 
high dose and very high fidelity and acceptability. Yet the intervention was unsuc-
cessful in improving compliance with guideline recommendations or reducing 
costs.
Trying to change a physician’s prescribing behavior is complex and dependent 





A literatura médica pode fornecer provas acerca do que devem ser os cuidados 
de saúde de elevada qualidade. Porém, há um hiato entre os resultados da investi-
gação e a sua aplicação regular na prática clínica. Os médicos nem sempre actuam 
de acordo com o que estaria de acordo com as melhores provas científicas, mas 
procurar cuidados de alta qualidade e elevado valor é importante, pois é benéfico 
para os doentes. As orientações clínicas procuram ajudar os clínicos nesta tarefa, 
fornecendo resumos com apreciação crítica do melhor conhecimento médico ac-
tual e recomendações sobre como os clínicos devem proceder. Porém, os médicos 
frequentemente falham no cumprimento das recomendações destas orientações. 
A prescrição médica não é só determinada por conhecimento, competência, rela-
ções benefício-risco e custo-efectividade. Outros factores como valores pessoais, 
crenças, atitudes e experiências, organização dos serviços de saúde, a disponi-
bilidade de informação, características e pedidos dos doentes, interacções entre 
pares, técnicas de vendas, reciprocidade, autoridade, validação social e relações 
pessoais são também decisivos. Em certa medida, os médicos de cuidados primá-
rios podem ser influenciados por especialistas a prescrever medicamentos que de 
outro modo não escolheriam.
Muitas intervenções têm sido estudadas com o propósito de melhorar a prática 
clínica. A maioria das intervenções mostra efeitos pequenos a moderados na me-
lhoria da prescrição. Contudo, há heterogeneidade significativa nos resultados, 
o que provavelmente reflecte falta de padronização e a interferência de factores 
específicos do contexto. Duas intervenções específicas são as visitas de divulgação 
educacional, com o objectivo de mudar o comportamento dos profissionais de 
saúde através da apresentação de conteúdos educacionais em visitas cara-a-cara; e 
medidas de minimização de risco por parte das autoridades reguladoras, que pro-
curam melhorar o equilíbrio benefício-risco dos medicamentos depois de terem 
sido aprovados.
O objectivo geral desta tese é contribuir para a compreensão de como os médi-
cos de cuidados primários decidem prescrever tratamentos com medicamentos 
e como podem ser influenciados. Os objectivos específicos são descrever como 
os médicos iniciam o tratamento da hipertensão arterial e da diabetes tipo 2 e 
se há diferenças entre médicos de família e outros especialistas; avaliar o efeito 
de acções regulatórias pela Agência Europeia de Medicamentos para restringir 
a utilização de trimetazidina e nimesulida; e determinar a eficácia e custo-efec-
tividade de visitas de divulgação educacional para melhorar o cumprimento de 
recomendações em orientações clínicas.
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Métodos
Esta tese contém sete manuscritos, divididos em três partes. Os primeiros dois 
estudos foram estudos transversais aninhados em coorte, realizados dentro da 
Rede Portuguesa de Médicos Sentinela. Os médicos de família notificaram casos 
incidentes de hipertensão arterial e diabetes tipo 2, descrevendo o tratamento, 
quem tinha feito a prescrição inicial e se tinham alterado o tratamento iniciado 
por outros médicos.
O segundo grupo contém duas análises interrompidas de séries temporais de re-
gistos de comparticipação de medicamentos em ambulatório do Serviço Nacional 
de Saúde Português. Foram medidos os efeitos das medidas de minimização de 
risco da Agência Europeia de Medicamentos sobre a prescrição de trimetazidina 
e nimesulida. As acções regulatórias foram identificadas pesquisando as páginas 
da internet da Agência Europeia de Medicamentos, da Autoridade Portuguesa 
do Medicamento e da Comissão Europeia. Foram também identificados factores 
de confundimento no mesmo período. Foram construídos modelos de regressão 
segmentada para avaliar os efeitos na dispensa de trimetazidina e nimesulida, tan-
to a nível global como para médicos nos cuidados primários do Serviço Nacional 
de Saúde, nos hospitais do Serviço Nacional de Saúde e em outros locais. Para a 
nimesulida, foram também medidas as reacções adversas ao medicamento.
O terceiro grupo contém um ensaio clínico aleatorizado paralelo, aberto, de 
superioridade, dirigido a médicos de cuidados primários. Os médicos foram re-
crutados em grupos (clusters) de unidades de cuidados primários e alocados alea-
toriamente para receber visitas de divulgação educacional no seu local de traba-
lho ou a disseminação habitual das orientações clínicas. Os resultados primários 
foram a proporção de inibidores da ciclo-oxigenase-2 (COX-2) prescrita dentro 
da classe dos anti-inflamatórios (AINE) e a proporção de omeprazol na classe 
dos inibidores da bomba de protões aos 18 meses após a intervenção. Os resulta-
dos secundários foram a proporção de inibidores da COX-2 dentro da classe dos 
AINEs a um e seis meses; a proporção de omeprazol na classe dos inibidores da 
bomba de protões a um e seis meses; e o número de doses diárias definidas de clo-
pidogrel prescritas por 1.000 utentes a 1, 6 e 18 meses. Os dados de prescrição fo-
ram recolhidos da base de dados regional de comparticipação. Os custos também 
foram medidos para realizar uma análise de custo-benefício. O ensaio também 
foi sujeito a uma avaliação de processo recolhendo dados sobre o recrutamento 
de médicos e visitantes, registo de um questionário pós-visita, condução de um 
grupo focal com visitantes, realização de entrevistas a médicos participantes e 
envio de um questionário para os médicos no grupo de intervenção.
Resultados
Os estudos sobre o tratamento inicial da hipertensão e diabetes mostraram que 
os médicos de família fizeram a maioria dos diagnósticos e que havia um elevado 
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cumprimento das recomendações das orientações clínicas em ambas as patologias. 
Os inibidores da enzima de conversão da angiotensina foram os medicamentos 
mais usados para iniciar tratamento anti-hipertensor e a metformina foi a mais 
utilizada na diabetes tipo 2. Algumas diferenças foram observadas entre médicos 
de família e outros médicos, com os primeiros a prescrever menos beta-bloquean-
tes e diuréticos de ansa na hipertensão e menos inibidores da dipeptidil peptida-
se-4 e insulina na diabetes tipo 2. Em ambos os casos, as prescrições iniciadas por 
outros especialistas raramente foram alteradas pelos médicos de família.
Os estudos sobre a trimetazidina e a nimesulida mostraram diminuições sig-
nificativas no uso destes medicamentos associadas a intervenções complexas 
consistindo de medidas regulatórias de minimização de risco e outros factores 
concorrentes. Contudo, nem todas as acções das autoridades reguladoras levaram 
a alterações no uso dos medicamentos e factores concorrentes como a cobertura 
pelos media podem ter desempenhado um papel importante. Os médicos de fa-
mília foram mais cumpridores das recomendações para restringir a utilização de 
nimesulida que os médicos dos hospitais ou em actividade privada, enquanto que 
para a trimetazidina foram menos cumpridores (depois de ajustamento para dife-
renças na quota de mercado global). Não existiram alterações nos efeitos clínicos 
adversos para a nimesulida.
O ensaio aleatorizado e controlado das visitas de divulgação educacional foi im-
plementado com sucesso, as visitas decorreram como planeado e foram aceitáveis 
para os médicos participantes. Contudo, a intervenção não foi efectiva para me-
lhorar os resultados primários ou secundários ou reduzir custos.
Conclusões
Os dois estudos na Rede de Médicos Sentinela mostraram que os médicos maio-
ritariamente seguem as recomendações, mas que existem algumas diferenças en-
tre médicos de família e outros especialistas nos medicamentos escolhidos como 
tratamento de primeira-linha. Os médicos de família geralmente mantiveram as 
prescrições iniciadas por outros, indicando que é provável que ocorra indução da 
prescrição.
As medidas regulatórias de minimização de risco foram eficazes na redução do 
uso de medicamentos, mas não houve redução nos efeitos adversos reportados 
para a nimesulida.
As visitas de divulgação educacional foram implementadas com razoável alcan-
ce, dose elevada e fidelidade e aceitabilidade muito elevadas. Porém, a interven-
ção não foi bem-sucedida para melhorar o cumprimento das recomendações de 
orientações clínicas ou para reduzir custos.
Tentar mudar o comportamento de prescrição de um médico é complexo e de-
pendente de muitos factores que podem influenciar significativamente o resulta-
do de uma intervenção.
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To understand the importance of modifying physicians prescribing behavior 
one must first comprehend why it is desirable. Medical science can provide evi-
dence on what high quality care should look like. However, there is a gap between 
research findings and routine clinical practice.1 Physicians do not always act like 
what the best scientific evidence would recommend. Loss of efficacy means de-
creasing health benefits for patients; unsafe practices can increase patient risk; 
and lack of efficiency results in the use of more resources than would be needed 
or, in a world with finite resources, choices need to be made. This introduction 
will detail why healthcare systems should aim for high-quality, high-value care, 
why physicians need tools such as guidelines to help them reach that goal, reasons 
for physicians not always following recommendations, what determines medical 
prescribing and how it can be influenced.
Aiming for high-quality, high-value healthcare
The health of a population is determined to a great extent by social factors like 
economic status, inequality, education and employment.2 Providing access to high 
quality health services is key to reducing the intergenerational perpetuation of 
inequities.3 This was done to a large extent in Portugal by creating a public funded 
National Health Service in 1979, which contributed to reductions in morbidity 
and mortality and increased life expectancy.4 Access to high quality care is still 
an important problem in many parts of the world and, even in highly developed 
countries in the 21st century, improving access to care has been shown to result in 
significant gains in mortality and reductions in inequality.5,6 Aside from being a 
goal in its own right, better health is also an important tool for a society’s econom-
ic development by increasing labor productivity, maximizing cognitive develop-
ment and education, increasing savings, and influencing population numbers and 
age structure.7
However, no human endeavor is perfect, and healthcare systems are no excep-
tion. Inequalities remain and result in different health outcomes.3,4 In part, the 
full potential of health systems is not realized because resources are limited and 
may not be used in the most efficient way. High-value care is effective, safe, and 
cost-conscious.8 Health systems with higher efficiency achieve better health out-
comes with less resources.9 Inefficiencies can be caused by issues related with the 
healthcare entity being assessed (from a single treatment to the whole healthcare 
system, but usually a practitioner or group of practitioners), its links with the 
rest of the health system (the interaction between several healthcare entities) and 
external influences (factors outside the control of the healthcare entity).10 This 
thesis will focus on physicians as healthcare entities, particularly, their actions as 
prescribers of drugs.
Population aging in developed countries, economic recession, and increasing 
costs of new treatments and diagnostic tests place pressure on health systems to 
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strive for higher efficiency.11-13 Portugal fulfils all three criteria. Projections esti-
mate a decline from 10.5 to 8.6 million inhabitants between 2012 and 2060 and 
the aging index rising from 131.1 to 306.5.14 There were large cuts in the health 
budget associated with austerity measures, following the financial assistance 
bailout package agreed with the European Financial Stabilization Mechanism, 
the European Financial Stability Facility, and the International Monetary Fund.12 
And drug expenses have been rising well above inflation, especially in areas with 
new drugs, such as HIV/AIDS, oncology and rheumatic diseases for in hospital 
dispensing and anticoagulants and diabetes in ambulatory care.15,16
Decreases in the government’s health budget led to a significant increase in pri-
vate health spending.12,17 A literature review on the impact of citizen co-payment 
of drug costs in high-income countries showed increases led to higher health in-
equalities and caused patients to forego both essential and non-essential drugs.18 
This review found that only two strategies were able to improve efficiency without 
generating inequality: enabling patients to opt for more cost-effective alternatives 
and introducing mechanisms to protect poorer people and heavy users of pre-
scription drugs.
When resources are scarce, it is not possible for everyone to have everything and 
choices need to be made. One important principle in medical ethics is justice, in 
this case, distributive justice: the extent to which benefits and burdens are distrib-
uted among society’s members in ways that are fair and just.19 Justice is funda-
mental to ensure social cohesion. This principle is reflected on the World Medical 
Association’s International Code of Medical Ethics, which states that a physician 
shall strive to use health care resources in the best way to benefit patients and their 
community.20 Both providing more cost-effective alternatives and introducing 
mechanisms to protect the disadvantaged are in line with the principle of justice. 
When it comes to drugs, the first can be achieved by policy actions, such as allow-
ing the patient to opt for generic drugs, and by having prescribers take optimal 
decisions; the second depends on policies, such as increased reimbursement for 
specific health problems.
Health technologies assessments can be used to determine if a drug is cost-ef-
fective and to compare its effectiveness with other alternatives.21 This can help 
guide choices in a world where resources are not infinite. Different approaches 
have been tried evaluate cost-effectiveness. Currently, one of the most widely dis-
seminated uses quality adjusted life years (QALYs), where the number of years of 
life gained is multiplied by the quality of life during that time (considering 1 to 
be perfect health).22,23 Cost-effectiveness analyses calculate the amount spent for 
each gained QALY, and this information is then used to guide decisions on alloca-
tion of resources.24 Its main advantage is that it allows for comparison of different 
treatments and diseases, by transforming their results into a common measure.25 
It also allows society to decide how much it is willing to spend for each QALY.26,27 
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However, QALYs are far from perfect. Major issues include it being very sensitive 
to the premises that are chosen (like the variation in replies used to calibrate the 
tool, and their possible lack of representativeness), ignoring individual values 
(since each person feels their illness differently), considering an average patient 
(ignoring degrees of severity), and is difficult to use in end-of-life situations.25,28
Health technologies assessment is currently used throughout the world by na-
tional authorities, including in Portugal.17,29 These assessments help shape policies, 
but are not meant to guide decisions by an individual clinician. For the clinician, 
translating research into actual clinical practice is a complex process and the path 
has many hurdles that need to be overcome. 
The role of guidelines
Medicine is ever evolving, and to keep current with medical literature, a primary 
care clinician would have to spend every waking minute reading new publications 
and that still would not be enough.30 There is a gap between research and clinical 
practice and one of the major barriers is how much time, effort and skill a clini-
cian needs to access the right information and understand how to use it.31 Ideally, 
individual studies would be pooled in systematic reviews, which would be avail-
able for clinicians to use and answer every clinical question. This is not the case, as 
many questions have not been adequately answered by medical literature,32,33 and 
time limits the ability of clinicians to search for answers.34
Clinical practice guidelines aim to assist clinicians in this task by providing 
critically appraised summaries of the best current medical knowledge and rec-
ommending how to proceed.35 They have the potential to save the physician from 
having to find, read and interpret new literature, all while improving quality of 
care and health outcomes like morbidity, mortality and quality of care.36-38 How-
ever, guidelines also have limitations and disadvantages. Scientific evidence may 
be lacking or misinterpreted, leading to recommendations that are suboptimal, 
wrong or, at least, wrong for certain groups of patients.36 The case of postmeno-
pausal hormone replacement therapy, once recommended as a standard of care 
based on low quality evidence, should be a reminder of this potential for harm.39 
Guidelines may not take individual patient characteristics into account and the 
quest for standardization has been criticized by some as having the potential to 
create “cookbook” medicine.40 Recommendations may be influenced by the be-
liefs of the persons writing them and conflicts of interest are frequent in guideline 
panels.41,42 They may be designed to serve other priorities than improving patient 
health, like reducing costs.36 Guidelines may have low methodological quality,43 or 
evidence may not be solid enough to have a common interpretation and lead to 
conflicting guidelines.44 The slow pace at which most guidelines are updated may 
lead clinicians to follow outdated recommendations.45
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Why physicians do not always follow guidelines
Although most clinicians have a positive attitude towards guidelines,46-48 hav-
ing them is not guaranteed to change medical practice. Often, clinicians will fail 
to follow guideline recommendations,49,50 even when they self-report doing so.51 
Several reasons have been identified for why this happens.31,52-54 Physicians may 
lack knowledge of the guideline, not being aware it exists given the increasing 
number of guidelines or lacking familiarity with its contents. Physicians may 
not agree with a guideline because they interpret evidence differently, believe 
the benefit-risk relation of an intervention is not favorable, that the guideline is 
not applicable to their population of patients, that it oversimplifies their patients 
ignoring complexity and multimorbidity, reduces their autonomy and flexibili-
ty to make individual decisions, would make the patient-physician impersonal, 
they distrust the guideline’s authors or feel they are biased. Physicians may feel 
that they lack ability or efficacy to implement guideline recommendations, that 
the recommendations themselves will not be effective or will not lead to the de-
sired outcomes. Overcoming the inertia to maintain previous practice may be 
an important issue when physicians lack motivation to implement a guideline. 
Even when a physician accepts a guideline and wishes to follow it, he or she may 
forget or neglect to act on it at the appropriate time. The guideline can be consid-
ered too complex, lacking adequate summaries, not easy to use, not convenient, 
cumbersome, vague, confusing or ambiguous. A guideline may be outdated or 
conflict with a different organization’s recommendations. Patients may be barriers 
to implementing guideline recommendations when their preferences collide with 
recommendations, they do not understand the need for change or fail to act on 
the physician’s prescribed action (even when they had agreed to it). Finally, there 
can be external factors such as lack of facilities, staff or time, lack of reminder 
systems, costs and increased liability.
Some of the barriers mentioned above may be overcome, provided the right 
causal diagnosis is made and there is an effective implementation strategy.52How-
ever, how best to make professionals adhere to guideline recommendations is not 
well established.55-57 
Determinants of medical prescribing
Medical prescribing is not only determined by knowledge, competence, bene-
fit-risk and cost-effectiveness. Factors such as personal values, beliefs, attitudes 
and experiences, health services organization, the availability of information, 
patient characteristics and requests, and peer interactions are also important to 
shape the prescriber’s decisions. 58,59 Marketing techniques, reciprocity, authority, 
social validation and personal relationships may also play a part in persuading 
physicians.31 
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A review of studies with primary care physicians found three major influences 
on prescribing:60 hospital specialists often act as prescription initiators, which is 
then maintained by primary care doctors; pharmaceutical representatives are as-
sociated with increases in use of new drugs; and prescribing advisors, who help 
disseminate guidelines. External factors such as the existence of clinical practice 
guidelines, incentives and quality monitoring programs were also recognized as 
influential. The cost of drugs was considered in prescribing decisions, but only 
after efficacy and safety.
A review on adoption of new drugs found that early adoption was not a person-
al trait of a physician, but varied with the prescriber, patient, practice and drug 
characteristics.61 Physician male gender was associated with early adoption of new 
drugs in seven of fifteen studies included reporting this variable, making this an 
inconsistent finding. The influence of age was unclear, with most studies reporting 
a positive association with younger physicians, but others showing no association 
or even association with older age.
In most studies included in the review, specialists in the therapeutic area of a 
new drug were more likely to be early adopters than general practitioners or spe-
cialists in other areas, but in others studies general practitioners were more often 
early adopters. Doctors working as clinical trial investigators were more likely to 
prescribe new drugs, but this decreased with the number of clinical trials the phy-
sician had participated. Physicians attending meetings, congresses, conferences 
and symposia also showed higher adoption of new drugs. Higher prescription 
volume within the therapeutic class of the new drug, higher total prescription 
volume and higher prescribing volume of drugs by the same pharmaceutical com-
pany were positively associated with early adoption. Having a larger portfolio of 
drugs prescribed decreased time to adoption.
Pharmaceutical promotion, namely higher marketing budget, detailing, provid-
ing samples and direct-to-consumer advertising increased the likelihood of early 
adoption. The effect of continuous medical education meetings was less consistent. 
Interactions through social networks such as key opinion leaders and informal in-
teractions with other doctors were positively associated with early adoption. The 
impact of practicing in a rural or urban area, in a solo or group practice, and the 
size of the practice were inconsistent and showed no association in most studies.
Excluding drugs specifically designed for the elderly, younger patients were more 
likely to be prescribed new drugs. Higher patient referral and comorbidities were 
associated with early adoption of new drugs, as was higher patient socioeconomic 
status.
Another review, focusing on physicians working in secondary care settings, also 
found that physicians on Drug and Therapeutic Committees can exert influence 
on secondary care prescribers; that in patients with more advanced stages of dis-
24
ease physicians accepted greater risks and used new drugs more; and that physi-
cians who adhere to clinical practice guidelines are less likely to be early adopters 
than those that use pharmaceutical industry provided information more often.62
In Switzerland, allowing physicians to dispense drugs lead to higher costs possi-
bly associated with overprescribing or choosing more expensive options.63 
Two Portuguese studies used questionnaires and self-reported information 
sources.64,65 Pharmaceutical industry was reported as one of the major sources 
of information in both studies. Results for other sources such as journals and 
official tools were not consistent. Another study done in Portugal showed that 
clinicians try to choose drugs with greater proof of effectivity, but that brands also 
are important in their decision.66 One study on antibiotic prescribing behavior 
found that working in the emergency room, seeing more patients, ignoring the 
link between antibiotic prescribing and resistance, complacency or attributing the 
responsibility of antibiotic resistance to others were associated with poor quality 
antibiotic prescribing.67 
Interventions to modify prescribing
Chochrane’s Effective Practice and Organization of Care group has published 
several systematic reviews on the effect of different types of interventions to mod-
ify prescription behavior. 68 Most interventions show small to moderate effects on 
prescription improvement, but there is considerable heterogeneity in results of 
the included studies. Heterogenous results probably reflect lack of standardization 
for each intervention and the interference of setting specific factors.
Dissemination strategies
Physicians may not always be aware and familiar with the most current medical 
literature and guideline recommendations. Dissemination strategies may be need-
ed to overcome these barriers. A review on continuing education meetings and 
workshops found they could have a small effect to improve professional practice 
and patient outcomes.69 But the authors also concluded that educational meetings 
alone were not likely to be effective for changing complex behaviors. Strategies 
to increase attendance at educational meetings could increase their effectiveness.
Using educational games to improve health care professional practice and care 
for patients was not found to yield consistent results.70
Printed educational materials were shown to slightly improve healthcare pro-
fessional practice, but there was insufficient evidence to estimate their effect on 
patient outcomes.71
Educational outreach visits alone or combined with other interventions were 
found to have small effects on prescribing, but relatively consistent and potentially 
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important when hundreds of patients were affected.72 Effects on other types of 
professional performance varied from small to modest improvements.
A review on the use of opinion leaders to disseminate and implement evi-
dence-based medicine showed variable effects, from decreased compliance to sig-
nificant increases.73 Overall, there was a positive effect, but heterogenous results 
prevented a solid conclusion.
Designing and providing additional tools along a guideline to improve its im-
plementation led to better compliance with guidelines on non-specific low-back 
pain and thyroid function tests.74 However, this strategy has been evaluated in few 
studies, limiting conclusions on its effectiveness.
Feedback
Providing a practitioner with data on his or her own performance and com-
paring it to other peers is intended to encourage compliance with professional 
standards. A review on processes of audit and feedback found that results varied 
widely across the included studies, ranging from little to no effect to a substan-
tial effect.75 This strategy was most effective when health professionals were not 
performing well to start with, the person responsible for the audit and feedback 
was a supervisor or colleague, the process was repeated more than once, feedback 
was given both verbally and in writing, and it included clear targets and an action 
plan.
In-hospital medication review was found to reduce emergency department con-
tacts, but not mortality or readmissions.76
Use of enablement (providing advice or feedback) and restrictive (rules to make 
physicians conform to prescribing guidelines) techniques was shown to be ef-
fective in increasing compliance with antibiotic policy and reducing duration of 
antibiotic treatment in hospital settings.77
Decision support technology
Computerized systems have the potential to provide real time advice to a pre-
scriber during a patient encounter. A review on the effect of reminders generated 
automatically by a computer and delivered to the physician on paper found that 
reminders improved quality of care slightly overall; that the absolute effect was 
higher for reminders alone when compared with adding reminders to one or more 
co-interventions; but it was uncertain if reminders improved patient outcomes.78 
On screen computer reminders were studied to prescribe specific medications, 
to warn about drug interactions, to provide vaccinations, or to order tests.79 They 
were found to have small to moderate effects achieving improvements in prescrib-
er behavior. Some studies showed larger effects, but there were no specific features 
consistently associated with larger benefits.
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Computerized advice on drug dosage was found to have low quality evidence of 
improving clinicians’ performance to achieve target doses in drugs with narrow 
therapeutic windows and reducing related patient adverse events.80
A review on the effects of telemedicine found studies mostly focusing on diabetes 
and heart failure.81 There was some evidence that glucose control, LDL cholesterol 
and blood pressure could improve in patients with diabetes. There was evidence 
for reduced admission rates in patients with heart failure and slight improvement 
in disease-specific quality of life, although there were no differences in mortality. 
There was limited data for costs and acceptability by patients and health profes-
sionals.
Interventions to increase the use of electronic health information by health-
care practitioners, although effective in increasing use of these systems, were not 
shown to translate into improved clinical practice or patient outcomes.82
Financial incentives
Financial incentives have been studied as tools to change how healthcare is de-
livered. They would act as extrinsic motivation factors for health professionals or 
organizations. A systematic review providing an overview of this field grouped 
financial incentives in five areas: payment for working for a specified time period; 
payment for each service, episode or visit; payment for providing care for a patient 
or specific population; payment for providing a pre-specified level or providing 
a change in activity or quality of care; and mixed or other systems.83 The authors 
found that payment for working for a specified time period was mostly ineffective; 
payment for each service, episode or visit, payment for providing care for a patient 
or specific population and payment for providing a pre-specified level or provid-
ing a change in activity or quality of care were usually effective; and there were 
mixed results on the effectiveness of mixed and other systems. Overall, results 
showed improvement in processes of care, referrals and admissions and prescrib-
ing costs; mixed effectiveness on consultation or visit rates; and no improvement 
in compliance with guidelines outcomes.
A more recent review focused specifically on the effects of financial incentives on 
prescribers.84 It found low quality evidence that pharmaceutical budget caps may 
lead to a modest reduction in drug use. Evidence for effects of pharmaceutical 
budget caps on drug costs, healthcare utilization, and health outcomes, pay for 
performance policies and reimbursement rate policies was of very low quality or 
non-existent.
A review focusing on methods of payment of primary care physicians found 
some evidence that the method of payment of primary care physicians affected 
their behavior, but few studies to make more specific and generalizable conclu-
sions.85
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Patient directed interventions and policies
Interventions directed at patients or policies affecting patients may indirectly 
result in changes in health professionals’ behavior. A review on the effects of pub-
lic release of performance data found a small body of evidence and inconsistent 
results that this intervention resulted in behavior changes of the public, healthcare 
professionals or healthcare organizations.86
A review on the effects of mass media found poor quality evidence that it could 
have an important role in influencing the use of health care interventions.87 How-
ever, there were no specific conclusions about effects on drug use.
Reference pricing was shown to increase the use of reference drugs and reduce 
expenditures for insurers.88 However, the effects on patient’s drug expenditures 
and health were uncertain due to lack of evidence.
Cap and co-payment policies were found to reduce drug expenditure for health 
insurers, but also to reduce patients’ drug use, including life-sustaining and other 
important drugs for treating chronic conditions, even if these conditions were 
symptomatic.89 There was no evidence for health outcomes. Fixed co-payment 
with a ceiling and tiered fixed co-payment were less likely to reduce the use of 
essential drugs.
A review on policies that restrict reimbursement aimed at better use of drugs 
found that, where drugs have cheaper, effective alternatives and they target symp-
toms, reimbursement restriction polices could ensure better use of drugs with 
reduced costs and without an increase in the use of other health services.90 Re-
moving restrictions for drugs used for secondary prevention could result in an 
intended increase in their use. However, the authors also concluded that policies 
need to be designed based on good quality research, quantifying the harm and 
benefit profiles of target and alternative drugs to avoid unwanted health system 
and health effects, namely impacts on health equity.
Tailored interventions
Tailored interventions are planned after an investigation into the factors that ex-
plain current professional practice and any reasons for resisting new practice, and 
have the potential to yield greater effects since they address the determinants of 
practice. A review found tailored implementation could be effective, but the effect 
was variable and tended to be small to moderate.91 There was insufficient evidence 
on the most effective approaches to achieve tailoring, including how determinants 
should be identified, how decisions should be made on which determinants were 
most important to address, and how interventions should be selected to account 
for the important determinants.
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Research in the thesis
A PhD thesis would not be feasible if it aimed to study all areas related with the 
determinants of medical prescribing and factors that can modify prescribing de-
cisions. In the following paragraphs, I will limit the scope of research and provide 
context to the research manuscripts that will be later presented.
Specialist influence in primary care prescribers
The influence of specialist physicians on primary care prescribers is still in-
completely understood. Some studies show that specialists are more often earlier 
adopters, initiating treatments with a new drug, which family physicians then 
continue.92-94 When specialists initiate treatment with a different drug, family 
physicians might feel compelled to keep it, feel they do not have all the informa-
tion needed to recommend a different treatment or patients might be resistant to 
change.95 This could cause part of the family physician’s prescribing pattern to be 
induced by specialists with whom he or she shares patients. Yet this is not always 
the case, as the same studies show that the rate of adoption varied considerably 
for different drugs and it was not specialist induced in all case. Clarification of this 
phenomenon is needed to understand primary care prescribing behavior.
Effect of regulatory actions on drug use
When a medicine is brought to market, knowledge about its benefits and risks is 
usually incomplete.96 Often, authorities are later required to take regulatory action 
regarding safety concerns. Risk minimization measures are meant to improve the 
benefit-risk balance of drugs after they have been approved.97 Risk minimiza-
tion measures may involve requiring additional or more frequent safety studies, 
changes in approved indications or restrictions on use in certain conditions or 
patient groups (which are reflected in the summary of product characteristics and 
patient leaflet), changes to package size, sending educational material to prescrib-
ers or patients, or even withdrawal from market.98 Evaluating the efficacy of risk 
minimization measures to change actual clinical practice is recommended by the 
European Medicines Agency (EMA) and the European Parliament. 99,100
A systematic review evaluated the impact of safety-related regulatory action 
on clinical Practice.101 It found that safety regulatory recommendations could 
modify use of drugs in clinical practice, but there was considerable heterogene-
ity in outcome measures and analyses across studies, which limited the authors’ 
conclusions. The intended effects were achieved in 57% of the included analyses, 
were negative in 26% and had mixed effects in 16%. Direct healthcare professional 
communications, black box warnings and public health advisories had similar 
impact. Half the studies used before and after designs and the other half used 
interrupted time-series analyses. The intended effect was reported to have been 
successful in 72% of before and after studies, but only 41% of the interrupted 
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time-series designs. None of the studies could rule out the influence of confound-
ing factors.
It is not known why previous studies found such heterogeneous results. Possi-
bly, the type of regulatory intervention, medicine involved and prescriber being 
targeted are important in determining if an intervention will result in clinical 
practice changes.
The authors of the review conclude that there is a clear need for further research 
and make several recommendations regarding future studies. Appropriate study 
designs are recommended, particularly the interrupted time series, as it allows 
for greater reliability compared to before and after studies. Other authors agree 
that interrupted time-series are a reasonable study design to assess the effect of an 
intervention when identification of a control group is impractical and when inter-
ventions are implemented at a clearly defined point in time.102-104 The estimates of 
ITS seem comparable to estimates of cluster randomized trials assessing the same 
research question.105 They also recommend adequate statistical analysis, includ-
ing confounding factors in the models. More attention to confounding factors is 
recommended in general, such as to the effect of media coverage. Intended and 
unintended effects should be assessed, including impact on the clinical outcomes 
that were the intended target of the safety warning. It is also recommended that 
all individual warnings should be assessed and not only a selection, reporting the 
impact per warning instead of an overall effect. 
Educational outreach visits
Educational outreach visits (also known as academic detailing) are aimed at 
changing healthcare professionals’ behavior by delivering educational content in 
face-to-face visits performed by trained persons (usually another health profes-
sional, termed detailer) to health professionals in their own settings.72
The process of an educational outreach program has been described by its pro-
ponents.106 It begins with the definition of the areas to be addressed and specific 
behaviors to be encouraged or discouraged. The outcome of concern should be 
the highest possible quality of care at the lowest possible cost. Identifying the spe-
cific cases of practice that are of highest concern in terms of quality and/or cost 
could be used to initiate a program. It is then important to understand the moti-
vations for physician behavior. Focus group interviews, surveys and direct com-
munication between detailers and physicians in ongoing programs can be used 
to this purpose. The next step is to establish credibility for the program. It can be 
achieved by having the support of neutral professional groups, such as physician 
associations or academic centers. Programs should then target who prescribe 
inappropriately or in high volumes to maximize the program’s effects. Involving 
local opinion leaders can help spread and consolidate the program’s messages.
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During visits, communication by detailers should present both sides of an ar-
gument instead of focusing only on the aspects that favor the desired change, as 
doing so would damage their credibility. Controversial issues should be acknowl-
edged, while providing information that supports the visit’s goals. Physicians 
receiving visits should be actively engaged by inquiring about their opinions, 
motivations and how their patients reacted to prescribing recommendations. Pre-
scribers should be offered alternatives to the practice being discouraged. Repeti-
tion during the visit and reinforcement in follow-up visits are two techniques that 
should be used. Detailers should be accompanied by graphic print materials that 
emphasize the main clinical recommendations in a straightforward way.
This detailer is usually a healthcare professional (physician, nurse or pharma-
cist) with special training in communication skills. He or she presents educational 
contents previously prepared using the above stated principles. At the end of each 
visit, details should be recorded to help understand the performance of the pro-
gram and of that detailer.
Although this was the proposed process, a systematic review found there are 
currently several ways of conducting educational outreach visits, as some of the 
components originally described have been altered by different researchers.72
The same review concluded that educational outreach visits had a small but con-
sistent effect on improving prescribing behavior, and small to modest improve-
ments in other types of professional performance.72 It also highlighted several 
key areas that future research should address. The authors concluded that the 
long-term performance of educational outreach visits was not known, namely if it 
deteriorated or improved over time and if multiple visits would be worth the ad-
ditional cost. Head-to-head comparisons between different educational outreach 
strategies were recommended, including different types of visitors, contents of 
visits, and sustained programs versus one-time visits. Studies should be adequate-
ly powered to detect the anticipated small effects. Process evaluation should be 
embedded into trials to assess which components influence the effectiveness of the 
intervention, if the intervention was fully implemented as intended, and to shed 
light on the variable effectiveness of educational outreach visits. There could also 
be contextual factors that lead to variable effectiveness in different subgroups.107 
The review’s authors recommend that a realist number of behaviors be targeted 
for improvement and that investigators clearly indicate a primary outcome. The 
inclusion of patient outcomes and not only professional performance was also 
recommended. Finally, economic analyses should be included to measure the use 
of resources with educational outreach visits.
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Part II – Aim and Objectives
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The general aim of this thesis is to contribute to the understanding of how pri-
mary care physicians decide to prescribe drug treatments. It is composed of three 
separate sets of research papers, each focusing on a different aspect of this field 
and using different methodologies.
The first set is composed of two observational studies which aim to describe how 
physicians choose to initiate treatment in two chronic conditions very common in 
primary care: diabetes and hypertension. They report on the drugs chosen as first-
line therapy, which physicians are responsible for initiating treatment, if family 
doctors and specialist physicians have different choices, and if family physicians 
alter prescriptions initiated by other doctors.
The second set reports on two quasi-experimental studies with the objective of 
assessing the effect of regulatory actions taken by the European Medicines Agen-
cy to restrict the utilization of trimetazidine and nimesulide in real-world use of 
these drugs. For nimesulide, the study additionally aims to assess the effects on 
drug-related adverse reactions.
Finally, the third set describes a randomized controlled trial that was designed 
to compare educational outreach visits with passive guideline dissemination on 
family physicians’ compliance with guideline recommendations and the cost-ef-
fectiveness of this intervention. The first manuscript describes the trial protocol 
in detail. The second reports a process evaluation to analyze the implementation 
of the intervention regarding reach, dose, fidelity, acceptability of different com-








Manuscript 1: Initial therapeutic choices for arterial 
hypertension in the Portuguese Sentinel Practice Network
Daniel Pinto*, Ana Paula Rodrigues¶, Baltazar Nunes¶
* Family Medicine Unit, NOVA Medical School – Lisbon, Portugal




Finding which agents are chosen to treat incident cases of hypertension may help 
interpret prevalent use of anti-hypertensive agents. We aimed to determine the 
proportion of patients who begin treatment with each anti-hypertensive medicine 
class, which physicians initiate treatment, if family physicians alter prescriptions 
initiated by others, and to compare prescribing patterns of family physicians and 
other specialists.
Methods
Cohort-nested cross-sectional study within the Portuguese Sentinel Practice 
Network between 2014 and 2015. Family physicians notified incident cases of 
arterial hypertension reporting treatment, who made the initial prescription and 
if they had changed treatments initiated by other physicians.
Results
681 incident cases were notified. The initial prescription was made by the pa-
tient’s family physician in 86.9% (95%CI 84.2-89.3%) of cases. The most used 
agents were angiotensin converting enzyme inhibitors (51.3% of patients, 95%CI 
47.5-55.0%), thiazide and thiazide-like diuretics (32.2%, 95%CI 28.8-35.8%), and 
angiotensin receptor blockers (21.4%, 95%CI 18.5-24.7%). Compared to other 
specialists, family physicians used less beta-blockers (20.4 vs 5.9%, p<0.001) and 
loop diuretics (8.2 vs 0.8%, p=0.003). Prescriptions initiated by other specialists 
were changed by family physicians in 11.6% of cases (95%CI 6.0-19.6%).
Conclusion
Angiotensin converting enzyme inhibitors were the most prescribed anti-hyper-
tensive class. Most diagnoses were made by the patients’ own family physician. 
Prescriptions initiated by other specialists were usually continued by family phy-
sicians. Prescribing patterns were similar between family physicians and other 
specialists except for lower use of beta-blockers and loop diuretics.
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Introduction
Following the trend in developed countries, hypertension prevalence has been 
steadily rising in Portugal.1 This has led to a near doubling in use of antihyperten-
sive medicines, in line with other OECD countries, and a corresponding increase 
in expenses.2,3 A report from the Portuguese National Medicines Authority found 
growing costs were mainly attributable to higher use of angiotensin II receptor 
blockers (ARBs), despite increased use of generic medicines.2 Compared with 
other European countries, use of ARBs was higher in Portugal, where in 2011 
there were almost as many prescriptions for ARBs as for angiotensin-converting 
enzyme (ACE) inhibitors. The same report found that primary care physicians 
were the prescribing source for 76% of cardiovascular medicines dispensed in 
ambulatory pharmacies in Portugal; used more ARBs than hospitals, but less 
than physicians in private practice; and prescribed as much generics as hospitals 
and more than private practice physicians. In addition to higher cost, ARBs have 
weaker evidence than ACE inhibitors for reducing morbidity and mortality, al-
though they have fewer withdrawals due to adverse effects.4,5
Portuguese guidelines recommend as first-line therapy for patients with low to 
medium cardiovascular risk: thiazide or thiazide-like diuretics, ACE inhibitors, 
low cost ARBs, long acting calcium channel blockers, or low dose and low cost 
fixed dose associations of diuretics with ACEs or ARBs.6 For patients with high 
cardiovascular risk, low cost fixed dose associations of thiazide diuretics or cal-
cium channel blockers with ACEs or ARBs are recommended. Beta-blockers are 
also considered appropriate as initial therapy for younger patients and those with 
coronary heart disease and certain arrhythmias. The European Society of Hyper-
tension and European Society of Cardiology guidelines state that the main ben-
efits of treating hypertension are due to lowering blood pressure, independently 
of which medicines are used.7 Therefore, thiazide and thiazide-like diuretics, 
beta-blockers, calcium channel blockers, ACEs and ARBs are all considered ap-
propriate as first-line agents. European guidelines recommend lifestyle changes 
alone for young individuals with isolated elevation of systolic blood pressure and 
as initial treatment for patients with grade I hypertension at low to moderate car-
diovascular risk.
Most studies on antihypertensive medication prescribing focus on prevalent 
use.2,8-10 However, this means no conclusions can be drawn about how doctors 
choose to use each medicine as a first-line agent, as an alternative when initial 
therapy results in side effects or add-on treatment when the patient fails to achieve 
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blood pressure goals.11 Focusing on incident use can determine which medicines 
are chosen as first-line treatment.
The prescription of ARBs and of thiazide diuretics have been used as quality 
indicators for primary care in Portugal since 2013.12 The implicit objective was to 
decrease ARB use. Although family physicians issue most prescriptions,2 it is not 
known how often they are responsible for initiating treatment or maintain pre-
scriptions decided by other physicians. Specialists have been shown to influence 
primary care physicians by being earlier adopters of new medicines.13,14
Determining how anti-hypertensives are used to initiate treatment and who is re-
sponsible for their prescription can help guide future quality improvement efforts 
in the Portuguese National Health Service (NHS). If family physicians have the 
responsibility for initiating treatment, then quality indicators targeting them may 
change how anti-hypertensives are used. If, however, most decisions are made by 
other doctors, targeting only family physicians will probably be ineffective.
With this study, we aimed to determine the proportion of patients with newly 
diagnosed hypertension who began treatment with each class of antihypertensive 
medicines. Secondary objectives were to determine which physician was respon-
sible for diagnosing and initiating hypertension treatment, the proportion of cas-
es where family physicians altered prescriptions initiated by other prescribers, and 
to compare family physicians prescribing patterns with other specialists.
Methods
Study design and setting
The Portuguese NHS is a public funded single payer system, with each citizen 
being registered in a primary care practice and having an assigned family physi-
cian.15 Some of these family physicians participate as volunteers in the Portuguese 
Sentinel Practice Network.16 Each of them contributes with a cohort of their reg-
istered patients. This allows the network to have an open cohort of patients that is 
reasonably stable in each year and it is possible to calculate the incidence of health 
problems in this sample of the Portuguese population. The network was set up to 
conduct weekly surveillance of communicable and non-communicable diseases; 
and it has also been used for observational epidemiological research to answer 
specific questions (satellite studies).
Between January 2014 and December 2015, the network expanded the informa-
tion being reported about incidence of hypertension for surveillance purposes, 
to conduct a continuous notification cross-sectional study among new cases of 
hypertension notified in the cohort.
Participants
In 2014 and 2015 the population under observation was comprised of 35,535 in-
dividuals, distributed among 82 family physicians participating in the Portuguese 
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Sentinel Practice Network. Participant physicians were asked to notify all incident 
cases of hypertension. Hypertension was defined using the criteria adopted by the 
National Health Directorate (systolic blood pressure of 140mmHg or higher or 
diastolic blood pressure of 90mmHg or higher on several separate occasions).17
Measurements
Data was collected using paper or online forms. Notifications included infor-
mation on patient age at diagnosis, gender, pharmacological treatment (the paper 
form had a free text field, which was subsequently coded by the investigators into 
the international non-proprietary name; the online form had a list of antihyper-
tensives available in the Portuguese market by international non-proprietary 
name, up to three medicines could be entered), other treatment measures (free text 
field), who had made the initial prescription (the family physician participating in 
the sentinel practice network or a different physician, who was then specified in 
a separate free text field; these were later divided in two categories: family physi-
cians and other specialists), and, for prescriptions initiated by other physicians, if 
the notifying physician had changed the treatment. The Sentinel Practice Network 
coordinating team followed-up any submissions with incomplete or incoherent 
information, contacting the notifying physician to gather missing data.
Outcomes
The main outcome in this study was the proportion of patients who initiated 
treatment with each class of antihypertensive. Classes were defined using the Ana-
tomical Therapeutic Chemical classification categories for C02 antihypertensives, 
C03 diuretics, C07 beta blocking agents, C08 calcium channel blockers, and C09 
agents acting on the renin-angiotensin system.18
Secondary outcomes were the proportion of patients where initial diagnosis and 
therapy were made family physicians (those participating in the Sentinel Prac-
tice Network or other family medicine specialists) or other specialists (hospital 
and private based); the proportion of patients where Sentinel Practice Network 
physicians altered prescriptions initiated by others; and the proportion of each 
class of antihypertensives prescribed by family physicians compared with other 
specialists.
Medicines were compared regarding use as unique treatment combinations in 
a given patient and total use (as part of any combinations of anti-hypertensive 
therapy – alone, in fixed dose associations or combined with the administration 
of other medicines as separate pills).
Study size
To estimate the proportion of patients beginning treatment with each class of 
antihypertensive medicines with 5% precision and 95% confidence, assuming 
as a wort case scenario that 50% of patients would begin with a given class, a 
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minimum sample size of 384 cases of hypertension was calculated. Given the no-
tification rates in previous years of 206 new cases of hypertension per year, we 
estimated two years of continuous notifications would be needed to achieve our 
targeted sample size.
Statistical analysis
Proportions of each antihypertensive class prescribed as initial therapy were esti-
mated with their respective 95% confidence interval (95%CI). Patient distribution 
regarding gender among family physicians and other specialists were compared 
using Fisher’s exact test; age distribution was compared using the T-test. Pre-
scription patterns between family physicians and other specialists were compared 
using multivariable logistic regression analysis adjusting for patient gender and 
age. A level of significance (α) of 0.01 was used as the threshold for statistical 
significance to account for multiple comparisons. 
Ethics approval
This study was approved by the Ethics Committee of National Health Institute 
Doutor Ricardo Jorge (Portugal).
Results
Between 2014 and 2015, 72 family physicians participating in the Portuguese 
Sentinel Practice Network notified 681 new cases of hypertension. Ten partici-
pants did not contribute with any hypertension notifications, but notified other 
health conditions, hence their patient lists were included to estimate incidence. 
Hypertension incidence in the cohort was 9.6 / 1.000 person-years. Mean age at 
diagnosis was 57.0 years (standard deviation 13.2), and 50.1% of patients were 
male.
Initial diagnosis and prescription was made by the patient’s family physician in 
592 cases (86.9%, 95%CI 84.2-89.3%), other family physicians in 21 cases (3.1%, 
95%CI 2.0-4.7%), other specialists in 49 cases (7.2%, 95%CI 5.5-9.4%) and phy-
sicians with unknown specialty in 19 cases (2.8%, 95%CI 1.8-4-3%). There were 
no statistical differences between family physicians (Sentinel Practice Network 
participants and other family doctors) and other specialists (excluding unknown 
specialty) regarding patient age (56.7 vs 60.4 years, p=0.058) or gender (49.1 vs 
59.2% male, p=0.19).
Pharmacological treatment was initiated in 95.5% (95%CI 93.6-96.8%) of cases, 
whereas lifestyle changes alone were introduced in 4.4% (95%CI 3.1-6.2%) and no 
treatment was reported in one notification. Among patients who were prescribed 
medicines, lifestyle changes were also prescribed in 50.1% (95%CI 46.3-54.0%).
A single pharmacological substance was used in 68.3% (95%CI 64.6-71.8%) of 
patients who were prescribed medicines, two substances in 30.3% (95%CI 26.9-
34.0%) and three substances in 1.4% (95%CI 0.7-2.7%). No significant differences 
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were found between family physicians and other specialists in the use of a single 
substance compared with two or more antihypertensives (69.5 vs 53.1% of pa-
tients, p=0.025).
Fixed dose associations were used in 27.9% (95%CI 24.5-31.4%) of patients who 
were prescribed pharmacological treatment. No differences were seen in the use 
of fixed dose associations between family physicians and other specialists (27.6 vs 
32.7% of patients, p=0.45).
The proportions of each class of antihypertensive agents prescribed as initial 
therapy are shown in tables 1 (unique treatment combinations) and 2 (total use of 
each pharmacological class). ACE inhibitors were the most often prescribed med-
icines, both as single treatment (31.4% of patients) and in total (51.3%). Lisinopril 
was the most used ACE (32.4% of the class), followed by perindopril (26.1%) and 
ramipril (21.2%). There were no differences between family physicians and other 
specialists in use of ACE inhibitors as single treatment (table 1, p=0.38) or in total 
(table 2, p=0.81).
Thiazide and thiazide-like diuretics were the second most used medicines, with 
hydrochlorothiazide leading the class (43.9%; always used as part of fixed associ-
Table 1 – Proportion of patients who were prescribed each unique combination 














Lifestyle changes alone 4.7 (3.3-6.7) 0.0 (0.0-8.7) 5.3 (0.0-26.5) 4.4 (3.1-6.2)
ACE inhibitor 31.8 (28.3-35.6) 26.5 (16.1-40,4) 31.6 (15.2-54.2) 31.4 (28.1-35.0)
Thiazide-like diuretic 15.3 (12.7-18.4) 2.0 (0.0-11.7) 10.5 (1.7-32.6) 14.2 (11.8-17.1)
ARB 11.9 (9.6-14.7) 10.2 (4.0-22.2) 15.8 (4.7-38.4) 11.9 (9.7-14.6)
ACE inhibitor and  
thiazide diuretic
10.3 (8.1-13.0) 6.1 (1.5-17.2) 21.1 (8.0-43.9) 10.3 (8.2-12.8)
ACE inhibitor and CCB 7.7 (5.8-10.1) 12.2 (5.4-24.6) 0.0 (0.0-19.8) 7.8 (6.0-10.1)
ARB and thiazide diuretic 6.2 (4.5-8.4) 12.2 (5.4-24.6) 5.3 (0.0-26.5) 6.6 (5.0-8.7)
Beta-blocker 4.7 (3.3-6.7) 12.2 (5.4-24.6) 5.3 (0.0-26.5) 5.3 (3.8-7.3)
CCB 2.1 (1.2-3.6) 2.0 (0.0-11.7) 0.0 (0.0-19.8) 2.1 (1.2-3.5)
ARB and CCB 2.1 (1.2-3.6) 2.0 (0.0-11.7) 0.0 (0.0-19.8) 2.1 (1.2-3.5)
Other 3.1 (2.0-4.8) 14.3 (6.8-27.0) 5.3 (0.0-26.5) 4.0 (2.7-5.7)
ACE – agiotensin-converting enzyme, ARB – angiotensin II receptor blocker, CCB – cal-
cium channel blocker.
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ations as it is not available as a single agent in the Portuguese market), followed 
by indapamide (39.4%) and chlorthalidone (16.7%). No differences were found 
in the use of thiazide-like diuretics as single treatment (p=0.032) or in total use 
(p=0.16) between family physicians and other specialists.
ARBs were the third most used medicines as single treatment (table 1) and in 
total (table 2), with losartan being used most often (30.8% of class), followed 
by olmesartan (20.5%), valsartan (17.8%) and telmisartan (15.1%). There were 
no differences between family physicians and other specialists regarding single 
(p=0.88) or total use (p=0.081).
Calcium channel blockers were rarely used as single treatment (2.1% of patients), 
but they were the fourth most used class in total (13.1%), with amlodipine being 
the most prescribed (51.1% of class). Again, no differences were seen between 
family physicians and other specialists (p=0.93 for single use and p=0.44 for total 
use).
Beta-blocker was less used by family physicians than other specialists, both as 
single treatment (4.7 vs 12.2%, p=0.007) and in total (5.9 vs 20.4% of patients, 
p<0.001). Bisoprolol was the most prescribed beta-blocker (44.7% of class).
Total use of loop diuretics was also lower in primary care physicians (0.8 vs 8.2%, 
p=0.003). Loop diuretics were used as single treatment in only one case. Potas-
Table 2 – Proportion of patients who were prescribed each class of antihyperten-














ACE inhibitor 51.2 (47.3-55.2) 51.0 (37.5-64.4) 52.6 (31.7-72.7) 51.3 (47.5-55.0)
Thiazide-like  
diuretic*
32.8 (29.2-36.6) 22.5 (12.9-36.0) 36.8 (19.1-59.1) 32.2 (28.8-35.8)
ARB 20.7 (17.7-24.1) 30.6 (19.4-44.6) 21.1 (8.0-43.9) 21.4 (18.5-24.7)
CCB 13.1 (10.6-16.0) 18.4 (9.8-31.6) 0.0 (0.0-19.8) 13.1 (10.7-15.8)
Beta-blocker 5.9 (4.3-8.0) 20.4 (11.3-33.8) 5.3 (0.0-26.5) 6.9 (5.2-9.1)
Loop diuretic 0.8 (0.3-2.0) 8.2 (2.7-19.7) 0.0 (0.0-19.8) 1.3 (0.1-2.5)
Potassium-sparing 
diuretic
0.3 (0.0-1.3) 0.0 (0.0-8.7) 0.0 (0.0-19.8) 0.3 (0.0-1.1)
Renin inhibitor 0.0 (0.0-0.8) 0.0 (0.0-8.7) 0.0 (0.0-19.8) 0.0 (0.0-0.7)
* Includes thiazide diuretics. ACE – agiotensin-converting enzyme, ARB – angiotensin II 
receptor blocker, CCB – calcium channel blocker.
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sium sparing diuretics were never reported as single initial treatment, and were 
only used in combination with other anti-hypertensives in two cases. Direct renin 
inhibitors were not used as part of the initial treatment for hypertension.
In the 89 cases where treatment was not initiated by physicians participating in 
the Sentinel Practice Network, there was a change in pharmacological treatment 




The clear majority of patients with newly diagnosed hypertension were pre-
scribed pharmacological treatments. Two thirds of patients were started on a sin-
gle medicine, with physicians preferring, in decreasing order, ACE inhibitors, thi-
azide-like diuretics and ARBs. Most patients who were prescribed more than one 
medicine were started on fixed associations, where ACE inhibitors with thiazide 
diuretics or with calcium channel blockers were preferred. Loop and potassium 
sparing diuretics were rarely prescribed in first-line treatments, and there were no 
reports of direct renin inhibitors use.
Most diagnosis were made by the patient’s family physician. Family physicians 
did not differ significantly from other specialists regarding the use of most classes 
of anti-hypertensives, but used less beta-blockers and loop diuretics. When other 
specialists initiated therapy, it usually was continued by family physicians.
Strengths and limitations
By prospectively collecting data within the Sentinel Practice Network cohort we 
could gather accurate data regarding medicines being prescribed to new cases of 
hypertension, avoiding recall bias and inaccuracies in administrative data. In most 
cases, the physician reporting the case was the same who had made the diagnosis 
and therapeutic decision a few moments before. For cases where the diagnosis 
had been made by other physicians, information was gathered from patients when 
they visited their family physicians to request refill prescriptions or for other med-
ical problems. If needed, additional information could be gathered in the patient’s 
national record, which allows the family physician to view details of prescriptions 
made elsewhere, including by hospital and private physicians (electronic prescrip-
tion has been mandatory since August 2011 to be eligible for reimbursement by 
the Portuguese National Health Service).19 Having this information available to 
Sentinel physicians greatly reduced patient recall bias in our study.
Some patients might have been diagnosed with hypertension by other physicians 
and not have visited their family physician during the study period and, therefore, 
not have been reported to the Sentinel Practice Network. Hence, the incidence of 
hypertension may be underestimated and the proportion of diagnosis made by 
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family physicians may be overestimated in our study. However, hypertension in-
cidence was similar to that reported previously in the Sentinel Practice Network,20 
and by authors in other settings.21 This suggests underreporting was low.
The study did not collect data on disease severity, the presence of comorbidities 
or contra-indications to specific medicines. These could influence the choice of 
initial treatment, particularly under Portuguese guidelines. However, gathering 
such information would have increased the amount of time physicians had to 
dedicate to each notification and the space needed in paper notification forms. 
Both would make the study unacceptable to the Sentinel Practice Network. We 
cannot exclude that patients with more severe clinical situations on initial presen-
tation, such as acute cardiovascular events or heart failure, were more often seen 
and managed by specialists than by family physicians. This may explain higher 
prescription of beta-blockers and loop diuretics.
Yet these differences between family physicians and other specialists must be 
taken as hypothesis generating only. The comparison of prescribing patterns was 
a secondary outcome in our study and multiple comparisons were made. Despite 
having used a statistical threshold of 0.01 instead of 0.05 for significance to account 
for multiple testing, it is still possible that these differences represent false positive 
results. We did not define a formal adjustment method for multiple comparisons 
in the study’s methods since we could not have known how many combinations 
of anti-hypertensive treatments would be present in our sample. It is also possible 
that other differences exist, but our study was underpowered to find them.
Although not statistically significant, there were large absolute differences be-
tween family physicians and other specialists in the proportion of men diagnosed, 
average age at diagnosis, and the proportion of patients treated with a single sub-
stance. Our study may have been underpowered to find these differences, as there 
were relatively few cases diagnosed by other specialists.
Another limitation is that physicians who volunteer to participate in the Sentinel 
Practice Network might be different than other family physicians, resulting in dif-
ferent prescribing patterns. However, other authors have found these differences 
to be small.22,23 Also, given that the observed prescribing patterns for Sentinel phy-
sicians and other specialists were similar, it is unlikely that they differ significantly 
from other family physicians.
Interpretation of results
Previous research on prevalent use of anti-hypertensives had reported greater 
use of multiple agents, of ARBs relative to ACE inhibitors, of diuretics, calcium 
channel blockers and beta-blockers.8,24 A higher use of combination therapy than 
in our study is to be expected, since an analysis of prevalent use will include 
patients with longer disease duration. Higher use of diuretics, calcium channel 
blockers and beta-blockers might be explained by the use of these agents mainly 
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as add-on therapy when blood pressure goals are not achieved. Our study showed 
ACE inhibitors to be used almost two and a half times more than ARBs for initial 
treatment. This is different than what was observed in previous studies on preva-
lent use and administrative data on drug dispensing, where ACE inhibitors were 
used less often than ARBs.2,8,24 Since ACE inhibitors and ARBs are seldom used in 
combination in the same patient, comparing prevalent use can approximate the 
relative proportion of patients treated with each of them. Lower prevalent use of 
ACE inhibitors may indicate that, after initiating treatment, a significant propor-
tion of patients substitute them for other classes like ARBs. It is also possible that 
prescription patterns have changed since the previous studies and physicians are 
now preferring ACE inhibitors over ARBs.
Participants in the Sentinel Practice Network usually did not alter medicines ini-
tiated by other physicians. This may happen because they agree with the prescrip-
tion, as our results show no major differences in prescribing patterns of family 
physicians and other specialists. It is also possible that family physicians feel they 
do not have enough information to change initiated by specialists, the patient will 
continue under the responsibility of the other physician or the patient would be 
resistant to change.25
Implications for practice and research
Pharmacological treatment employed a large variety of medicines of different 
classes, and both family physicians and specialists seem to be following Portu-
guese and European hypertension guidelines for treating new patients. 6,7 Since 
use of ARBs is much lower in incident cases than in prevalent patients, future 
studies should focus on how medicines are used after the initial diagnosis, name-
ly if ARBs are introduced because of adverse reactions, as substitutes or add-on 
treatment due to lack of blood pressure control with initial therapy or other 
reasons. If Portugal is to reduce use of ARBs, guidelines should include further 
recommendations on how to manage patients who are not adequately controlled 
or who experience adverse reactions with medicines initially prescribed.
Family physicians and specialists had similar prescribing patterns, but the first 
were the main initiators of anti-hypertensive treatment. Therefore, efforts to im-
prove quality of care in treating hypertension should be mainly directed at family 
physicians.
Conclusions
The most used medicines classes in incident cases of hypertension were, in 
decreasing order, ACE inhibitors, thiazide diuretics and ARBs. Most cases were 
diagnosed by the patients’ family physician, but when they weren’t, family doctors 
opted to keep treatments initiated by other physicians most of the time. Prescrib-
ing patterns were similar between family physicians and other specialists except 
for less use of beta-blockers and loop diuretics.
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To determine the proportion of new patients with type 2 diabetes who begin 
treatment with each antidiabetic medicine class, if therapy was initiated by their 
family physician and if family physicians alter prescriptions initiated by other 
physicians. To compare prescribing patterns of family physicians and other spe-
cialists.
Methods
Cohort-nested cross-sectional study within the Portuguese Sentinel Practice 
Network. Between 2014 and 2015 family physicians notified incident cases of type 
2 diabetes reporting treatment, who made the initial prescription and if treat-
ments initiated by other physicians were changed.
Results
415 incident cases of diabetes were notified. The initial prescription was made 
by Sentinel Practice Network physicians in 89.4% (95%CI 86.0-92.0%) of cases. 
Metformin was most often chosen as the first treatment, prescribed to 85.5% of 
patients (95%CI 81.8–88.6%). Family physicians used less dipeptidyl peptidase-4 
inhibitors (4.2% vs 30.3%, p<0.001) and insulin (0.3% vs 12.1%, p<0.001) than 
other specialists. Prescriptions initiated by others were changed in 4.6% of cases 
(95%CI 0.4-16.0%).
Conclusions
Metformin was most often chosen as initial therapy. Sentinel Practice Network 
physicians made the initial prescription in most cases, seldom changed prescrip-
tions initiated by others, and had a different pattern of antidiabetic medicines use 
than other specialists.
Keywords




Type 2 diabetes pharmacotherapy is one of the major drivers of pharmaceutical 
spending in Portugal and other developed countries.[1] Rises in expense are partly 
related to increased diabetes prevalence, but mainly to the greater use of newer 
and more expensive medicines, such as the dipeptidyl peptidase-4 (DPP-4) inhib-
itors and insulin glargine.[1,2]
Both international and Portuguese guidelines favour metformin as the first-
line agent of choice for most patients with type 2 diabetes after lifestyle changes 
have been tried.[3,4] Portuguese guidelines prefer a sulfonylurea if metformin is 
contra-indicated or not tolerated, and recommend insulin if there is markedly 
symptomatic hyperglycaemia (with glycaemia above 300mg/dL or an HbA1C over 
10%).[4] Starting with dual combination therapy is not recommended by Portu-
guese guidelines, but is considered optional for patients with HbA1C over 9% by 
the American Diabetes Association and the European Association for the Study 
of Diabetes joint position statement.[3]
Studies regarding diabetes medicines prescription patterns mainly focus on 
prevalent use,[1,2,5,6] with only a few identifying the agents used as first-line therapy.
[7] Finding which agents are chosen as first-line therapy for new cases of type 2 dia-
betes may help determine if physicians are following guideline recommendations; 
and if more expensive agents are being used to initiate treatment or introduced 
later on (e.g., when initial therapy fails to achieve goals or causes side effects).
Although family physicians account for most diabetes prescriptions in Portu-
gal,[1] it is unknown if new medicines are introduced by them or prescribing is in-
duced by hospital or private practice based specialists. The influence of specialist 
prescribing of new medicines on primary care physicians has been shown to occur 
often, but not in all cases. In some studies, specialists are earlier adopters, initiat-
ing treatments with a new drug, which family physicians then continue;[8-11] while 
in other studies family physicians are reported to use new drugs more often.[12]
The main objective of this study was to determine the proportion of new patients 
with type 2 diabetes who began treatment with each antidiabetic medicine class. 
Secondary objectives were to determine the proportion of new patients with type 
2 diabetes whose initial therapy was prescribed by their family physician, the pro-
portion of cases where family physicians altered prescriptions initiated by other 
doctors, and to compare family physicians prescribing patterns with private or 
hospital based specialists.
Methods
Study design and setting
The Portuguese Sentinel Practice Network is composed of volunteer family phy-
sicians working in the Portuguese National Health Service (NHS).[13] The Portu-
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guese NHS is a single payer public funded system, where each citizen is registered 
with a family physician.[14] Therefore, each participant in the Sentinel Practice 
Network contributes with a cohort of their patients. This allows the network to 
have a reasonably stable cohort each year and calculate incidence of health prob-
lems in the Portuguese population. The network collects data for two different 
purposes: surveillance of communicable and non-communicable diseases for 
which specified events are systematically reported each week; and epidemiolog-
ical research that comprises satellite studies, where data is collected to answer a 
specific question. Only observational research studies are performed within the 
network.
In 2013, the network agreed to expand the information being collected about 
incidence of diabetes mellitus for surveillance purposes, to conduct a continuous 
notification cross-sectional study among new cases of type 2 diabetes notified in 
the cohort. Data was collected from January 2014 to December 2015.
Participants
In 2014 and 2015 there were 82 active family physicians participating in the Por-
tuguese Sentinel Practice Network, which comprised an observed population of 
35,535 individuals. We asked participants to notify all incident cases of diabetes of 
any age. Diagnosis of diabetes was made using the nationally adopted criteria (the 
same as those recommended by the World Health Organization in 2006, updated 
in 2011 to include HbA1C).
[15] Only cases of type 2 diabetes were included.
Measurements
Notifications were sent using either online or paper forms. Data were collected 
on patient age at diagnosis, gender, type of diabetes (type 1, type 2 – only these 
were included, gestational, other or unknown), pharmacological treatment (the 
online form had a list of marketed antidiabetic medicines using the international 
non-proprietary name; the paper form had a free text space; up to three medi-
cines could be entered), other treatment measures (free text), who made the initial 
prescription (the family physician or another doctor, who was then specified in 
a separate free text field), and if the initial prescription had been changed by the 
family physician (only for prescriptions initiated by other physicians). Free text 
fields were latter coded by the investigators. When incomplete submissions were 
received, the Sentinel Practice Network coordination contacted the notifying 
physician to gather missing information.
Outcomes
Our main outcome was the proportion of patients who began treatment with 
each antidiabetic medicine class. Classes were defined using the Anatomical Ther-
apeutic Chemical classification categories for A10B blood glucose lowering drugs 
excluding insulins and A10A insulins and analogues.[16]
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Secondary outcomes were the proportion of patients whose diagnosis and initial 
therapy was prescribed by their family physician; the proportion of cases where 
family physicians altered prescriptions initiated by others; and the proportion 
of each class of antidiabetics prescribed by primary care physicians (family phy-
sicians participating in the Sentinel Practice Network or other family medicine 
specialists) or private and hospital based specialists.
Study size
We calculated a minimum sample size of 384 cases of type 2 diabetes needed to 
estimate the proportion of patients beginning treatment with each class of anti-
diabetic medicines with 5% precision and a 95% confidence interval, assuming 
as worst case scenario that 50% of patients would begin with one class. Given 
the previous notification rate, we estimated that two or three years of continuous 
notification would be needed. To maximize the ability of the network to conduct 
new projects, we planned to count the number of notifications by the last trimes-
ter of the second year and only continue notifications into the third year if the 
desired sample size had not been achieved.
Statistical analysis
Proportions of each antidiabetic class prescribed as initial therapy were estimated 
with their respective 95% confidence interval (95%CI). Proportions of medicines 
prescribed by primary care and non-primary care physicians were compared us-
ing Fisher’s exact test. A level of significance (α) of 0.01 was used as the threshold 
for statistical significance to account for multiple comparisons.
Ethics approval
This study was approved by the Ethics Committee of National Health Institute 
Dr. Ricardo Jorge (Portugal).
Results
During the years 2014 and 2015, 415 incident cases of type 2 diabetes were 
notified to the Portuguese Sentinel Practice Network by 72 participating family 
physicians. Ten physicians did not contribute with any diabetes notifications, but, 
as they notified other health conditions under observation, their patient lists were 
included when calculating incidence. Having achieved the planed sample size, 
data collection ended by the end of the second year of the study. Type 2 diabetes 
incidence in the cohort was 5.8 / 1 000 person-years. Median age at diagnosis was 
62 (interquartile range 54 - 71) and 54.5% of patients were male. There were no 
differences between patients diagnosed by primary care and non-primary care 
physicians regarding mean age (62.7 vs 60.2 years, p=0.25) and gender (53.7 vs 
63.6% male, p=0.28).
The diagnosis and initial prescription was made by physicians participating in 
the Sentinel Practice Network in 371 cases (89.4%, 95%CI 86.0-92.0%), other 
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family physicians in 11 cases (2.7%, 95%CI 1.4-4.7%), and other specialists in 33 
cases (8.0%, 95%CI 5.7-11.0%).
Lifestyle changes alone were introduced in 12.0% (95%CI 9.2-15.6%) of patients, 
all were prescribed by Sentinel Practice network physicians. In total, lifestyle 
changes were prescribed to 65.8% (95%CI 61.1-70.2%) of cases.
In 81.4% (95%CI 77.4-84.9%) of cases patients were started on one single med-
icine, in 5.8% (95%CI 3.9-8.5%) two medicines were used and in 0.7% (95%CI 
0.1-2.2%) three antidiabetics were prescribed. Family physicians used two or 
more medicines less often than other specialists (4.2 vs 33.3%, p<0.001). Fixed 
associations were used in 3.4% of cases, less often by primary care physicians than 
other specialists (2.4 vs 15.2%, p=0.003).
Tables 1 and 2 show the proportion of each antidiabetic class prescribed as initial 
therapy by family physicians or other specialists grouped by distinct combina-
tions and total class use, respectively. Metformin was used as a single agent or 
in combinations in 85.5% of patients (95%CI 81.8–88.6%), with no differences 
between primary care and non-primary care physicians (85.6 vs 84.8%, p=0.801). 
Table 1 – Proportion of patients prescribed each distinct combination for initial 
therapy (by class and type of practitioner). Antidiabetics with and without associ-










Lifestyle changes alone 13.1 (10.1 - 16.9) 0.0 (0.0 - 12.4) 12.0 (9.2 – 15.6)
Biguanides (metformin) 81.4 (77.2 - 85.0) 54.5 (38.0 – 70.2) 79.3 (75.1 – 82.9)
Biguanide and DPP-4-i 2.4 (1.2 - 4.5) 24.2 (12.6 – 41.2) 4.1 (2.5 – 6.5)
DPP-4-i 1.0 (0.3 - 2.8) 6.1 (0.6 – 20.6) 1.4 (0.6 – 3.2)
Biguanide and sulphonylurea 1.0 (0.3 - 2.8) 0.0 (0.0 - 12.4) 1.0 (0.3 – 2.5)
Insulin 0.0 (0.0 – 1.2) 9.1 (2.4 – 24.3) 0.7 (0.1 – 2.2)
Biguanide, sulphonylurea and 
DPP-4-i
0.5 (0.0 – 2.0) 0.0 (0.0 - 12.4) 0.5 (0.0 – 1.9)
Sulphonylureas 0.3 (0.0 - 1.6) 0.0 (0.0 - 12.4) 0.2 (0.0 – 1.5)
Biguanide and GLP1 agonist 0.0 (0.0 - 1.2) 3.0 (0.0 – 16.7) 0.2 (0.0 – 1.5)
Biguanide and insulin 0.0 (0.0 - 1.2) 3.0 (0.0 – 16.7) 0.2 (0.0 – 1.5)
Biguanide, DPP-4-i and insulin 0.3 (0.0 – 1.6) 0.0 (0.0 - 12.4) 0.2 (0.0 – 1.5)
DPP-4-i - dipeptidyl peptidase-4 inhibitor. GLP1 - Glucagon-like peptide-1. 95%CI – 95% 
confidence interval.
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Metformin alone was used more often by family physicians than other specialists 
(81.4% vs 54.5%, p=0.01). Sulphonylureas alone or in combination were used in 
1.7% of cases (95%CI 0.8-3.5%), with no differences between primary care phy-
sicians and other specialists (1.8 vs 0.0%, p=1.0). The proportion of patients who 
began treatment with a DPP-4 inhibitor as a single agent or in combination was 
6.3% (95%CI 4.3-9.1%), 4.2% for primary care physicians and 30.3% for other 
specialists (p<0.001). Insulin alone or in combination was prescribed to 1.2% 
(95%CI 0.4-2.9%) of cases, by family physicians to 0.3% of patients and by other 
specialists to 12.1% (p<0.001). 
When we excluded cases treated with lifestyle changes alone, the differences 
between family physicians and other specialists in use of metformin alone (93.7 
for family physicians vs 54.5% for specialists, p<0.001), DPP-4 inhibitors (4.8 vs 
30.3%, p<0.001) and insulin (0.3 vs 12.1%, p<0.001) as single agents or in combi-
nations, and fixed combination therapy (2.7 vs 15.2%, p=0.005) remained statis-
tically significant. Total metformin use (as a single agent or in combinations) also 
achieved statistical significance (98.5% vs 84.5%, p=0.001). There were still no 
differences in sulphonylurea use (2.1 vs 0%, p=1.0).
Among the 44 cases where treatment was not initiated by physicians participat-
ing in the Sentinel Practice Network, the prescribed medicines were changed in 
two cases (4.5%, 95%CI 0.4-16.0%).
Discussion
Main findings
In this study, most cases of type 2 diabetes were diagnosed by family physicians. 
The majority of patients began treatment with metformin as a single agent, as 
recommended by Portuguese and international guidelines.[3,4] This occurred more 
Table 2 – Proportion of patients prescribed each class as part of their initial ther-








Lifestyle changes 68.3 (63.5 – 72.8) 36.4 (22.1 – 53.4) 65.8 (61.1 – 70.2)
Biguanides (metformin) 85.6 (81.7 – 88.8) 84.8 (68.6 – 93.8) 85.5 (81.8 – 88.6)
DPP-4-i 4.2 (2.5 – 6.7) 30.3 (17.3 – 47.5) 6.3 (4.3 – 9.1)
Sulphonylureas 1.8 (0.8 – 3.8) 0.0 (0.0 – 12.4) 1.7 (0.8 – 3.5)
Insulin 0.3 (0.0 – 1.6) 12.1 (4.2 – 27.9) 1.2 (0.4 – 2.9)
GLP-1 agonists 0.0 (0.0 - 1.2) 3.0 (0.0 - 16.7) 0.2 (0.0 – 1.5)
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often when treatment was initiated by family physicians than when initiated by 
other specialists. Lifestyle changes alone were the initial strategy used by family 
physicians in about 13% of patients, but in none of the cases diagnosed by other 
specialists. When these two options are taken together, family physicians man-
aged new cases of type 2 diabetes with lifestyle changes or metformin in 94.5% 
of cases, compared with 54.5% of cases diagnosed by specialists. Other specialists 
were more likely than family physicians to use DPP-4 inhibitors, insulin or fixed 
combinations as their initial choice. Despite these differences, family physicians 
usually didn’t change prescriptions initiated by others.
Sulphonylureas and glucagon-like peptide-1 receptor agonists were seldom used 
as first-line agents. We observed no use of alpha glucosidase inhibitors, thiazoli-
dinediones or sodium/glucose cotransporter 2 inhibitors for initial therapy.
Strengths and limitations
The main strength of this study is the prospective data collection about therapeu-
tic choices among new cases of diabetes. Almost 90% of cases were reported by 
the prescribers themselves on the same day or a few days after the diagnosis and 
a therapeutic decision had been made. For the remaining 10% of cases, Sentinel 
Practice Network physicians gathered information from the patient or available 
patient records. In the Portuguese NHS, electronic prescription has been manda-
tory for reimbursement since August 2011.[17] Information about electronic pre-
scriptions made elsewhere is available to family physicians through the national 
Health Data Platform.[18] The availability of such information would have limited 
patient recall bias.
There may have been some cases of type 2 diabetes diagnosed by other physi-
cians that were not reported by participants in the Sentinel Practice Network. 
However, these should be rare, as the diagnosis of type 2 diabetes grants special 
benefits to patients in the Portuguese NHS and most would visit their family phy-
sician to be entitled to them. Also, incidence during the study period was similar 
to that previously reported in the cohort (since here we are only considering type 
2 diabetes),[19] and to what is reported in other countries (considering these are 
estimates for the adult population only).[20-22]
It is possible that patients diagnosed by other specialists who were prescribed 
lifestyle changes alone would not come immediately to their family physician, 
reporting their diagnosis only when medicines are prescribed. However, when we 
excluded patients treated with lifestyle changes alone the differences in prescrib-
ing pattern did not disappear. Sentinel Practice Network participants could also 
have underreported lifestyle changes prescribed by other physicians, as patients 
may have not have valued non-pharmacological treatment and there were no oth-
er sources for this information.
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We did not collect data on disease severity or presence of contra-indications to 
specific medicines. Both could influence the decision of initial treatment. Howev-
er, the number of variables that can be collected in the Sentinel Practice Network 
is limited, as the paper notification form for all studies in a given year has to fit in 
one sheet.
Socio-economic status may have been a confounder, as patients with more pur-
chasing power may have been more likely not to use the NHS and also to afford 
more expensive medicines.
An important limitation is that family physicians participating in the Sentinel 
Practice Networks might sometimes have different prescribing habits than other 
family physicians. Participating in a research network is voluntary and could be 
associated with other physician or patient characteristics that influence prescrib-
ing. This has not been thoroughly studied in the Portuguese Sentinel Practice 
Network, but other authors have found differences to be small.[23,24]
Care must be taken when interpreting differences in use of specific drugs, as we 
did multiple comparisons, which make false positive results more likely, and this 
was not the study’s primary outcome. Therefore, our findings should be consid-
ered mostly as hypothesis generating. Nonetheless, we decided to use a lower than 
usual threshold for statistical significance (α=0.01 instead of α=0.05) to reduce 
false discovery rate. A formal adjustment method, such as the Bonferroni cor-
rection, was not defined in the study’s methods since the number of comparisons 
to make would be dependent on the number of medicines classes used in our 
sample. Even so, most of the associations found were very unlikely to be due to 
chance, with a p value less than 0.001.
Interpretation of results
As expected, metformin was the most frequently prescribed first-line medicine. 
Second came DPP-4 inhibitors, mainly when used in a fixed association with 
metformin, with sulphonylureas coming in third place. This goes against recom-
mendations in Portuguese guidelines, which prefer sulphonylureas for having 
a better cost-benefit relation.[4] It may, however, reflect physician perception of 
better safety with DPP-4 inhibitors,[25] despite their sparse data on reduction of 
diabetes complications.[26]
Our findings suggest family physicians prescribe more in line with guidelines 
than other specialists, who use more intensive pharmaceutical regimens, includ-
ing newer and more expensive medicines. This may be partially explained by oth-
er specialists seeing patients with more severe disease, possibly with symptomatic 
hyperglycaemia. Since the study did not collect information on disease severity 
at diagnosis, we are unable to test this hypothesis. Alternatively, specialists might 
be more willing to use newer medicines or feel more often that their patients do 
not fit guideline recommendations.[10,27] However, our results are consistent with a 
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study conducted in the Lisbon region that showed only 17.2% of initial prescrip-
tions for new oral anticoagulant agents originated in primary care.[11]
Family physicians seem to be reluctant to change prescriptions initiated by other 
specialists. This might be explained by the fact that most these patients would 
continue to be followed by those specialists. On the other hand, family physicians 
might feel compelled to keep the treatment initiated by specialists, feel they do not 
have all the information needed to recommend a different treatment or patients 
might be resistant to change.[28]
Implications for practice
When considering prevalent prescribing patterns of antidiabetic medicines, pol-
icymakers and managers should consider that most patients diagnosed with type 
2 diabetes begin with metformin, and probably only escalate to other treatments 
later in the disease. However, more aggressive initial treatment, including more 
expensive agents, is more frequent when the diagnosis has been made by spe-
cialists. Thus, interventions to reduce inappropriate prescription need to target 
hospital and private-based specialists and not only primary care doctors.
Future studies should address disease severity at diagnosis, but also when and 
why patients change their initially prescribed treatment as the duration of diag-
nosis lengthens and which agents are chosen by physicians then.
Conclusion
Metformin was the agent most often chosen as initial therapy, followed by life-
style changes alone, fixed combinations of metformin and DPP-4 inhibitors and 
DPP-4 inhibitors. The diagnosis and initial prescription was made by Sentinel 
Practice Network physicians in almost 90% of cases. Family physicians changed 
prescriptions initiated by others in less than 5% of cases. DPP-4 inhibitors and 
insulin were more likely to be prescribed by other specialists.
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Abstract
Purpose
Following safety concerns regarding trimetazidine, the European Medicines 
Agency (EMA) recommended restrictions on its use. Our objective was to de-
termine the impact of regulatory actions on trimetazidine utilization in Portugal.
Methods
Retrospective interrupted time-series analysis of ambulatory pharmacy reim-
bursement records for the Portuguese National Health Service between January 
2006 and December 2015. Regulatory actions were identified by searching the 
EMA, Portuguese Medicines Authority and European Commission’s websites. 
Confounding factors in the same period were also identified. The main outcome 
was the dispensing of trimetazidine containing products per month in Portugal.
Results
Two interruption periods were defined in the series: May 2011, when EMA an-
nounced it would review trimetazidine safety; and June 2012 to January 2013, 
when EMA announced it had reached a final opinion recommending restrictions; 
the European Commission approved EMA’s recommendation; the Portuguese 
Medicines Authority issued safety alerts, changed the summary of product char-
acteristics and approved a direct health-care professional letter; and a regional 
bulletin was issued.
Interruption 1 had no effect on trimetazidine use, but interruption 2 resulted in 
decreases in level and trend – from 8.3 million defined daily doses in 2010 to 2.8 
million in 2015. After interruption 2, trimetazidine use tended towards a lower 
steady state.
Conclusions
There was a significant decrease in trimetazidine use in Portugal following a 
complex intervention that included safety alerts, changes to the summary of prod-
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uct characteristics, a direct health-care professional letter and a regional drug bul-
letin. No effect was seen when EMA announced its review of trimetazidine safety.
Introduction
When a medicine is brought to market, knowledge about its benefits and risks is 
usually incomplete.1 Often, authorities are later required to take regulatory action 
regarding safety concerns. A systematic review concluded that safety regulatory 
recommendations regarding the use of medicines could modify their utilization 
in clinical practice.2 However, it also described considerable heterogeneity in 
outcome measures and analyses across studies, which limited the authors’ con-
clusions. It is not known why previous studies found such heterogeneous results. 
Possibly, the type of regulatory intervention, medicine involved and prescriber 
being targeted are important in determining if an intervention will result in clin-
ical practice changes. The authors recommend further research in this field, with 
attention to the use of interrupted time series designs, assessment of individual 
regulatory warnings and decisions, and considering possible confounding factors.
One recent example of safety regulatory interventions targeted trimetazidine 
in Europe. Trimetazidine was indicated for the prophylactic treatment of angina 
pectoris and, in some European countries (but not in Portugal), also as ancil-
lary symptomatic treatment for vertigo, tinnitus and visual disturbances due to 
vascular reasons.3 However, in 2011, following increased reports of parkinson-
ism,4,5 France questioned the European Medicines Agency’s (EMA) Committee 
for Medical Products for Human Use (CHMP) if the marketing authorization for 
trimetazidine containing medicines should be maintained, altered, suspended or 
withdrawn, initiating an Article 31 procedure.3
The CHMP concluded that the benefit-risk ratio remained positive in angina 
pectoris if use was restricted to add-on therapy to existing treatments in patients 
not adequately controlled by or intolerant to other medicines. The Committee 
recommended that the indications for use in tinnitus, vertigo and visual field 
disturbances should be removed.3 Finally, it also concluded that trimetazidine 
should be contra-indicated in patients with movement disorders and severe renal 
impairment.3 This recommendation was adopted by the European Commission 
in September 2012.6 The effect of these restrictions in real world clinical use is 
unknown. Our hypothesis was that trimetazidine use decreased after regulatory 
intervention and that there were differences in the effects on different types of 
prescribers.
The objectives for this study were to determine the effect of EMA’s recommenda-
tion to restrict trimetazidine use on its dispensing in Portugal; and if there were 




Retrospective interrupted time-series analysis of ambulatory trimetazidine use 
in the Portuguese National Health Service (NHS) using pharmacy reimbursement 
records between January 2006 and December 2015. Possible confounding factors 
in the same period were also identified.
Setting
The Portuguese NHS reimburses community pharmacies for 69% of trimetazi-
dine containing medicines costs and the remainder is paid by the patient. Ad-
ministrative data for mainland Portugal is collected in a central NHS database 
and anonymized records are made available for research. Inpatient hospital use 
information was not collected.
Data collection
Trimetazidine utilization
Dispensing information is aggregated by the Portuguese NHS reimbursement 
database in monthly intervals and includes the international nonproprietary 
name, dosage, package size, number of defined daily doses (DDDs) in each pack-
age (the Anatomical Therapeutic Chemical classification for 2015 was used),7 
number of packages sold and their cost. Data can be analyzed per prescribing site 
category, which for this study was divided in: NHS primary care, NHS hospitals, 
and other prescribing sites (mainly physicians in private practice, private hospitals 
and clinics, and private companies’ health services). Prescribing site category data 
was available since January 2008. Dispensing data was provided by the Portuguese 
National Medicines Authority - INFARMED - and the Ministry of Health Central 
Administration.
Regulatory interventions
Regulatory interventions were defined as changes to the summary of product 
characteristics and patient leaflet, changes to package size or direct communi-
cations to prescribers regarding trimetazidine safety. These interventions were 
proposed by EMA, approved by the European Commission and implemented in 
Portugal by INFARMED.
EMA and INFARMED press releases, meeting reports and other public commu-
nications on the progress of the safety evaluation, but not on a final opinion, were 
considered as regulatory concurrent factors.
A site-wide search was performed in EMA’s, the European Commission’s and 
INFARMED’s websites using the international nonproprietary name trimetazi-
dine. We also conducted specific searches in EMA’s section on human medicines 
referrals and INFARMED’s sections on safety alerts and health professional di-
rected communications. For EMA and the European Commission, only English 
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language documents were included. Two authors (AS and DP) classified each 
result independently as pertaining to trimetazidine safety. Divergences were re-
solved by consensus.
Concurrent factors
Contextual factors occurring between January 2006 and December 2015 that 
could have influenced trimetazidine use were collected. These factors were identi-
fied by consensus among all study authors when planning the study.
News in general media regarding trimetazidine safety were identified by search-
ing the websites of generalist or news television and radio stations or networks, 
and the most widely circulated national generalist newspapers and magazines. 
Specialized media were not included. The search was performed independently 
by two authors (AS and DP) using both the website’s search function and Goo-
gle (within the website’s domain) for the international nonproprietary name or 
each of trimetazidine’s brand names. Each result was classified as pertaining or 
not pertaining to trimetazidine safety and diverging opinions were resolved by 
consensus.
Internet searches were measured using the freely available Google Trends tool. 
Trimetazidine and its brand names were used as key-words and results were re-
stricted to searches in Portugal between January 2006 and December 2015. Data is 
presented in a scale of 0 to 100, where 100 is the greatest number of total searches.8 
Results for trimetazidine and brand names were added in a total score.
National guidelines and therapeutic bulletins were searched for news regarding 
trimetazidine safety or recommendations for its use.
The total number of packages dispensed for all reimbursed medicines in com-
munity pharmacies by prescribing site category was used to calculate each site’s 
market share.
Outcomes
The main outcome was the number of trimetazidine containing products DDDs 
dispensed per month in mainland Portugal. The variation of trimetazidine pre-
scriptions originating in each prescribing site category were considered as sec-
ondary outcomes. 
Statistical analysis
As data for all mainland Portugal was available, no sample size calculations were 
made. A segmented regression multivariable model was used to analyze chang-
es in level and slope of monthly trimetazidine dispensing between the pre- and 
post-intervention periods.9 Regulatory interventions and concurrent factors were 
tested as predictors in the model: each was considered as an interruption defining 
a regression segment. All factors were modeled as discrete interventions, except 
for monthly site market share and internet searches, which were entered as con-
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tinuous variables. For each interruption, we included variables for the event, time 
after event and square time after event when non-linear effects were observed. 
Interruption periods were censored when calculating the model.
When multiple discrete events occurred less than six months apart, they were 
modeled as a single interruption. To gain insight on the relative contribution of 
each event, a sensitivity analysis was conducted replacing the multiple event inter-
ruption in the model with each separate event.
Since the relative importance of each prescription site category in providing care 
for the Portuguese population was not constant during the study period, for sec-
ondary outcomes the site’s market share for all reimbursed medicines was used 
as an adjustment variable, to account for global changes in prescription volume 
within each category.
Autocorrelation was tested using the Durbin-Watson statistic, and, when need-
ed, a Prais-Winsten correction was introduced. A dummy variable for each calen-
dar month was introduced to account for seasonality in the model. Only factors 
with p values <0.05 were considered statistically significant and retained in the 
final model. All analyses were conducted using SPSS Statistics software version 
23.0 (IBM Corp.), and regression models calculated using the AREG command.
Ethics approval and funding
The study protocol was approved by the Ethics Committee of NOVA Medical 
School. No external funding was received.
Results
Intervention and concurrent factors timeline
We found 246 results in the European Commission, EMA and INFARMED 
websites, of which 25 were considered relevant. These are summarized in figure 1. 
In May 2011 EMA announced that an article 31 procedure had been initiated by 
France regarding trimetazidine’s safety.10,11 This was labeled interruption 1.
In June 2012 EMA recommended restrictions on trimetazidine use.12,13 These 
were accompanied by proposed amendments to the summary of product charac-
teristics and patient leaflet.14 Simultaneously, INFARMED issued a national safety 
alert summarizing EMA’s recommendations.15 In July 2012 these recommenda-
tions were publicized in EMA’s monthly highlights newsletter.16 In September 
2012 the European Commission published a decision supporting EMA’s recom-
mendation and concluding the article 31 procedure.17 EMA then published the 
procedure report and a questions and answers document.18,19 In the final decision, 
the European Commission required changes to the summary of product char-
acteristics and patient leaflet, a direct healthcare professional communication, 
a safety study to assess the effect of renal impairment and age on trimetazidine 
pharmacokinetics, a post-authorization safety study to address the identified 
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risks, and a drug utilization study to verify the compliance of prescribers with the 
restrictions. INFARMED implemented the first three measures nationally also in 
September.20
In January 2013, the Pharmacy and Therapeutics Committee of Lisbon’s Region-
al Health Administration published a drug bulletin discussing the evidence for 
trimetazidine use and EMA’s opinion.21 This bulletin was made available on the 
Regional Health Administration’s website and sent as a newsletter to NHS prima-
ry care clinicians in the region.
The period between June 2012 and January 2013 was labeled interruption 2, with 
the regulatory intervention occurring in September 2012.
No news regarding trimetazidine safety were published in major Portuguese 
media outlets between January 2006 and December 2015. Internet searches are 
shown in figure 1.
Impact on global trimetazidine use
The number of trimetazidine DDDs dispensed per month increased from a 
mean 6.9 million in 2006 to 8.3 million in 2010, but decreased to 2.8 million in 
2015 – figure 2. Table 1 shows the segmented regression model for trimetazidine 
dispensing, and the predicted results are superimposed on figure 2. At the begin-
ning of the study period trimetazidine use was increasing, but tending towards 
a plateau. There were no significant changes in level or trend after interruption 
1. After interruption 2 there was a decrease in level, resulting in less 1.6 million 
Figure 1 – Interventions and concurrent factors timeline. Vertical lines: regu-
latory and concurrent events. Dashed line: Google Trends searches. Gray boxes: 
interruption periods.
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Figure 2 – Global trimetazidine use. Gray line: observed dispensing of trimetazi-
dine (millions of defined daily doses per month). Black line: segmented regression 
model.
Table 1 – Segmented regression model for global trimetazidine use. Effect esti-
mated in defined daily doses. Adjusted for seasonal variation. Model R2=0.988.
Variable Effect estimate (95% CI) p value
Intercept  6 660 306.6 (6 492 683.8, 6 827 929.3) <0.001
Time†  61 963.7 (52 607.4, 71 320.0) <0.001
Time squared†  -536.7 (-653.1, -420.3) <0.001
Interruption 2‡  -1 638 746.6 (-1 974 524.6, -1 302 968.6) <0.001
Time after interruption 2‡  -166 339.0 (-199 318.4, -133 359.6) <0.001
Time after interruption 2 squared‡  3 150.6 (2 294.1, 4 007.1) <0.001
† January 2006 = 1. ‡ February 2013 = 1.
DDDs dispensed in the month following the interruption; and a trend to de-
creasing use (166 thousand DDDs less for each month after the interruption), but 
attenuating over time and tending towards a plateau (3 thousand DDDs more for 
each month squared after the interruption). Internet searches were not a signifi-
cant predictor. Seasonal effects were observed for the months of February, April, 
August and November.
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Sensitivity analysis considering each separate event within interruption 2, 
showed best fit for the model considering the announcement of CHMP recom-
mendations for restricted use of trimetazidine in June 2012 (adjusted R2 = 0.987; 
see table A1 in the appendix). However, in this model changes in level were not 
significant, only those in trend. When the European Commission’s decision and 
national implementation were used, the model had similar performance (adjusted 
R2 = 0.986, table A2), but changes in level became significant. The worst perform-
ing model was the one considering the publication of a Lisbon regional health 
administration drug bulletin (adjusted R2 = 0.979; table A3).
Impact on trimetazidine use by prescribing site
Between 2008 and 2015, most trimetazidine prescriptions originated in NHS 
primary care (72.7%), followed by other prescribing sites (22.0%), and then NHS 
hospitals (5.3%). Trends before interruption 1 were different among these sites 
(figure 3): NHS primary care and other prescribing sites had reached a peak by 
2010, while use in NHS hospitals continued to grow. Interruption 1 corresponded 
to a jump in NHS hospitals use of 23.8 thousand DDDs (a 6% relative increase) 
compared to what was expected had the intervention not occurred (table 2). How-
ever, interruption 1 was not significant for NHS primary care or other prescribing 
sites.
Interruption 2 was associated with a decrease in level and slope for all sites, but 
the later attenuated over time. Comparing the six months before interruption 2 
with those that followed, trimetazidine monthly use decreased from 6.1 to 4.0 
million DDDs in NHS primary care (-34.1%), from 444 to 319 thousand DDD in 
NHS hospitals (-28.0%), and from 1.5 to 1.3 million DDDs in other sites (-15.2%). 
Average dispensing in the second half of 2015 had decreased to 1.8 million DDDs 
in NHS primary care (-70.9%), 155 thousand DDDs in NHS hospitals (-65.0%) 
and 749 thousand DDDs in other sites (-50.0%).
However, in the same period, the relative importance of each site for the provi-
sion of care in Portugal was not constant, as shown by each site’s market share on 
global dispensing of medicines – figure 3. We estimate that, had each site’s global 
market share remain at a constant level (January 2008 to April 2011 average), 
trimetazidine use in the second half of 2015 would have been 2.6 million DDDs 
Figure 3 (oposite) – Trimetazidine use by prescribing site. Panel A – NHS pri-
mary care, panel B – NHS hospitals, panel C – other prescribers. Solid gray line: 
observed dispensing of trimetazidine (millions of defined daily doses per month). 
Dotted gray line: global medicines market share (percent). Solid black line: re-
gression model considering average global market share in the segment. Dashed 
black line: regression model considering global market share remained constant 
(January 2008 to April 2011 average).
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Table 2 – Segmented regression model for trimetazidine use by prescribing site 
category. Effect estimated in defined daily doses.
Variable Effect estimate (95% CI) p value
NHS Primary Care – model R2=0.988¶
Intercept  -3 285 767.3 (-6 580 924.9, 9 390.3) 0.101
Time†  55 555.1 (41 943.0, 69 167.3) <0.001
Time squared†  -801.7 (-1 048.2, -555.2) <0.001
Interruption 2‡  -959 212.6 (-1 317 601.6, -600 823.5) <0.001
Time after interruption 2‡  -81 582.0 (-116 848.6, -46 315.4) <0.001
Time after interruption 2 squared‡  2 565.1 (1 879.7, 3 250.6) <0.001
Global market share (proportion)  14 045 680.3 (8 799 302.6, 19 292 058.0) <0.001
NHS Hospitals – model R2=0.982¶
Intercept  275 692.0 (195 076.0, 356 308.0) <0.001
Time†  978.5 (600.8, 1 356.1) <0.001
Interruption 1§  23 778.9 (11 525.7, 36 032.0) 0.002
Interruption 2‡  -103 203.7 (-117 646.4, -88 761.1) <0.001
Time after interruption 2‡  -11 310.4 (-12 943.1, -9 677.8) <0.001
Time after interruption 2 squared‡  116.0 (73.6, 158.4) <0.001
Global market share (proportion)  907 915.8 (257 425.1, 1 558 406.5) 0.02
Google searches score  -361.1 (-573.6, -148.5) 0.006
Other prescribers – model R2=0.970¶
Intercept  71 852.5 (-268 216.4, 411 921.3) 0.73
Time†  12 995.5 (8 973.4, 17 017.5) <0.001
Time squared†  -165.6 (-249.4, -81.9) 0.002
Interruption 2‡  -213 125.9 (-332 948.1, -93 303.6) 0.004
Time after interruption 2*‡  -32 608.4 (-45 008.3, -20 208.6) <0.001
Time after interruption 2 squared‡  582.2 (384.3, 780.1) <0.001
Global market share (proportion)  5 822 791.3 (4 403 067.2, 7 242 515.3) <0.001
Google searches score  -1 288.8 (-2 217.0, -360.5) 0.024
† January 2008 = 1. ‡ February 2013 = 1. § May 2011 = 1. ¶ Adjusted for seasonal 
variation.
in NHS primary care (-57.7% than in the six months before interruption 2), 
127 thousand DDDs in NHS hospitals (-71.5%) and 537 thousand in other sites 
(-64.1%).
Seasonal effects were observed among all sites. Google searches were inversely 
associated with trimetazidine prescription in NHS hospitals and other sites.
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Discussion
We examined trimetazidine dispensing in Portugal before, during and after the 
European Medicines Agency recommended restrictions to its use. A complex reg-
ulatory intervention was associated with a reduction in trimetazidine use, which 
by 2015 had declined to about one third the average use in 2011.
Between 2006 and 2015 we documented two interruption periods. In May 
2011, EMA’s announcement of an article 31 procedure caused no effect on global 
trimetazidine use. As the national authority issued no communications to pre-
scribers or the public, there was no media coverage and it is not expected that 
most practicing clinicians regularly visit EMA’s website, prescribers and patients 
were probably unaware trimetazidine’s safety had been questioned.
During interruption 2, there was a sharp decrease in trimetazidine dispensing. 
National safety alerts and a direct to health-care professional communication 
probably had an important role making physicians aware of EMA’s recommen-
dations. A regional bulletin on trimetazidine safety seems to have been published 
when most changes had already taken place, but may have helped consolidate the 
trend.
All prescribing site categories showed decreased trimetazidine use. The relative 
reduction was highest for NHS primary care both in the six months after the in-
tervention and by late 2015, and lowest for other sites. However, when adjusted 
for the total amount of medicines being prescribed in each site category, NHS 
primary care had the lowest relative reduction and NHS hospitals the highest. 
This highlights the need to consider global changes in context when analyzing 
effects by prescriber type.
In the years following interruption 2, the trend to decreased trimetazidine use 
continued, suggesting some physicians were late adopters of the recommenda-
tions. However, by 2015, dispensing was tending towards a new steady state. This 
may indicate that only patients meeting EMA’s recommendations were being 
prescribed trimetazidine by then or that most physicians willing to change their 
practice had done so. Since data on individual patients or physicians was not col-
lected, we are unable to verify these hypotheses.
Changing the package leaflet was the only intervention targeting patients that 
we could identify. No media coverage of trimetazidine safety was found during 
this period and there was no clear pattern showing changes in Google searches 
around interruption 2. The significance of the inverse association of trimetazidine 
use with Google searches in NHS hospitals and other sites is unclear, as it was not 
present in the global model and Google searches fluctuated throughout the study 
period. It is unlikely that patients had a major role in the reduction of trimetazi-
dine use.
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A systematic review found direct healthcare professional communications and 
black boxed warnings to be effective in achieving the intended effect 56% and 57% 
of cases, respectively.2 Our results are concordant with a positive effect for these 
regulatory interventions. However it should be noted that black boxed warnings 
are not the same as changes to the summary of product characteristics and patient 
leaflet, and our study considered the effects of these interventions together.
We aimed to address some of the key recommendations from the mentioned 
systematic review on the impact of safety related regulatory action: to use an in-
terrupted time series design (ITS), include confounding factors and assess impact 
for each individual warning.2 ITS are a reasonable study design to assess the effect 
of an intervention when identification of a control group is impractical and when 
interventions are implemented at a clearly defined point in time.22-24 The estimates 
of ITS seem comparable to estimates of cluster randomized trials assessing the 
same research question.25 In our analysis we tried to account for several concur-
rent effects, although there may have been other influences on both physicians 
and patients that we have not collected. We were unable to measure the impact 
in clinical outcomes or assess if trimetazidine discontinuation only happened in 
patients with indications that were removed. We also could not distinguish among 
several interventions happening during interruption 2 as there were not enough 
data points between them to estimate a regression segment with reasonable confi-
dence. It is possible that these interventions had different impact among prescrib-
ers, but we cannot determine how each factor contributed to the overall result 
and how they interacted with each other. Finally, we could not study unintended 
effects, namely, if there was substitution with other drugs. 
In conclusion, we found a significant decrease in trimetazidine use from 8.3 to 
2.8 million DDDs per month, following a complex intervention that included 
safety alerts, changes to the summary of product characteristics a direct health-
care professional letter and a regional drug bulletin. No effect was seen when 
EMA announced it would begin to review trimetazidine safety. The individual 
impact of each component and the importance of the order in which they were 
used remains unknown.
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Appendix
Sensitivity analysis for global trimetazidine use
The following tables show alternative segmented regression models for global 
trimetazidine use if the events in interruption 2 are considered separately. Event 1 
took place in June 2012 (see figure 1 and results in the main text). EMA’s monthly 
newsletter on July 3rd is considered together with event 1, since it was published 
so early in the month. For event 1, June data was censored and July is considered 
the first month after the interruption (table A1). Similarly, event 2 took place in 
September (table A2) and event 3 in January 2013 (table A3), therefore October 
2012 and February 2013 were respectively considered the first month after the 
interruption.
Table A1 – Segmented regression model for global trimetazidine use using EMA’s 
recommendation for restrictions as interruption 2 (see figure 1). Effect estimated 
in defined daily doses. Model R2=0.987.
Variable Effect estimate (95% CI) p value
Intercept  6 662 082.0 (6 495 085.7, 6 829 078.4) <0.001
February  -786 816.1 (-1 001 622.7, -572 009.6) <0.001
April  -346 599.9 (-561 409.0, -131 790.8) 0.002
August  -421 468.6 (-635 901.4, -207 035.8) <0.001
November  -252 107.8 (-466 576.8, -37 638.7) 0.022
Time†  61 837.9 (52 458.6, 71 217.3) <0.001
Time squared†  -532.9 (-649.4, -416.4) <0.001
Interruption 2‡  -49 399.0 (-328 363.7, 228 485.7) 0.723
Time after interruption 2‡  -235 312.6 (-260 629.5, -209 995.6) <0.001
Time after interruption 2 squared‡  3 603.0 (3 045.9, 4 160.2) <0.001
† January 2006 = 1. ‡ July 2012 = 1.
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Table A2 – Segmented regression model for global trimetazidine use the Europe-
an Commission’s decision and national implementation by INFARMED as inter-
ruption 2 (see figure 1). Effect estimated in defined daily doses. Model R2=0.986.
Variable Effect estimate (95% CI) p value
Intercept  6 615 465.1 (6 445 484.2, 6 785 446.0) <0.001
February  -748 449.7 (-969 449.0, -527 450.4) <0.001
April  -310 946.4 (-531 600.7, -90 292.1) 0.006
August  -427 874.0 (-648 348.6, -207 399.4) <0.001
November  -217 653.0 (-440 503.5, 5 197.5) 0.056
Time†  65 492.7 (56 286.8, 74 698.7) <0.001
Time squared†  -590.1 (-700.2, -480.0) <0.001
Interruption 2‡  -692 441.7 (-988 404.9, -396 478.5) <0.001
Time after interruption 2‡  -199 186.9 (-228 334.1, -170 039.6) <0.001
Time after interruption 2 squared‡  3 469.8 (2 776.9, 4 162.7) <0.001
† January 2006 = 1. ‡ October 2012 = 1.
Table A3 – Segmented regression model for global trimetazidine use using Lis-
bon Regional Health Administration’s drug bulletin as interruption 2 (see figure 
1). Effect estimated in defined daily doses. Model R2=0.979.
Variable Effect estimate (95% CI) p value
Intercept  6 514 374.4 (6 313 727.0, 6 715 021.7) <0.001
February  -739 156.1 (-990 081.7, -488 230.5) <0.001
April  -289 143.0 (-539 568.2, -38 717.8) 0.024
August  -460 835.2 (-710 696.1, -210 974.2) <0.001
November  -351 781.9 (-602 598.1, -100 965.7) 0.006
Time†  75 673.6 (65 240.9, 86 106.2) <0.001
Time squared†  -740.8 (-859.6, -621.9) <0.001
Interruption 2‡  -1 251 566.6 (-1 623 770.4, -879 362.8) <0.001
Time after interruption 2‡  -137 991.4 (-179 203.1, -96 779.7) <0.001
Time after interruption 2 
squared‡  3 194.2 (2 104.6, 4 283.7) <0.001
† January 2006 = 1. ‡ February 2013 = 1.
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Abstract
Purpose
Severe hepatic adverse events led the European Medicines Agency to recom-
mend restrictions on nimesulide use. Our aim was to determine their effect on 
nimesulide dispensing in Portugal.
Methods
Interrupted time-series using pharmacy billing records of the Portuguese Na-
tional Health Service. Regulatory actions, concurrent events and nimesulide dis-
pensing were recorded from 2006 to 2015. The primary outcome was the number 
defined daily doses (DDD) of nimesulide dispensed per month. Secondary out-
comes were the number of adverse reactions to nimesulide, and the variation of 
nimesulide prescriptions by prescribing site category.
Results
We found three possible interruption periods: 1) May 2007 to March 2008: 
nimesulide was withdrawn from Ireland, the European Medicines Agency initi-
ated a safety review and this was reported by Portuguese media; 2) October 2009 
to April 2010: the European Commission reached a decision and mandated a 
broader safety review; and 3) December 2010 to April 2012: the Commission’s 
decision was implemented in Portugal, the broader safety review was concluded 
and implemented. Nimesulide use showed a declining trend at the start of the 
series (-12.2 thousand DDD/month). Interruptions 1 and 3 were associated with 
decreases in level (-824.7 thousand and -449.0 thousand DDD, respectively). In-
terruption 3 was associated with a greater decrease in primary care than in other 
sites. The number of reported adverse events did not decrease.
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Conclusions
Nimesulide use decreased significantly following two complex interventions 
including regulatory measures, media reports and other concurrent factors. How-
ever, this was not associated with a decrease in reported adverse drug reactions.
Key words
Drug regulation, physicians practice patterns, nimesulide.
Introduction
Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) marketed in 
more than 50 countries worldwide.1,2 Since being first authorized in 1985,3 it has 
been associated with an increased risk of severe hepatotoxicity, which led to its 
withdrawal in some countries (Finland and Spain in 2002) and restrictions on its 
use in others.2
In May 2007, the Irish Medicines Board suspended marketing authorizations af-
ter several cases of fulminant hepatic failure.4 This prompted the European Medi-
cines Agency (EMA) to review nimesulide’s safety, resulting in recommendations 
for restricted use.1,2 Yet, the efficacy of these recommendations is unknown.
Risk minimization measures are meant to improve the benefit-risk balance of 
drugs after they have been approved.5 A systematic review found mixed results, 
with intended effects varying among different drugs and regulatory measures.6 
Overall, the intended effect of regulatory measures was successful in 56% of the 
analysis, but only in 41% of the analysis using an interrupted time series design. 
The authors concluded there was a clear need for more research to understand the 
effect of safety warnings, highlighting the need to assess the impact on both drug 
utilization and the outcomes intended by regulatory measures, the use of appro-
priate study designs (the interrupted time series being preferred) and to consider 
the impact of confounding factors on measured outcomes. 
We aimed to assess the effect of risk minimization measures adopted at European 
level on the nimesulide utilization and nimesulide-related adverse drug reactions 
in Portugal from 2006 to 2015.
Methods
Study design
Retrospective interrupted time-series analysis using pharmacy billing records of 
the Portuguese National Health Service (NHS) for oral NSAIDs between January 
2006 and December 2015, considering possible confounders during this time. 




Community pharmacies are reimbursed by the Portuguese NHS for 37% of the 
cost of oral NSAIDs. To be reimbursed, pharmacies are required to send dispens-
ing data to the Ministry of Health. This is collected in an anonymized database 
and made available for research purposes. It does not include information re-
garding inpatient hospital use, the Azores and Madeira islands (which have an 
autonomous health system) or non-reimbursed drugs.
Data collection
Regulatory interventions
Regulatory interventions were defined as actions mandated by regulatory au-
thorities on market authorization holders. Interventions were proposed by EMA, 
adopted by the European Commission and implemented by the Portuguese Med-
icines Authority (INFARMED). Regulatory concurrent factors were defined as 
public communications by any of these institutions, reporting that nimesulide 
safety was under scrutiny. 
We conducted site-wide searches for the international nonproprietary name 
nimesulide in the European Commission, EMA and INFARMED websites, and 
specific searches in EMA’s section on human medicines referrals and INFARMED’s 
sections on safety alerts and health professional directed communications. Only 
English language results were included in the European Commission and EMA’s 
websites. Results were classified by two authors (DP and AS) as relating to nime-
sulide’s safety. Changes to the summary of product characteristics were monitored 
using INFARMED’s publicly available drug database.
Concurrent factors
Potential factors that may have influenced nimesulide use were identified by 
consensus among all study authors at the planning stage.
Total NSAIDs dispensing was used to control for global market and site varia-
tions. NSAID dispensing data was used to identify market entry and exit of drugs, 
as prescriptions could have transferred from or to nimesulide, respectively. These 
were considered as possible concurrent factors if they had a peak market share of 
at least 5% of the NSAID class.
Media coverage was identified by searching for news containing the international 
nonproprietary name nimesulide or one of its brands. The search was conducted 
independently by two authors (DP and AS) in generalist or news television stations 
or networks, radio stations, and most widely circulated national newspapers and 
magazines. Specialized media were excluded. Each media outlet website’s search 
function and Google search limited to the website’s domain were used. Results 
were classified as relating or not to nimesulide safety, and the later were excluded.
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Google trends was used to measure internet searches for nimesulide or its brand 
names in Portugal. Results are presented in relative scale of 0 to 100, where 100 is 
the greatest number of total searches in a location during the period.7 Searches for 
nimesulide and brand names were added in a total score.
Estimates for the incidence of influenza-like illness in Portugal were considered, 
as nimesulide was used for many years to treat its symptoms. Incidence data was 
provided by the Portuguese Sentinel Practice Network. However, influenza-like 
illness was introduced as a contraindication during the study period. Therefore, 
this variable was divided into two by multiplying the incidence by two dummy 
variables (one with value 0 before the contraindication and 1 after and the other 
with these values reversed). This allowed us to calculate two separate beta coef-
ficients for influenza like illness incidence: before and after the contraindication.
Prescription data
Data on NSAID dispensing was provided to the authors by INFARMED and the 
Ministry of Health Central Administration. Dispensing information is compiled 
in monthly intervals and includes the international nonproprietary name, dosage, 
package size, number of defined daily doses (DDD) in each package (the Anatom-
ical Therapeutic Chemical classification for 2015 was used), number of packages 
sold and their cost. Data by type of prescribing site is available since 2008, which 
for this study was categorized in: NHS primary care, NHS hospitals and other 
prescribing sites (mostly, private care).
Adverse drug reactions
INFARMED provided the authors with national pharmacovigilance data regard-
ing adverse drug reactions for nimesulide containing substances. Information was 
available on date of notification, severe / non-severe categorization, and reaction 
group categorization using the MedDRA dictionary of terms. These were then 
divided by the authors in severe hepatobiliary, other severe and non-severe reac-
tions and grouped in years.
Outcomes
The primary outcome was the number of nimesulide containing products DDD 
dispensed per month. Secondary outcomes were the number of adverse reactions 
to nimesulide containing products, and the variation of nimesulide prescriptions 
originating in each prescribing site category.
Statistical methods
No sample size calculation was made, as data for the whole NHS was available. 
Data was analyzed using a segmented regression multivariable model to test for 
changes in level and/or trend in nimesulide dispensing in the pre- and post-inter-
vention periods.8 Regulatory and concurrent factors were tested as predictors of 
nimesulide dispensing. Discrete events occurring less than six months apart were 
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modeled as the same intervention. For each intervention, we included variables 
for the event, time after the event and square time after the event to account for 
non-linear effects. Total NSAID use, Google search trends, and influenza-like ill-
ness incidence were treated as continuous variables.
The model was tested for autocorrelation using the Durbin-Watson statistic, 
introducing a Prais-Winsten correction if needed. Seasonality was modeled by in-
troducing a dummy variable for each calendar month.9 Only factors with p values 
<0.05 were retained in the final model. Analyses were done using SPSS Statistics 
software version 23.0 (IBM Corp.) using the AREG command.
Ethical approval and funding
This study was approved by the Ethics Committee of NOVA Medical School. 
No data on individual patients, physicians or health care practices was collected. 
There was no external funding.
Results
Interruptions
The search in the European Commission, EMA and INFARMED’s websites 
found 46 relevant results, these are summarized in figure 1 - panel A. Concurrent 
factors are shown in figure 1 – panel B. A detailed description of the events time-
line and additional references are given in the supplementary appendix.
Interruption 1 occurred between May 2007 and March 2008. It began with the 
withdrawal from market in Ireland,4 which led EMA to initiate an article 107 pro-
cedure to review nimesulide safety.10 This was reported by EMA and Infarmed, 
frequently in general media and associated with a peak in Google searches. Sub-
sequently, the CHMP recommended restrictions on marketing authorizations for 
nimesulide, which was again picked up by the media. However, the European 
Commission did not endorse the recommendations.
Interruption 2 began in October 2009 and ended in April 2010. During this peri-
od the European Commission reached a final decision recommending restrictions 
on nimesulide use, and mandated the CHMP to conduct a wider safety review in 
an article 31 procedure.11
Interruption 3 was the period between December 2010 and April 2012. A corri-
gendum was issued for Portugal regarding the article 107 decision.12 Summary of 
product characteristics and package leaflets were changed, a direct healthcare pro-
fessional communication was sent, and packages over 30 units were withdrawn 
in accordance with this decision. Shortly after that, the CHMP announced its 
opinion regarding the article 31 procedure, which was endorsed by the European 
Commission.13 Changes to the summary of product characteristics and package 
leaflets were implemented in Portugal, but there was no evidence of a second di-




Total NSAID use, Google trends searches and influenza-like illness activity are 
shown in figure 1 – panel B. NSAIDs entering or exiting the Portuguese market 
are shown in the appendix. None met the threshold for a peak market share of at 
least 5%.
Impact on nimesulide use
The evolution of nimesulide dispensing with the fitted segmented regression 
model is shown in figure 1 – panel C. The regression model variables are detailed in 
table 1. At the beginning of the series, nimesulide use was declining. Interruption 
1 was associated with a decrease in level and a deceleration in the declining trend. 
Figure 1 (oposite) - Timeline of interruptions and global nimesulide use. Panel 
A: regulatory authorities; CHMP - Committee for Medicinal Products for Human 
Use, DHPC - Direct Healthcare Professional Communication, EC - European 
Commission, EMA - European Medicines Agency, INFARMED - Portuguese 
National Authority of Medicines and Health Products, Q&A - Questions and 
Answers, SPC - Summary of Product Characteristics. Panel B: cofactors; non-ste-
roidal anti-inflammatory drugs dispensing (solid line), Google trends (dashed 
line), influenza-like illness (dotted line), and news (dark grey bars). Panel C: 
nimesulide dispensing in defined daily doses (gray line) with fitted segmented 
regression model (black line); gaps in the model represent periods when a signifi-
cant interruption occurred. Vertical light grey bars across panels A to C represent 
interruption periods.
Table 1 - Segmented regression model for global nimesulide dispensing. Model 
R2 = 0.992. 
Variable Effect estimate (95% CI) p value
Intercept  1 157 360.4 (851 947.0, 1 462 773.8) <0.001
Time since series start*  -12 246.7 (-16 022.9, -8 470.6) <0.001
Interruption 1†  -824 729.9 (-960 994.1, -688 465.7) <0.001
Time after interruption 1 squared†  55.5 (24.9, 86.1) 0.001
Interruption 3‡  -449 018.4 (-566 298.1, -331 738.7) <0.001
Influenza before interruption 3 
(cases / 100 000)
 1 685.0 (752.8, 2 617.3) 0.001
Total NSAID dispensing (DDD)  0.137 (0.115, 0.158) <0.001
January  108.621,4 (43 000.2, 174 242.6) 0.001
February  66 263.8 (4 168.5, 128 359.1) 0.037
December  72 937.4 (10 040.1, 135 834.7) 0.024
* January 2006 = 1. † April 2008 = 1. ‡ Mai 2012 = 1. DDD – defined daily doses.
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Interruption 2 did not show a significant effect. Interruption 3 was associated with 
a decrease in level, but no change in trend. Nimesulide dispensing declined from 
a monthly average of 3.1 million DDD before interruption 1, to 1.6 million from 
interruption 1 to interruption 3 (-45.3%) and to 0.5 million after interruption 3 
(-67.9% than in the previous period). Influenza-like illness incidence showed a 
positive association with nimesulide prescription before it was introduced as a 
contra-indication (interruption 3), but not after the changes.
Figure 2 shows the evolution in dispensing of the five oral NSAIDs with the 
highest market share in 2006 over the study period. The decrease in nimesulide 
during this period coincided with increased use of etoricoxib, ibuprofen and 
naproxen, decreased use of diclofenac, and globally decreasing NSAID sales.
Figure 3 shows nimesulide dispensing by prescribing site between 2008 and 
2015 and table 2 the respective segmented regression models. All sites showed 
a trend towards declining nimesulide use after interruption 1 (at the start of the 
Figure 2 – Dispensing of the five NSAIDs with highest market share in the Por-
tuguese market during the 2006-2015 period. Light grey vertical bars show the 
interruptions periods.
Figure 3 (oposite) – Nimesulide dispensing by prescribing site category. Panel 
A – National Health Service primary care. Panel B – National Health Service hos-
pitals. Panel C – Other prescribing sites. All panels show nimesulide dispensing 
in defined daily doses (gray line) with fitted segmented regression model (black 
line). Vertical grey bars across panels A to C represent interruption periods.
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Table 2 - Segmented regression model for nimesulide dispensing by prescribing site. 
Variable Effect estimate (95% CI) p value
NHS Primary Care – model R2=0.996
Intercept  253 373.6 (156 554.0, 350 193.1) <0.001
Time after interruption 1*  -11 219.8 (-14 890.0, -7 549.6) <0.001
Time after interruption 1 squared*  172.4 (70.1, 274.6) 0.001
Interruption 3†  -465 208.0 (-568 833.7, -361 582.2) <0.001
Time after interruption 3†  -7 958.8 (-14 819.1, -1 098.5) 0.024
Time after interruption 3 squared†  -148.4 (-264.3, -32.6) 0.013
Influenza before interruption 3 (cases/100 000)  747.5 (455.8, 1 039.2) <0.001
Total NSAID dispensing from NHS primary care (DDD)  0.102 (0.090, 0.115) <0.001
May  -19 157.2 (-35 945.2, -2 369.3) 0.026
July  -18 648.3 (-35 546.1, -1 750.5) 0.031
October  -35 363.4 (-53 396.7, -17 330.1) <0.001
November  -27 622.8 -44 659.8, -10 585.9) 0.002
NHS Hospitals – model R2=0.996
Intercept  86 992.3 (70 194.2, 103 790.4) <0.001
Time after interruption 1*  -1 418.4 (-1 642.7, -1 194.1) <0.001
Time after interruption 1 squared*  11.1 (5.6, 16.7) <0.001
Interruption 3†  -45 989.7 (-51 519.6, -40 459.8) <0.001
Time after interruption 3†  -946.9 (-1 573.3, -320.5) 0.004
Influenza before interruption 3 (cases/100 000)  115.0 (74.1, 155.8) <0.001
Influenza after interruption 3 (cases/100 000)  66.2 (30.9, 101.5) <0.001
Total NSAID dispensing from NHS hospitals (DDD)  0.045 (0.035, 0.055) <0.001
March  3 246.3 (346.8, 6 145.8) 0.029
October  2 591.5 (28.5, 5 154.5) 0.048
December  2 970.9 (242.0, 5 699.9) 0.033
Other prescribers – model R2=0.996
Intercept  338 779.751 (298 372.2, 379 187.3) <0.001
Time after interruption 1*  -1 939.9 (-2 283.6, -1 596.2) <0.001
Intervention 3†  -222 969.0 (-241 456.0, -204 481.9) <0.001
Influenza before indication removed (cases/100 000)  468.5 (316.2, 620.7) <0.001
Influenza after indication removed (cases/100 000)  232.8 (56.6, 409.0) 0.010
Total NSAID dispensing from other prescribers (DDD)  0.075 (0.062, 0.088) <0.001
January  26 465.9 (10 241.0, 42 690.8) 0.002
June  -26 059.6 (-37 871.7, -14 247.5) <0.001
August  -30 255.8 (-43 182.2, -17 329.4) <0.001
* April 2008 = 1. † May 2012 = 1.
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series), albeit decelerating in Portuguese NHS primary care and NHS hospitals. 
Interruption 2 was not associated with significant changes. Interruption 3 was 
associated with a level drop across all site categories, and an acceleration of the 
decline in NHS primary care and NHS hospitals. The average monthly dispens-
ing comparing the period between interruptions 1 and 3 and after interruption 
3 declined 75% in NHS primary care, 62.9% in NHS hospitals, 57.1% in other 
prescribing sites. Influenza-like illness incidence was associated with increased 
nimesulide use prior to it being introduced as a contraindication in all prescrib-
ing site categories. After that, the association continued only in NHS hospitals 
and other prescribing sites, although the absolute increase was lower than before 
interruption 3 (table 2).
Nimesulide adverse drug reactions
The number of reported adverse drug reactions per year is shown in figure 4. 
There was no apparent global trend. Severe hepatic reactions were rare, with two 
being reported in 2007 and two in 2015.
Discussion
Summary of main results
A high-profile removal from market in one member-state and subsequent com-
plex risk minimization strategies reduced nimesulide dispensing, but did not lead 
Figure 4 – Number of adverse drug reactions to nimesulide notified per year 
compared with the number of defined daily doses dispensed per 100.000 popula-
tion aged 12 years or older. Black: severe hepatic events. Gray: severe non-hepatic 
events. White: non-severe events.
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to any noticeable change in the number of reported adverse events. The number of 
interventions between 2006 and 2015 and the short intervals between them made 
it impossible to isolate which components of the risk minimization strategy were 
most effective.
Interpretation of the results
The largest absolute decline in nimesulide use occurred with interruption 1, 
when a referral procedure was triggered, generating safety alerts by EMA and 
INFARMED that were echoed by general media and despite no final decision had 
been made. Dispensing decreased most between May and June 2007, therefore, we 
hypothesize that the major driver for the effect of interruption 1 was the high-pro-
file removal from market in Ireland. Media coverage has been shown before to 
influence patients.14-16 Since there were no apparent changes in the prescriptions 
of the other NSAIDs, this strengthens the inference of causality between the 
high-profile market removal and the reduction in nimesulide dispensing.
Interruption 2 was not associated with significant changes in nimesulide dis-
pensing. As this intervention consisted of actions by the European Commission 
and EMA not yet implemented in Portugal, it is probable that physicians, phar-
macists and the population were unaware of them. This suggests that, to be more 
effective, EMA’s recommendations need to be approved quicker by the European 
Commission, to have their actions trickling down to member states.
A new drop in level was seen with interruption 3. There was no change in trend 
globally, but the rate of decline accelerated in NHS primary care and NHS hos-
pitals. Interruption 3 spanned the implementation of restrictions determined by 
both the first and second review procedures, as measures from the first decision 
were delayed in Portugal until a corrigendum was issued. The largest decline in 
nimesulide use happened between March and June 2011, when packages with 
more than 30 units were withdrawn from market and the direct healthcare pro-
fessional communication was sent. A smaller decrease was registered between 
January and April 2012, coinciding with the conclusion of second safety review, 
national changes in the summary of product characteristics, a safety alert and 
some media reports. Although mandated in the article 31 decision, we could not 
find evidence for a second direct healthcare professional communication, which 
could have reduced the impact of the new restrictions. A systematic review found 
similar effects of direct healthcare professional communications, black box warn-
ings and public health advisories, but did not present specific results for changes 
in the number of units per package.6 Nevertheless, causality between regulatory 
interventions and nimesulide dispensing is not as strong as in interruption 1, as we 
also observed changes in the dispensing of other NSAIDs following interruption 
3. This suggests that other events could have contributed to changes in the overall 
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pattern of NSAID prescribing in Portugal. One possibility, is the publication of 
several articles raising concerns about the cardiovascular safety of NSAIDs. 17
Interruption 3 was associated with a larger relative reduction in nimesulide use 
among NHS primary care clinicians than physicians in hospitals and in other pre-
scribing sites (mainly doctors in private practices). NHS primary care was also the 
only site category where the association with influenza-like illness incidence did 
not remain significant after it was introduced as a contraindication. This suggests 
changes in prescribing behavior in line with recommendations were more com-
mon among NHS primary care physicians. The possibility that regulatory mea-
sures have different results depending on the type of healthcare provider should 
be further researched.
Contrary to what was expected from the dramatic decline in nimesulide dispens-
ing, there was no reduction in the number of recorded nimesulide adverse events. 
The number of adverse events per year is small, but it is worrisome that severe he-
patic adverse events were not avoided by the decrease in nimesulide use, as shown 
by the two cases notified in 2015. One possible explanation is an increase in the 
overall number of adverse event notifications. This was shown to be the case in at 
least one Portuguese pharmacovigilance unit.18 It is also possible that increased 
awareness of the adverse reactions to nimesulide caused more notifications spe-
cifically to this drug and masked any reductions associated with decreased use.19 
Decreases in drug use without reduction in clinical adverse outcomes have been 
documented before,20 but positive effects have also been observed.21
Strengths and limitations
We used an interrupted time-series analysis, one of the most robust study designs 
when it is not feasible to have a control group.22,23 We believe that we have high 
quality data on dispensing since these data are routinely collected for reimburse-
ment purposes. We attempted to assess the clinical impact of the risk minimiza-
tion strategies by looking at the number of reported adverse drug reactions. We 
did a thorough search for other events that may have influenced the dispensing of 
nimesulide and included them in our analysis. Total NSAID dispensing was used 
to account for historical and instrumentation biases.
There are four main limitations. First, not enough temporal separation existed 
between events to examine each individually, and there could have been complex 
interactions between them. Sequential events could have added to, consolidated 
or decreased the effectiveness of previous events. Second, the small number of 
severe adverse drug reactions limits conclusions about clinical impact of risk min-
imization strategies. Third, diagnosis data was not available, which precludes us 
from knowing if prescribers stopped using nimesulide in patients in whom it was 
no longer recommended. We attempted to analyze ecological data to infer about 
use in influenza-like illness, but could not assess other conditions. Finally, our 
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study is unable to clarify how individual doctors responded to regulatory inter-
ventions, as we collected aggregate data. Nimesulide was the sixth highest selling 
oral NSAID in 2015, which is higher than would be expected for a drug limited 
to second line. Given the observed increases associated with influenza in NHS 
hospitals and other prescribing sites, we hypothesize that some physicians are not 
adhering to the contraindication in patients with fever or flu like symptoms. This 
merits further research with individually collected data.
Conclusion
Nimesulide use in Portugal decreased significantly after two complex interven-
tions including communication of safety evaluation procedures by regulatory 
agencies, media coverage, changes to the summary of product characteristics and 
patient leaflet, withdrawal of large packet sizes, and a direct healthcare profes-
sional communication. The decrease was highest for primary care prescribers. 
However, this was not associated with a decrease in the number of adverse drug 
reactions reported. Further research is needed to be able to discern the effect of 
each intervention individually and how contiguous interventions interact to pro-
duce changes in drug use.
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Effect of European Medicines Agency’s Regulatory Measures on 
Nimesulide Utilization in Portugal – Appendix
Timeline of events
When the Irish Medicines Board suspended marketing authorizations for nime-
sulide in May 2007,1 EMA started an article 107 procedure to review nimesulide’s 
safety. This was publicly reported by both EMA and INFARMED,2-4 and in 40 
news pieces from 20 media sources. It coincided with a peak in Google searches. 
In June and July, the procedure was reported in other public documents by EMA5,6 
and INFARMED7 and in one magazine. In September, the CHMP recommended 
that marketing authorizations for nimesulide should be restricted. EMA and IN-
FARMED informed health professionals and the public,8-13 and eight news from 
five sources were found. However, the European Commission did not endorse the 
recommendations and asked CHMP to reconsider its opinion in February 2008.14 
This was noted in an EMA press release in March.15 Thus, the period between May 
2007 and March 2008 was considered interruption 1.
In October 2009, the European Commission reached a final decision on the arti-
cle 107 procedure.16 The recommended restrictions are detailed in table A1.17 The 
CHMP was mandated to conduct a wider review of nimesulide’s benefits and risks 
under an article 31 procedure,1 which was reported to begin in February 2010.18,19 
The decision on the article 107 procedure had a corrigendum published by the 
European Commission in March20 and by EMA in April.21 Interruption 2 spanned 
the events from October 2009 to April 2010.
The summary of product characteristics and package leaflets changes in Portugal 
began in December 2010 and were concluded in March 2011. In January 2011, 
two news pieces reported on Prescrire’s decision to place nimesulide in its avoid-
ance list. In March, the European Commission published a second corrigendum 
on the article 107 procedure for Portugal.22 A direct healthcare professional com-
munication was sent also in March.23 Packages over 30 units or with the previous 
leaflet version could not be dispensed after June 20 2011.24 The CHMP issued 
its opinion on the article 31 referral in June and this was divulged by EMA and 
INFARMED.25-27 Nimesulide safety was mentioned by EMA again in July,28 and 
by INFARMED in October.29 The European Commission decided the article 31 
procedure in January 2012, endorsing the CHMP’s recommendations.30 Decision 
details are described in table A1.31 INFARMED published information regarding 
this decision in February and March and EMA in April 2012.32-34 The new restric-
tions were reported in the news once in January and in four instances in February. 
Changes to the summary of product characteristics and package leaflets began in 
February and ended in April 2012. We were unable to find any record of a direct 
healthcare professional communication sent in Portugal concerning this decision. 
Interruption 3 was thus defined as the period between December 2010 and April 
2012.
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Table A1 - Regulatory decisions regarding nimesulide.
Article 107 referral – 16 October 200917
EMA recommendations
- The decision to prescribe nimesulide should be based on an assessment of the individ-
ual patient’s overall risks.
- The minimum effective dose should be used for the shortest duration to reduce the 
undesirable effects.
- The maximum duration of a treatment course with nimesulide was limited to 15 days. 
Therefore, pack sizes above 30 units would be withdrawn and not authorized.
- New contraindications:
. Concomitant exposure to other potentially hepatotoxic substances;
. Alcoholism, drug addiction;
. Patients with fever and/or flu-like symptoms.
- New special warnings
. Patients receiving nimesulide who develop fever and/or flu-like symptoms should 
discontinue treatment.
- Maintenance of the Marketing Authorisations required: 
. Submission of 6-monthly Periodic Safety Update Reports with a specific overview of 
hepatic reactions;
. Conduct of a pre-clinical study on identification of reactive metabolites and protein 
adduct information.
. Conduct a review of epidemiological data to review the risk of hepatic damage from 
nimesulide.
. Implementation of a retrospective cohort study, followed by a prospective cohort 
study in transplant centers addressing the relative risk of nimesulide in respect to other 
NSAIDs to cause severe hepatic reactions;
. Update of Risk Management Plan;
. Information of healthcare professional via a ‘Direct Healthcare Professional Commu-
nication’ letter;
. Evaluate the effectiveness of risk communication on nimesulide;
. Perform a survey to clarify the modes of use of nimesulide in selected EU Member 
States to identify potential misuse.
Additional restrictions by the European Commission
- Limit the prescription of nimesulide to second line treatment;
- Introduce a clear obligation upon the marketing authorization holder to inform 
healthcare professionals of the safety risks associated with this product
Article 31 referral – 23 January 201231
- Nimesulide use should be restricted to acute conditions only (treatment of acute pain 
and primary dysmenorrhea)
- The risk-benefit balance is no longer favorable in symptomatic treatment of painful 
osteoarthritis, and the indication is to be removed.
- Market authorization holders should inform healthcare professionals via a Direct 
Healthcare Professional Communication.
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Sales of non-steroidal anti-inflammatory drugs
Tables A2 and A3 detail changes in the Portuguese NSAID market during the 
study period.
Table A2 - Non-steroidal anti-inflammatory drugs entering or leaving the Portu-
guese market between January 2006 and December 2015.







Lumiracoxib June 2007 December 2008 August 2007 308.8 2.38
Azapropazone Before 2006 January 2008 January 2006 78.5 0.52
Sulindac Before 2006 September 2009 June 2006 12.4 0.09
Niflumic acid Before 2006 August 2013 October 2008 4.2 0.03
Fenbufen Before 2006 December 2010 December 2006 2.8 0.02
Tiaprofenic acid Before 2006 February 2009 January 2006 2.8 0.02
Phenylbutazone Before 2006 May 2010 January 2006 0.1 0.001
Table A3 – Top 10 NSAIDs in the Portuguese market in 2006 and 2015
Substance 2006 market share (%) 2015 market share (%) Difference (%)
Nimesulide 21.5 4.2 -17.2
Diclofenac 17.2 15.9 -1.4
Etoricoxib 10.7 15.3 +4.6
Ibuprofen 9.9 21.6 +11.7
Naproxen 8.5 17.4 +8.9
Meloxicam 7.6 3.1 -4.6
Celecoxib 5.3 4.2 -1.1
Piroxicam 4.5 1.5 -2.9
Aceclofenac 3.9 2.9 -0.9
Etodolac 2.1 8.0 +6.0
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Abstract
Background: The Portuguese National Health Directorate has issued clinical 
practice guidelines on prescription of anti-inflammatory drugs, acid suppressive 
therapy, and antiplatelets. However, their effectiveness in changing actual practice 
is unknown.
Methods: The study will compare the effectiveness of educational outreach visits 
regarding the improvement of compliance with clinical guidelines in primary care 
against usual dissemination strategies. A cost-benefit analysis will also be con-
ducted. We will carry out a parallel, open, superiority, randomized trial directed 
to primary care physicians. Physicians will be recruited and allocated at a clus-
ter-level (primary care unit) by minimization. Data will be analyzed at the physi-
cian level. Primary care units will be eligible if they use electronic prescribing and 
have at least four physicians willing to participate. Physicians in intervention units 
will be offered individual educational outreach visits (one for each guideline) at 
their workplace during a six-month period. Physicians in the control group will 
be offered a single unrelated group training session. Primary outcomes will be the 
proportion of cyclooxygenase-2 inhibitors prescribed in the anti-inflammatory 
class, and the proportion of omeprazole in the proton pump inhibitors class at 18 
months post-intervention. Prescription data will be collected from the regional 
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pharmacy claims database. We estimated a sample size of 110 physicians in each 
group, corresponding to 19 clusters with a mean size of 6 physicians. Outcome 
collection and data analysis will be blinded to allocation, but due to the nature of 
the intervention, physicians and detailers cannot be blinded.
Discussion: This trial will attempt to address unresolved issues in the literature, 
namely, long term persistence of effect, the importance of sequential visits in an 
outreach program, and cost issues. If successful, this trial may be the cornerstone 





Educational outreach, Academic detailing, Guideline adherence, Family prac-
tice, Drug utilization, Program evaluation, Cost-benefit analysis
Background
Patients often do not receive treatment that is supported by best evidence. This 
includes both failure to provide treatment proven to be cost-effective and provi-
sion of care that is unnecessary or harmful [1]. High quality clinical guidelines 
synthesize the current best knowledge, make transparent recommendations for 
current best practice, and can improve the quality of care [2]. However, it is rec-
ognized that guidelines alone are insufficient to change clinical practice and that 
implementation strategies are required [3-5]. 
There is a wide range of such strategies but limited evidence to assess their 
comparative effectiveness, as there are few head-to-head trials. Some overviews 
of systematic reviews provide narrative synthesis of the evidence supporting the 
different interventions [1,4,6,7]. However, primary studies are too diverse and 
heterogeneous to allow for more robust methods of indirect comparison. The 
Cochrane Collaboration Effective Practice and Organization of Care Group has 
assessed several strategies through high quality systematic reviews. Printed ed-
ucational materials have no apparent effect on processes of care, while educa-
tional meetings, educational outreach, local opinion leaders, audit and feedback, 
computerized reminders, and tailored interventions are associated with small but 
clinically significant improvements [8-14]. 
Educational outreach interventions are personal visits by a trained individual 
(hereafter named as detailer) to health professionals in their own settings [10]. 
This detailer is usually a healthcare professional (physician, nurse or pharmacist) 
with special training in communication skills. He or she presents educational con-
tents prepared by an independent organization (such as a university) to an indi-
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vidual physician. The Cochrane Review estimates a small but consistent effect on 
prescription improvement (median 4.8%, interquartile range 3.0% to 6.5%) [10].
Local context
In Portugal, healthcare is provided by two overlapping systems: a publicly fund-
ed National Health Service (NHS), and voluntary private and public health insur-
ance. The NHS has universal coverage, and 20% of the population has additional 
insurance coverage [15]. Thus, most primary care is provided by the NHS.
NHS primary care physicians work in units typically with 4 to 12 doctors, along 
with nurses and secretaries. On average, each family physician cares for about 
1,700 patients. The NHS distinguishes two types of primary care units. The default 
one is the ‘personalized care units’ model, in which professionals receive a fixed 
salary. The other model is the ‘family health units’, which enjoy greater functional 
and organizational autonomy [16]. ‘Family health units’ start as type-A units, in 
which professionals receive a fixed salary as in the former model. If these A units 
meet quality indicators targets, they become type-B units, in which health profes-
sionals have a mixed payment scheme that includes salary, capitation, and pay for 
performance.
Within this context, prescription drugs have a variable patient co-payment, 
depending on their therapeutic value [15]. Electronic prescribing has been man-
datory for all NHS reimbursed drugs since 2012. All prescription information is 
collected centrally by NHS [17].
National prescribing guidelines are commissioned by the National Health Di-
rectorate (a government agency) to academic researchers and key opinion lead-
ers. This agency also monitors the quality indicators set in each of its guidelines 
[18,19]. These guidelines are published in the agency’s website (www.dgs.pt). 
Health professionals are expected to visit this website regularly to keep up-to-date 
with the latest guidelines. Therefore, this study will not have a group of naive phy-
sicians unexposed to guidelines. For this reason, the control group is composed of 
physicians exposed to passive guideline dissemination (the usual implementation 
strategy).
Choice of design
The design is a parallel, open, cluster, superiority randomized trial with a 1:1 
allocation ratio. This study will assess the effect of educational outreach visits on 
physician compliance with prescription guidelines. Although the intervention is 
targeted at individual physicians, there is a risk of contamination if the random-
ization occurs at the individual level. This is because physicians in the same prac-
tice might be influenced by intervention subjects (e.g., by raising awareness of the 
topics, through discussion of difficult patient cases, or by sharing visit content). 
Therefore, a cluster-randomized design is appropriate. Also, the costs (e.g., travel 
expenses, salary costs of the detailers) in a cluster-randomized design will better 
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approach the real costs of this intervention if implemented as a public health pro-
gram. Therefore, to minimize contamination and for practical reasons, the unit 
of allocation will be the primary care unit. The unit of analysis will be the family 
physician.
Aim and objectives
This trial aims to assess whether educational outreach visits are superior to 
usual implementation of guidelines regarding the reduction of inappropriate 
prescribing. The primary outcomes will be the long-term (18 months) effects in 
the prescription of cyclooxygenase-2 (COX-2) inhibitors, and omeprazole, by 
family physicians. The secondary outcomes will be the short (1 month) and me-
dium-term (6 months) effects of educational outreach visits in the prescription of 
these two drug classes. Other secondary endpoints will be the short, medium and 
long-term effects of educational outreach visits in the prescription of clopidogrel. 
Finally, the trial will determine the cost-benefit of educational outreach visits.
Methods
The study will be a parallel, cluster-randomized controlled trial comparing ed-
ucational outreach visits with usual guideline implementation. Besides the stan-
dard description below, we also provide a summary of the intervention, a PaT 
plot, and a cascade diagram in Additional file 1 [20,21]. This protocol was written 
in accordance with the Consolidated Standards of Reporting Trials (CONSORT) 
statement - Additional file 2.
Participants and setting
The trial will recruit family physicians employed in primary care units of the 
National Health Service of the Lisbon region, Portugal. This region comprises 
over 3.5 million patients. A primary care unit (the cluster) will be eligible if it has 
at least four family physicians (which represent about 6,800 patients). Physicians 
that are planning to retire within two years, and those without an assigned or still 
building (far from the average number of patients) patient list will be excluded. At 
least four family physicians in each unit have to be willing to participate in order 
for the unit to be included in the trial.
The expected participant flow is described in Figure 1. The research authors will 
meet with the coordinators of each unit, briefly explaining the protocol and ex-
tending them an invitation to participate. The coordinators will be asked to share 
trial information with other physicians in their units. The researchers will then 
contact and screen willing primary care units until the target number is met. The 
enrollment period will last six months. There will be no financial incentive for 
participation.
Baseline data will be collected from the primary care units (number of family 
physicians, type of primary care unit, urban versus rural setting, baseline pre-
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scription of COX-2 inhibitors, baseline prescription of omeprazole) and from the 
family physicians (age, gender, number of years of practice after vocational train-
ing, currently training residents). Participating physicians will agree to schedule 
three educational outreach visits, one for each guideline.
Allocation to intervention and blinding
Clusters will be enrolled and allocated randomly. To achieve a good balance 
regarding baseline characteristics that can influence the outcome, the allocation 
sequence will be determined by minimization [22]. This stratified randomization 
method will balance the control and intervention groups for number of physi-
cians (4 or 5, 6 or 7, 8 to 12), median baseline prescription of COX-2 inhibitors 
(above or below the regional median), median baseline prescription of omepra-
zole (above or below the regional median), proportion of physicians with fewer 
than 10 years of practice after completing vocational training (above or below 
Figure 1 - Flow of participants.
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50%), and type of primary care unit (family health unit or personalized care unit). 
All physicians sending the consent statement before the cluster allocation will be 
included in the study.
The sequence of intervention visits for each unit will be determined by simple 
randomization.
Allocation concealment will be ensured by the following procedures: the trial 
manager (hired and not part of the authors research team) will assign a sequential 
number to each unit as participation forms are received; only anonymized data 
about participating units will be sent to the trial statistician (sequential number 
and minimization variables); data will be sent in two batches, one for each half 
of all units; the sequence of visits will be determined using the random sequence 
generator from Random.org (http://www.random.org/sequences/); the statisti-
cian will blindly allocate units to each trial arm using minimization and return 
allocation information to the trial manager.
Due to the nature of the intervention, neither family physicians nor detailers can 
be blinded. Outcomes are routinely collected by the regional health administra-
tion independently of the researchers or the trial and will only be sent to research-
ers after the intervention has ended. Upon receiving prescription data, the trial 
manager will generate a random code (using http://www.randomcodegenerator.
com) to designate intervention and control units and another code for the order 
of the visits. Data analysts (the trial statistician plus one of the members of the 
research team) will receive a file with these codes, ensuring they will be blinded to 
group and visit sequence allocation until all analyses are completed.
Intervention and comparison
Physicians in units randomized to the intervention will have three educational 
outreach visits during a six-month period. These visits will promote the imple-
mentation of governmental guidelines on the prescription of the following agents: 
non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors, acid se-
cretion modifiers, and antiplatelets [23-25]. The outcomes for the trial were cho-
sen according to the main key-message from each guideline. For NSAIDs, COX-2 
inhibitors should be prescribed only in patients with increased gastrointestinal 
risk who do not tolerate a classic NSAID associated with a gastroprotective agent; 
for acid secretion modifiers, all proton pump inhibitors are equivalent in effec-
tiveness, so omeprazole should be used in most patients as it is the least expensive; 
for antiplatelets, there is no benefit of maintaining long term clopidogrel after a 
myocardial infarction, acute coronary syndrome, or percutaneous coronary in-
tervention.
During each 15- to 20-minute visit, an academic detailer will promote one of the 
guidelines to a family doctor (up to three physicians may be present in each visit if 
they wish to, but one-to-one visits will be preferred and encouraged). The detailer 
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will also distribute a point of care summary highlighting the main messages. The 
team of academic detailers will be as following: three members of the steering 
committee (two family physicians and one academic pharmacologist), three fam-
ily physicians, and nine family medicine residents in the fourth and final year of 
their specialty training. The three members of the steering committee completed 
training in the methodology of academic detailing with the National Resource 
Center for Academic Detailing (Boston, MA). The other 12 detailers were trained 
locally by this steering committee, with pretraining study assignments, and 12 
hours of face-to-face training that included the principles of academic detailing, 
role-playing, video-recording and feedback, discussion of the scientific content of 
each guideline, and knowledge assessment. To ensure consistency, the contents of 
each visit (structure, guideline features to highlight, and written materials) have 
been prepared in advance by the steering committee and were used in the training 
sessions. Whenever possible, a single detailer will perform all three visits to the 
same physician. The definition and methodology of educational outreach visits 
has been published elsewhere [10,26].
Usual guideline implementation consists of passive dissemination by their pub-
lication on the National Health Directorate’s website. Physicians in units random-
ized to the control group will be offered an unrelated training session (coding 
with the International Classification of Primary Care, second edition) as a token 
of good will for participating in the trial.
This trial has a pragmatic purpose. To improve adherence to the educational out-
reach visits, the Regional Health Administration will allow family physicians to 
use a patient visit slot (15 to 20 minutes) for each of the three visits, but physicians 
may also choose to have the visit before or after their regular hours. The first visit 
will be scheduled by the trial manager contacting the target family physician. Sub-
sequent visits will be scheduled directly between the detailer and the target family 
physician. Also to improve adherence, participating physicians will be asked to al-
low us to use their personal phone numbers and emails. We will use these to send 
them a reminder of the visit two days before it is scheduled. Rescheduling the visit 
will be allowed up to the day before it is scheduled to take place; if the physician is 
unable to attend the visit but cannot warn the detailer beforehand, no additional 
efforts will be made to reschedule that visit (i.e., the program will continue with 
the next guideline). The intervention will be discontinued at physician request or 
if the physician changes workplace. Participating physicians will not be prohibited 
from receiving any other interventions during the trial.
Outcomes
Primary and secondary outcomes
There are two primary outcomes, measured at the physician’s level. One is the 
proportion of COX-2 inhibitors (anatomical therapeutic classification [ATC] 
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M01AH) prescribed within the entire NSAID class (ATC M01A) in defined daily 
doses 18 months after the intervention. The other is the proportion of omeprazole 
(ATC A02BC01) within the entire proton pump inhibitors class (ATC A02BC) in 
defined daily doses 18 months after the intervention.
There are seven secondary outcomes, also measured at the physician’s level: the 
proportion of COX-2 inhibitors within the NSAID class at one and six months; 
the proportion of omeprazole within the proton pump inhibitors class at one and 
six months; and the number of defined daily doses of clopidogrel prescribed per 
1,000 registered patients at 1, 6 and 18 months. The proportion of clopidogrel 
(ATC B01AC04) within the platelet aggregation inhibitors (ATC B01AC) was not 
selected as an outcome because the most commonly used drug in that class is 
acetylsalicylic acid (ATC B01AC06). This drug is generally sold over the counter, 
and no reliable data of its consumption exists.
Timing of outcome collection
Unlike a randomized controlled trial for a drug, we do not expect the interven-
tion to be delivered immediately after allocation. This is because there are a limited 
number of detailers, and their time for visits is also limited (as they themselves are 
practicing physicians). Plus, family physicians’ availability to receive visits from 
these detailers is also constrained by their heavy workload. These constraints will 
prevent us from delivering the intervention to all physicians in a short period 
(e.g., less than one month). We plan to deliver the full intervention to all physi-
cians in the experimental group over a period of six months. For each guideline, 
we will seek to visit all the physicians belonging to the same cluster in the shortest 
time possible, to limit contamination within clusters. This will cause the gap be-
tween allocation and intervention dates to vary depending on the participating 
unit. Thus, if we assess the outcome at a fixed time following randomization, par-
ticipating units will have different follow-up times after the intervention, and as a 
result the observed intervention effect will be unreliable. Moreover, since we will 
have three visits for each physician, there will also be differences in the time of 
intervention between guidelines. For these reasons, outcomes will be measured 
from specific intervention dates rather than from the general allocation date. This 
will provide more reliable data about the efficacy of the intervention.
Using the intervention dates poses a problem for the control group, for whom 
these do not exist. If we were to measure outcomes from the allocation date, there 
would be up to a six-month time gap compared with intervention units. In this 
relatively long interval, other factors influencing prescription of the study drugs 
could arise (e.g., new research or guidelines being published, changes in drug 
policy in the Portuguese NHS, seasonal trends of prescription of NSAIDs, etc.). 
We will address this problem by randomizing the dates from which we measure 
outcomes for each guideline among control units. This will distribute control 
units along the intervention period, making them more comparable to the exper-
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imental group. This will be done by selecting a random month falling within the 
first and last months of the visits in the intervention group. The trial statistician 
will blindly assign a random month for each guideline in every control unit after 
the final visit in the intervention group is made and before outcomes are collect-
ed. Outcomes will be measured using the same monthly prescription data for all 
physicians within a given cluster.
Cost analysis
Global prescription spending will be defined as the sum of the cost of all drug 
prescriptions of NSAIDs (ATC M01A), acid suppressive therapy (proton pump 
inhibitors ATC A02BC and their alternatives: H2-receptor antagonists ATC 
A02BA, antacids ATC A02A, misoprostol ATC A02BB01, and sucralfate ATC 
A02BX02), and antiplatelets (ATC B01AC), up to 18 months after the interven-
tion. These costs will be compared with the amount spent training the detailers, 
preparing and printing educational materials, travel expenses to intervention 
units, payment of detailers, program coordination, and physician time spent with 
a detailer rather than with a patient. Costs will be analyzed from the point of 
view of an educational outreach program rather than from conducting research. 
Therefore, research related costs (such as researcher time for data collection and 
analysis) will not be considered. Similarly, the unrelated training session offered to 
the control units will not be accounted for because it is only intended to improve 
recruitment and would not be necessary for the implementation of an educational 
outreach program.
Data collection
Researchers will have access to prescription data through a data monitoring 
system operated by the Regional Health Administration. Data will be collected 
and provided by employees from this Administration according to researcher 
defined specifications. Importantly, researchers will not be directly involved in 
data collection. This information arrives with a two-month delay from the date 
the prescription is dispensed. The prescription information contained there can 
be either for acute conditions – single prescriptions with up to two packages to be 
dispensed within 30 days; or for chronic usage - three identical prescriptions (up 
to two packages each) to be dispensed within 6 months. Within the drug classes 
of this study, only NSAIDs cannot be prescribed for chronic usage. Adverse events 
cannot be collected in this study because only prescription data is available.
Detailers will record whether the planned visit was effectively accomplished, 
whether it had the planned duration, the number of physicians (including resi-
dents) present, whether the visit was made on patient visit time or off hours, the 
number of times the detailer had previously visited that physician, and feedback 
from the physician about the educational materials.
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Sample size
The research team has obtained pilot data from all physicians of three prima-
ry care units. This data was used to estimate within unit variability and the in-
tra-cluster correlation coefficient (ICC). Data was also gathered for all the units in 
the Regional Health Administration to estimate the mean prescription and stan-
dard deviation for the primary outcomes. The mean proportion of omeprazole 
dispensed was 54.0% of all PPIs (standard deviation, SD, 10.1%) and the ICC was 
0.027. The mean proportion of COX-2 inhibitors dispensed was 20.6% of all oral 
NSAIDs (SD 7.4%), and the ICC was 0.249. The Cochrane review on educational 
outreach visits found a median adjusted risk difference for improvement in com-
pliance with desired practice of 5.6% (interquartile range 3.0% to 9.0%) and 4.8% 
specifically for prescribing (interquartile range 3.0% to 6.5%) in previous trials 
[10]. Therefore, we chose to calculate our sample size assuming the intervention 
would lead to a 5% absolute difference in compliance with guidelines between 
intervention and control units.
If we assume a mean cluster size of six physicians per unit, a 1:1 allocation ratio 
of controls per intervention unit, an alpha type error of 0.025, and a dropout rate 
of about 15%, then a sample of 110 physicians in each group will allow for 80% 
power to demonstrate a 5% absolute increase in the proportion omeprazole and 
a 5% absolute decrease in COX-2 inhibitors. To recruit the necessary number of 
physicians, 38 primary care units will be required. STATA 12.0 (STATA Corp, TX, 
USA) and its sampsi and sampclus commands were used to calculate sample size.
Statistical methods
Physicians will be analyzed according to their randomly allocated group regard-
less of adherence to the intervention (intention to treat analysis). If physicians 
transfer to another unit within the health region, we will still be able to monitor 
their prescriptions. If the transfer is to a different health region (i.e., not Lisbon) 
we will contact the physician and ask for the missing prescription data. In both 
cases, prescription of clopidogrel will be adjusted to the new patient list. If a phy-
sician retires or we are unable to retrieve data from a physician who moved to a 
different region, then we will use the last working month’s prescription.
Both groups will be compared on primary outcomes using generalized mixed-ef-
fects models. The ratio of COX-2 inhibitors to the entire NSAID class and the 
ratio of omeprazole to the entire proton pump inhibitor class and respective 95% 
confidence intervals will be calculated. Statistical significance will be assumed for 
a p-value less than 0.025. STATA 12.0 (STATA Corp, TX, USA) will be used to 
conduct the analysis.
Data monitoring
Given the nature of the intervention, which poses minimal risks to patients, no 
data monitoring committee will be established.
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Ethical approval
This protocol has been approved by the ethics committee of the Regional Health 
Administration of Lisbon and Tagus Valley. Family physicians invited to partici-
pate will receive written information about the main aspects of the trial, namely 
which data are being collected and the procedures to ensure the non-identifiabil-
ity of individual prescriber data. They will sign a written consent for researchers 
to access their data. The trial will only collect aggregated and non-identifiable 
patient data. As such, the ethics committee waived patient informed consent.
Trial status
At the time of protocol submission, we have obtained ethical approval and have 
started to contact eligible primary care units. No primary care unit has been ran-




Our pilot data about prescription of NSAIDs, acid-suppressive therapy, and anti-
platelet therapy suggests that there is room for improving physicians’ prescribing, 
aligning it with evidence, and potentially leading both to improvements in patient 
outcomes and cost savings to the Portuguese National Health Service. This paper 
describes a protocol for a cluster-randomized trial to assess whether educational 
outreach visits have a long-term (18 months) effect on physician prescriptions. 
Randomized trials are the gold standard to assess intervention effects, and clus-
ter-randomized trials are an appropriate design when the intervention is an edu-
cation intervention targeted at healthcare providers [27].
In this trial, it will be impossible to blind physicians and detailers to the in-
tervention. Lack of blinding is expected to overestimate the intervention effects 
[28,29]. To minimize the effect of this bias, we are using prescription, which is an 
objective outcome measured independently from the researchers. This outcome 
also minimizes attrition, since it is possible to continue to assess the prescription 
behavior even if a physician changes workplace (within the same region).
We have chosen prescription-related outcomes over clinical outcomes. In 
Portugal, hospital discharge diagnoses (coded through the 9th revision of the 
International Classification of Diseases) are routinely collected for hospital reim-
bursement purposes, but are only available after considerable delay. Primary care 
diagnoses (coded through the 2nd edition of the International Classification of 
Primary Care) began to be collected in 2007 and are available in the regional data-
base within only one month of registration in the medical record. However, both 
hospital and primary care diagnoses have not been validated for comprehensive-
ness and accuracy. Moreover, diagnoses associated with incentives may be record-
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ed more often than those without incentives [30,31]. Hence, we have chosen to 
use prescription patterns as main outcomes. All prescription data in the National 
Health Service is gathered by the Ministry of Health for pharmacy reimbursement 
purposes. Data are available for both ordered and dispensed prescriptions. Pilot 
data from three primary care units showed that only about 60% of the prescribed 
drugs are actually dispensed. This likely arises from several factors: lack of patient 
adherence to prescriptions, the inability of physicians to match monthly amounts 
of different medicines in the same prescription sheet (hence the patient will not 
fill the entire prescription), and errors in printing and composing prescriptions 
that are subsequently not handed to the patient nor removed from the electronic 
medical record. For all these reasons, we opted to use dispensed prescriptions data 
as primary outcomes rather than ordered prescriptions.
Proton pump inhibitors and antiplatelets may be placed in chronic prescriptions, 
valid for up to six months. This means that data for these drugs may include pre-
scriptions as old as six months prior to dispensing (and hence up to six months 
prior to the intervention). This may result in an underestimation of the interven-
tion’s effect in secondary outcomes (one and six months, which may still include 
many lingering old prescriptions). This underestimation will be resolved for the 
primary outcomes (18 months) because by that time all prescriptions issued prior 
to the intervention will have been dispensed. However, if the intervention effect 
decreases over time, prescriptions issued as early as 12 months after the interven-
tion may still be dispensed at 18 months and thus lead to an overestimation of the 
primary outcomes.
The intervention’s effect on physicians may change over time. As the program 
moves forward, detailers are expected to build a relationship with visited physi-
cians. This may improve the detailer’s ability to change the physician’s prescribing 
behavior. On the other hand, the physician’s curiosity and willingness to partici-
pate may decrease, making him or her less receptive to the intervention. To avoid 
confounding resulting from the order by which each guideline is presented, we 
will randomly assign the guideline order for each unit.
We are recruiting family physicians from the three types of primary care units 
described in the introduction. Preliminary data at the regional level suggests that 
prescription patterns have greater room for improvement in ‘personalized care 
units’ (COX-2 inhibitors market share within NSAIDs is 22.8% in personalized 
care units vs. 17.8% in family health units; and omeprazole market share within 
PPIs is 53.1% in personalized care units vs. 55.5% in family health units). How-
ever, it is possible that recruitment is stronger in type A and type B ‘family care 
units’, since their contracts with the Regional Health Administrations state in-
centives for participation in research projects and lower drug expenditure. This 
differential participation may compromise the generalizability of our findings to 
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the Portuguese NHS, especially if physicians respond differently to educational 
outreach according to the type of unit in which they practice.
Relationship to other studies and expected contribution of this trial
In 2008, a Cochrane Systematic review concluded that educational outreach 
visits had a small but consistent effect on improving prescribing behavior, and 
identified areas for further research, namely: head-to-head comparisons between 
different educational outreach strategies, process evaluation embedded into tri-
als to assess which components influence the effectiveness of the intervention, 
inclusion of patient outcomes, measurement of costs and sustained/long term/
multiple visits educational efforts [10]. Since its publication, a large number of 
trials of multifaceted interventions that included educational outreach visits have 
been published. However, it is not yet clear whether educational outreach has a 
sustained effect and whether the intervention is cost-effective in a broad range of 
healthcare systems. The current study is innovative and important internationally 
as it addresses both these questions. Locally, this trial may show the effectiveness 
and feasibility of a sustained educational outreach program. If successful, it may be 
the cornerstone for deploying large-scale programs within the Portuguese NHS. 
This may range from other types of prescription improvement (e.g., much needed 
increase of generic market share, which in Portugal is only about half the share 
of Germany or the US; targeting innovative therapy for appropriate patients) to 
rational ordering of tests and even adequate screening practices. Ideally, govern-
ments and academic centers should be well positioned to apply our findings to a 
variety of educational outreach programs.
Data sharing
All data is property of the Lisbon Regional Health Administration (Portuguese 
Ministry of Health). Other researchers wanting to access raw data will need to 
obtain authorization from this institution before data can be shared.
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Additional file 1: An open cluster-randomized, 18 month trial to compare the 
effectiveness of educational outreach visits with usual guideline dissemination to 
improve family physician prescribing.
Summary of the interventions:
a Trial setup
a1
Clinical practice guidelines development
Prescribing guideline developed from the cultural adaptation 
of an existing international guideline, public discussion with 
medical specialists associations, and endorsement by Govern-
mental Authorities and the Portuguese Medical Association.
a2
Questionnaire with baseline characteristics of participating units: 
type of primary care unit, number of physicians, proportion of phy-
sicians with less than 10 years of practice.
a3
Data collection from regional prescription registry: median pre-
scription at baseline for COX-2 inhibitors and omeprazole for each 
of the primary care units willing to participate.
b Usual care: passive guideline dissemination
b1
The three guidelines are published in the website of the National 
Health Directorate’s (governmental authority) website.
b2
Single group-based training session unrelated to prescription 
(coding with the International Classification of Primary Care, 2nd 
Edition)
b3
For the control group the date for the “start” of intervention will be 
allocated randomly. These will be selected between the date of the 
first and last visit in the trial.
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c Intervention arm: educational outreach visits
An academically trained detailer will meet with family physicians (FP) in their 
practices, presenting the key messages of the guidelines and discussing barri-
ers to guideline implementation. Individual visits will be encouraged, but up 
to three physicians may be present in each visit. There will be a total of three 
visits (one for each of the three guidelines) each lasting between 15 and 20 
minutes. The order of the detailing visits will be randomised for each unit in 
the intervention arm.
c1
Training of academic detailers: Three members of the steering com-
mittee (2 FPs and 1 pharmacist) completed training in the method-
ology of academic detailing with the National Resource Center for 
Academic Detailing (Boston, MA). The other 12 detailers (3 FPs 
and 9 FP-trainees) were trained locally by the steering committee, 
with pre-training study assignments, and 12 hours of face-to-face 
training which included the principles of academic detailing, role-
play, video-recording and feedback, discussion of the scientific 
content of each guideline, and knowledge assessment. To ensure 
consistency, the contents of each visit (structure, guideline features 
to highlight, and written materials) have been prepared in advanced 
by the steering committee and were used in the training sessions.
c2
c2(1-3). Academic detailer delivers a detailing session. For each of 
the three guidelines, there will be a single detailing visit. Whenever 
possible, a single detailer will perform all visits to the same physi-
cian. 
c3
c3(1-3). The detailer will also distribute a point of care summary 
highlighting the main messages. 
x Interaction between physicians reinforce the intervention within a 
practice
d Outcome collection
l. Regional prescription registry extraction: COX-2 and NSAIDs pre-
scription data will be collected at 1 month(d1), 6 months (d2) and 18 
months (d3) after the respective educational visit has been performed 
(intervention group) or the equivalent randomly assigned visit date 
(control group).
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Timing of interventions and assessments (PaT plot)i
Time line Educational outreach visit Usual guideline dissemination
2-6 months pre-randomisation
a1     a2     a3
b1     c1
a1     a2      a3
b1
Allocation (minimization)
During 6 months (0 ≤ t ≤ 6)
b1     c2.1     c3.1     x
b1     c2.2     c3.2     x
b1     c2.3     c3.3     x
b1     b2     x
1 month post-intervention






6 months post-intervention 












i Perera R, Heneghan C, Yudkin P: Graphical method for depicting randomised 
trials of complex interventions. BMJ 2007, 334:127–129.
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Plan for the delivery of the intervention (Cascade diagram)ii
Additional file 2: Table S1. CONSORT 2010 checklist of information to include 
when reporting a cluster randomised trial. Table S2. Extension of CONSORT 
for abstracts 1, 2 to reports of cluster randomised trials.
Not included in the thesis. Available from: 
https://static-content.springer.com/esm/art%3A10.1186%2F1748-5908-9-10/
MediaObjects/13012_2013_845_MOESM2_ESM.pdf (short URL: goo.gl/TM-
K4eY)
ii Hooper R, Froud RJ, Bremner SA, Perera R, Eldridge S: Cascade diagrams for 
depicting complex interventions in randomised trials. BMJ 2013, 347:f6681.
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Abstract
Background
Educational outreach visits are complex interventions where educational con-
tent is delivered to improve a health professional’s behavior. The Trial to Assess 
the Effectiveness of Educational Outreach in Prescription Guidelines (TEP) was 
aimed at improving prescribing patterns in primary care. We conducted a process 
evaluation to analyze TEP´s implementation regarding reach, dose, fidelity, ac-
ceptability and perceived impact (the intervention’s effectiveness will be reported 
elsewhere).
Methods
During the pre-intervention stage, data on recruitment of physicians and detail-
ers was recorded by the trial study coordinator. During the intervention, detail-
ers recorded how each visit was delivered and perceived by filling an online visit 
tracker. After the interventional stage, all detailers were invited to a focus group to 
share their views on how the intervention was implemented and to gather ques-
tions for subsequent physicians´ interviews. Five participating physicians were 
interviewed by a trained psychologist to gather qualitative data on their views 
about the intervention. Interviews were used to create a questionnaire, which was 
sent to all physicians participating in the intervention arm.
Results
The target 38 units (239 physicians) were recruited in a 10-month period, with 
higher participation of family health units than personalized care units (36.5% vs 
2.2% of invited units). Overall visit success rate was 89.4%, with the full educa-
tional content being delivered in 97.8% of visits. The physician survey had a 68% 
response rate, with 98% of physicians considering visits useful to their practice, 
96% wishing visits would continue and 96% stating they would recommend the 
program to other physicians. Five of the twelve active detailers participated in 
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the focus group, all were pleased to have participated in the trial and would like 
to continue their activity as detailers in the future alongside their jobs as family 
physicians.
Conclusions
Process evaluation for the TEP trial showed reasonable reach, high dose and 
very high fidelity for the implementation of the planned intervention. Acceptabil-
ity was very high among both participating physicians and detailers. Perceived 
impact was moderate among physicians and low among detailers. Overall, the 
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Background
Educational outreach visits (also known as academic detailing) are aimed at 
changing healthcare professionals’ behavior by delivering educational content in 
face-to-face visits performed by trained persons (usually another health profes-
sional).1 A Cochrane review of available literature found there are currently sev-
eral ways of conducting educational outreach visits, as some of the components 
originally described have been altered by different researchers.2 Although these 
variations are expected in complex interventions, they may have an impact on the 
effectiveness of outreach visits to change behavior. Moreover, complex interven-
tions, such as educational outreach visits, may sometimes fail to be fully imple-
mented in randomized trials, or be implemented in different ways in separate trial 
locations. There could also be contextual factors that lead to variable effectiveness 
in different subgroups.3 Consequently, the review’s authors conclude that research 
is needed to understand the sources of variability in effectiveness.2 Thus they rec-
ommend that process evaluations should be embedded into educational outreach 
trials.
Process evaluations focus on the delivery of the intervention, and may help to 
interpret the trial’s results. Fidelity (the delivery of the intervention as planned), 
dose (how much of the intervention was actually implemented), reach (if the 
target audience came in contact with the intervention), acceptability (if the inter-
vention generates resistance) and mechanisms of impact (how does the delivered 
intervention produce change) should be evaluated in complex interventions to 
better understand their effects.3 Process evaluations can thus shed light on how 
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the intervention was implemented, evaluate separate components of the inter-
vention, how participants viewed the intervention, describe local and contextual 
factors that may influence the outcome, and identify subgroups where the effect 
may vary.4
The Trial to Assess the Effectiveness of Educational Outreach in Prescription 
Guidelines (TEP trial) is a cluster-randomized trial to compare the effectiveness 
of educational outreach visits with that of usual guideline dissemination aimed at 
improving family physician prescribing.5 We conducted a process evaluation of 
the TEP trial to analyze the implementation of the intervention regarding reach, 
dose, fidelity, acceptability of different components of the intervention and per-
ceived impact.
Methods
In this section, we first provide a summary of the TEP trial protocol, and then 
detail how the process evaluation was conducted (with data collected before, 
during and after the intervention stage). The TEP trial has been approved by the 
ethics committees of the Lisbon and Tagus Valley Regional Health Administration 
and NOVA Medical School. Physicians were required to give informed consent to 
participate in the trial.
Setting
In Portugal, primary care services are provided mainly by the government-run 
National Health Service. Health center groups provide care to a local population 
and consist of several units with 4 to 12 physicians, who are each responsible for 
about 1700 patients. Nurses and secretaries work alongside physicians in these 
primary care units, while psychologists, physiotherapists and other healthcare 
professionals are shared among units within a health center group. Most physi-
cians work for a fixed salary in personalized care units, but since 2006 they can 
volunteer to work in family health units, with greater functional and organiza-
tional autonomy, and working in a mixed payment system (salary, capitation, fee 
for service and pay for performance).6
Intervention in the TEP trial
The trial protocol for the intervention has been published in detail elsewhere.5 In 
summary, family physicians working in primary care units in the Portuguese Na-
tional Health Service in the Lisbon region were recruited to participate in a par-
allel, open cluster-randomized trial comparing educational outreach visits with 
usual guideline implementation. The intervention arm received three educational 
outreach visits on non-steroidal anti-inflammatory drugs (NSAIDs), acid secre-
tion modifiers, and antiplatelets guidelines published by the Portuguese National 
Health Directorate.7-9 Four of the investigators (BH, DP, IS, and PAC) are also au-
thors of these guidelines. Three investigators, two of them family physicians (DP, 
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DR) and one academic pharmacologist (PAC), received training in educational 
outreach and then acted as trainers for other detailers.10 These additional detailers 
were invited from a pool of family physicians and family medicine residents based 
upon the investigators’ knowledge about personal characteristics and geographic 
convenience. Detailers were trained to conduct each visit in several stages: intro-
duction, assessing the physician’s educational needs, describing features and ben-
efits of the guideline, handling objections, summarizing, obtaining a commitment 
for prescribing according to a particular key-message in the guideline, and sched-
uling the next visit. The three researchers and the additionally trained academic 
detailers performed one on one visits to family physicians (up to three physicians 
were allowed to be present in a single visit if they requested), which were planned 
to last for 15 minutes. In each visit a brochure was used by the detailer as visual 
aid and a small handout was given to the physician as a summary highlighting the 
main points of the guideline. The order of the visits was randomized to prevent 
a possible effect of the detailer-physician relationship on effectiveness if the se-
quence of visits was the same among all participants. Usual implementation in the 
control arm consisted of passive guideline dissemination by publication on the 
National Health Directorate’s website. To improve recruitment, we offered units 
in the control arm an optional training session on using the International Classifi-
cation of Primary Care (ICPC), second edition. We planned the enrollment of 38 
primary care units (clusters) with an average of 6 physicians per unit.
Monitoring implementation during the intervention
Before the intervention began, data on family health units and detailer recruit-
ment was recorded by the trial study coordinator as recruitment progressed. An 
online tool (visit tracker) was developed to help detailers plan and track their vis-
its and to allow investigators to monitor visit progress. It also included questions 
regarding each visit that detailers would fill out. To avoid inaccuracy in recording 
data, they were also given a paper version of the questions, which could be used 
on-site and then transposed to the web version at a later time. During the inter-
vention detailers collected data on the visit’s characteristics (location, scheduled 
and actual time, length, number of physicians present, and interruptions), deliv-
ery of the educational program as planned, barriers to change mentioned by the 
physician, physician interest and commitment to change, adequacy of educational 
materials, difficulties felt by the detailer, and overall detailer satisfaction with the 
visit. A successful visit was defined as an interaction between a detailer and one or 
more physicians where educational content was delivered.
Detailers’ perceptions and experience after the intervention
Three months after the last educational outreach visit we conducted a focus 
group discussion with active detailers. This was facilitated by a trained psycholo-
gist. Detailers were asked about their perceptions on the usefulness of academic 
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detailing, the clinical value of their visits for physicians, their feelings about con-
ducting the visits (namely, approaching participating physicians and the useful-
ness of each task within the visit), the adequacy of training before the visits and 
educational materials provided to physicians, personal styles of conducting visits, 
their perceived influence on physician’s prescribing behavior, and if payment was 
appropriate for their task and time. Input from the focus group was used to plan 
physician interviews and a first draft of the physician questionnaire. Detailers not 
able to participate in the focus group were invited to comment by email.
Physicians’ perceptions and experience after the intervention
An organizational psychologist conducted individual semi-structured inter-
views to five participant physicians. The main goal of the interviews was to iden-
tify which intervention elements worked well and resulted in behavior change, as 
well as those that were perceived as not being useful, their willingness to continue 
to receive educational outreach visits and their views on how well detailers per-
formed. The interviews were transcribed and subjected to content analysis. Based 
on the interviews’ content a questionnaire was developed and tested with four 
physicians not involved in the trial and slight modifications were introduced to 
improve readability. The questionnaire had 31 statements to be answered in a six 
item Likert scale (completely disagree, disagree, partially disagree, partially agree, 
agree, and completely agree), and also an open text comment section. Answers 
were categorized as agree or disagree. The questionnaire was sent to all physi-
cians in the intervention arm nine months after the last visit, along with a prepaid 
response envelope. Physicians could also opt to fill the questionnaire online. To 
improve response rates, physicians were told they would receive a study partici-
pation certificate upon completion of the questionnaire. One week after the ques-
tionnaires had been posted, a reminder email was sent to all unit coordinators. 
Three weeks after the questionnaires had been posted individual email reminders 
were sent to physicians who had not answered.
Results
We successfully recorded recruitment of family health units and detailers, de-
tailers entered information regarding all visits in the visit tracker, conducted a 
focus group with five of the twelve active detailers, interviewed five physicians 
and received 82 questionnaires from physicians in the intervention group (68% 
response rate).
Reach
Recruitment of primary care units and physicians
Recruitment of participants for the trial began on March 27, 2013. The study 
was presented to unit coordinators in 13 out of the 15 health center groups in the 
Lisbon region (the other two were not contacted as they were the most distant 
144
from Lisbon). We were able to recruit the target 38 units out of the 233 health 
units in these health center groups (16.3%), not all of which would have been el-
igible, as some had fewer than the specified minimum of four physicians. Within 
these units, 239 physicians agreed to participate. The mean cluster size was 6.3 
physicians per unit, slightly higher than had been anticipated (6.0). The first unit 
completed study entry procedures in April 2013 and the last in January 2014, 
hence recruitment lasted 10 months.
Recruitment was higher among family health units than among personalized 
health care units: 36.5% (35 of 96) vs 2.2% (3 of 137), p<0.001. Units that volun-
teered to participate had better prescription patterns in NSAIDs and acid secre-
tion modifiers than the regional average when we collected data prior to the trial 
for minimization purposes. The regional cyclooxygenase-2 (COX-2) inhibitors 
market share (in defined daily doses) in the oral NSAIDs class was 20.6% (stan-
dard deviation ±7.41), while it was 17.9% (SD ±6.39) in participating units (lower 
better) - p=0.028. Omeprazole market share in the proton pump inhibitors class 
was 54.0% (SD ±10.09) in the region and 56.4% (SD ±9.52) in participating units 
(higher better) - p=0.170.
Nineteen units were allocated to each arm, with 120 physicians assigned to the 
intervention arm and 119 physicians to control (Table 1).
Recruitment of detailers
Of the 22 physicians invited, 17 accepted to be trained as detailers, and 13 com-
pleted training. From these, nine performed at least one visit during the study. Six 
of these were specialists in family medicine, and three were in their final family 
medicine residency year. The mean age of the nine detailers was 31.5 years old. 
The remaining four out of the 13 detailers who had completed training did not 




The overall visit success rate was 89.4%, with 322 visits accomplished out of 360 
planned - table 2. Twenty-six visits were attempted but the physician was absent 
(21) or unavailable (5). Twelve visits were not attempted: two physicians had none 
of the three visits (one was on maternity leave and the other on extended sick 
leave); one physician did not wish to receive further visits after an unsuccessful 
first attempt; and four physicians did not received one of the visits (two because 
the detailer was unavailable, one was on compassionate leave and the other on 
sick leave). Each detailer attempted between 6 and 53 visits, median 28.5 visits 
per detailer. The nine recruited detailers made 66.7% of the visits (successful or 
attempted) and the three investigators acting as detailers made the remaining 
33.3%. All three visits were made by the same detailer in 88.3% of physicians. In 5 
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units a single detailer made all the visits; in 13 there were two detailers assigned; 
and in one unit three detailers made visits.
Optional session in the control arm
Eleven units accepted the optional session on ICPC, three chose not to receive it 
and the other five did not reply to our invitation.
Fidelity
Preparing educational content
The chosen guidelines were summarized by the investigators. Key clinical mes-
sages were identified by consensus and used to prepare mock visits to guide de-
tailers training sessions, handouts and color brochures. Brochures used figures 
and tables to support the discussion during the visit, and handouts listed key 
messages in plain text or tables and were meant to be used as a desk reference. 
Draft versions of both were discussed among the investigators and then presented 
to detailers during their training sessions. Detailer feedback was used to improve 
content and visual presentation and the final version of visits and educational 
materials was approved by both investigators and detailers. These materials are 
available (in Portuguese) from the investigators upon request.
Table 1 - Characteristics of participating physicians at the time of randomization.
Characteristic Intervention  (n = 120) Control (n = 119)
Female - % 70.8 79.0
Age - years, median (P25-P75) 52 (41-59) 47 (38-59)
Years in practice, median (P25-P75) 13 (6.5-28) 11 (4-28)
Training - %
    Family medicine residency
    On the job vocational training







Residency tutor - % 55.8 52.9
Patient list size - n, median (P25-P75) 1874 (1812-1923) 1813 (1746-1872)
Unit type - %
    Family health unit





SD - standard deviation. * After randomization, two personalized care units with 
13 participating physicians changed their organization to family health units, 
therefore, when visits were made 0% of physicians in the intervention group.
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Training of detailers
Detailers received course materials in advance and then participated in three 
training sessions with a total of 12 hours. The first session (3.5h) discussed the 
theory and components of educational outreach visits, and detailers practiced the 
opening stages of a visit. In the second session (6h), detailers practiced visits with 
each other using the three trial guidelines. The third session (2.5h) was used to 
answer questions about educational outreach visits and the guidelines. All train-
ing visits were video recorded and made available to detailers. An online support 
group was available to detailers throughout the trial, allowing questions about 
guidelines to be placed to their authors. In the focus group detailers mentioned 
not having enough time to read all materials sent before the first training session 
due to their daily activities as physicians. This led to an initial difficulty inter-
preting the guidelines during the first training session. However, they overcame 
Table 2 - Summary of visits.
Visit outcome - visits, n (%), n=360
    Successful 322 (89.4)
    Physician absent 21 (5.8)
    Physician unavailable 5 (1.4)
    Visit not attempted 12 (3.3)
Target physicians per successful visit - visits, n (%), n=322
    1 287 (89.1)
    2 23 (7.1)
    3 11 (3.4)
    4 1 (0.3)
Successful visits per physician - physicians, n (%), n=120
    0 3 (2.5)
    1 6 (5.0)
    2 17 (14.2)
    3 94 (78.3)
Different detailers per physician - physicians, n (%), n=120
    1 107 (89.2)
    2 13 (10.8)
Visits per detailer - visits, median (P25-P75) 28.5 (24.8 - 34.0) 
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the difficulty in the following sessions. Being able to watch video recordings of 
practice visits made by every detailer was considered very useful, as it allowed 
detailers to analyze their technique and compare themselves with others.
Delivering educational content
The full educational content was delivered in 97.8% of visits. In the remaining 
visits, the most common reason for not delivering the full content was physician 
lack of time for a full visit. Detailers followed all planned stages of the visit in 89.4% 
of visits. The introduction stage was missed in 0.9% of visits, needs assessment in 
4.3%, features and benefits in 10.6%, handling objections in 0.9%, summarizing 
in 1.6%, obtaining a commitment in 7.5% and scheduling the next visit in 0.3%.
Detailers reported feeling difficulties in their role in 11.5% of visits, the most 
common difficulties were: physicians claiming that they already followed the 
guideline, not enough time for the visit, not being able to obtain a prescribing 
commitment, and uncertainty when dealing with scientific questions. Overall, 
detailers reported being pleased or very pleased with their role in 93.8% of visits.
In the focus group, detailers mentioned that many physicians claimed to be al-
ready following the guideline, and therefore they would not need to change their 
behavior substantially. However, detailers felt there was still room for improve-
ment, which was not recognized by physicians. These views were consistent with 
the physician survey, where 91% of physicians agreed they were already prac-
ticing what the National Health Directorate’s guidelines recommended, but 63% 
mentioned they often didn’t have enough time in a patient visit to follow these 
guidelines. For detailers, this argument of already following guidelines made their 
request for a commitment to change prescribing behavior more difficult. Detail-
ers reported feeling more comfortable informing physicians about the guideline 
than asking for commitments to prescribing changes. After completing the visits, 
detailers mentioned that training had focused mainly on the scientific content of 
guidelines, partly because this was where they were more engaged. They consid-
ered that the scientific debate during the visits was the easiest part (unlike what 
they expected), attributing this to their training as physicians. In contrast, obtain-
ing a commitment to change prescribing behavior at the end of the visit was high-
lighted as the hardest part of the visit. These difficulties were attributed to lack of 
training, but also to detailers not being comfortable with asking for a prescribing 
commitment. In the focus group, some detailers questioned whether asking for a 
prescribing commitment changed the effectiveness of the intervention or it could 
be dispensed with. Their concern was that this could damage the empathy they 
had built with the physician in the first part of the visit.
Protocol deviations
During the trial, nine minor protocol deviations were recorded. Seven of these 
were changes in the planned order of the visits involving eleven physicians. In four 
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units the incorrect visit was mistakenly performed by the detailer; in two units 
the physician or the detailer were unable to schedule the visit in the appropriate 
month; and in one unit a pregnant physician asked to receive the final visit one 
week before the planned schedule as she would be on maternity leave. Another 
minor deviation occurred in one unit where two physicians did not receive the 
final visit due to unforeseen unavailability by both the assigned detailer and later 
the replacement detailer designated by the steering committee. The final minor 
deviation occurred when a detailer accepted to perform a visit to four physicians 
at once at their request, disrespecting the maximum allowed of three physicians 
at once in a single visit.
Acceptability
Scheduling visits
In the focus group detailers mentioned that in some places scheduling visits 
was difficult at first, as some physicians did not recall having volunteered for the 
study and some office secretaries blocked the access to physicians. After the first 
visit had been made, however, access to those hard-to-reach physicians usually 
improved considerably. At other units, the role of office secretaries in providing 
access to physicians was praised by detailers. Detailers mentioned that respecting 
the rules of each unit they visited and not asking for special privileges was helpful 
when dealing with office staff. They also considered it would have been better if 
secretaries were informed of the study beforehand (instead of just the physicians). 
Scheduling was easier when detailers already professionally knew the physician 
before the study. Sometimes detailers stayed in the waiting room until the physi-
cian was available, while in other units they were invited in to wait in the inside 
corridor or a meeting room. Detailers felt that an official identification badge was 
not needed. Sending a reminder on the day before the visit, arriving early, and 
notifying the physician they had arrived by text message were seen as facilitators. 
Some physicians also helped by walking the detailer to the next colleague’s office 
after the visit. Detailers felt frustrated when some physicians left the practice de-
spite having scheduled a visit.
Physicians per visit
In 89.1% of successful visits only the target physician was present, in 7.1% there 
were two target physicians, three in 3.4%, and four in one visit. All visits with 
more than one target physician happened at the doctors’ request. One or two fam-
ily medicine residents or medical students were present in 22.4% of visits.
Detailers in the focus group reported that when physicians asked to receive the 
visit in groups of two or three they were more interactive, asking more questions 
and ending the visit more convinced of the need to change. This was also thought 
to be the case, albeit to a lesser extent, when a physician was visited with one or 
more residents present. The detailers’ perceptions are consistent with the phy-
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sician survey, where 33% of physicians disagreed with the statement that they 
preferred individual visits.
Timing and location of visits
Physicians choose to receive detailers between patient appointments in 55.6% of 
visits and before or after seeing their patients in the remaining 44.4%. Nineteen 
percent of visits were scheduled between 8 a.m. and 12 p.m., 68.4% between 12 
and 5 p.m., and 12.6% between 5 and 8 p.m. Detailers reported 58.7% of visits 
began on time, 29.8% were late (median 15 minutes, interquartile range 15-30 
minutes) and 11.5% were early (median 15 minutes, interquartile range 15-30 
minutes). The length of the visits was the planned 15 minutes in 75.5%, shorter in 
13.0% (median 9.5 minutes shorter, interquartile range 5-10 minutes) and longer 
in 11.5% (median 10.0 minutes longer, interquartile range 5-18 minutes).
In the focus group, detailers mentioned it would be useful to have instructions 
on how long to wait when a physician was delayed. Detailers noted that shorter 
visits happened when the physician informed them he/she was pressed with time. 
Some physicians were described by detailers as disorganized, having not set aside 
enough time for the visit. Longer visits occurred when physicians showed interest 
in debating the guideline.
In the physician survey, 91% agreed that 15 to 20 minutes was the ideal duration 
for visits, and 18% said visits had cause some disruption of their schedule for that 
day.
Most visits were held in the physician’s office (86.3%), 8.1% in the unit’s meeting 
room, 2.5% in another physician’s office and 3.1% in other locations. There were 
interruptions in 24.2% of visits, 93.6% of which were considered by the detailer to 
cause none or little disturbance.
In the focus group detailers said they were indifferent about the location where 
the visit was held, but felt physicians were more comfortable in their own office. 
They also noted that the visit was more likely to be interrupted if it was conducted 
in the physician’s office. This was consistent with data entered in the visit tracker, 
where 26.6% of visits in the physician’s own office were interrupted compared 
with 9.1% of visits held elsewhere, odds ratio 3.6, 95% confidence interval 1.2-
14.4, p=0.001.
Barriers to change
Patient resistance to changing the usual prescription (28.3% of successful visits) 
and changing a prescription decided by another physician (26.7%) were the most 
common barriers to change recorded by detailers. Not knowing the guideline 
(13.4%), disagreeing with the guideline (5.0%), hospital specialists not following 
the guideline (4.3%) and lack of time (3.4%) were also common barriers identified 
during visits.
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Patients were willing to change their medications according to 80% of physi-
cians, and 83% considered patients were willing to change medications initiated 
by other physicians. When questioned about their sources of information about 
prescribing medicines, 87% of physicians identified the National Health Director-
ate’s guidelines, 98% consulted a colleague in the same unit, and 51% consulted a 
hospital specialist in that area.
Brochures and handouts
In 98.8% of the visits detailers considered the educational materials as adequate 
to answer all of the physician’s questions, and rated 90.4% of physicians as inter-
ested or very interested in the handout.
In the focus group, detailers rated physician’s reactions to the materials used in 
the visit as very positive. The large color brochure was considered very helpful as a 
visual aid, both for the detailer’s organization of the visit and for helping the phy-
sician understand the guideline’s content. The small handout guideline summary 
was considered very practical as a point of care aid in daily practice. Detailers 
mentioned some physicians kept all three handouts at hand in a specific folder on 
the desk or the bookshelf. In a few units, physicians requested electronic versions 
to be made available on physician’s desktops. Some physicians asked for the large 
brochure, but most felt the handout was enough. 
In the questionnaire, 98% of physicians agreed that brochures were useful in 
explaining the visit’s educational content, and 96% found the handouts useful in 
clinical practice. 79% of physicians wanted future visits to include patient hand-
outs.
Detailers
Detailers felt most physicians had enjoyed their work and had found the visits 
useful. Younger detailers felt their age was not a problem and even had a positive 
impact. Participating in the trial was seen by detailers as allowing them to gain 
detailed knowledge of the three guidelines in the trial, update medical knowledge 
in general, improve their own practice as physicians and critical reading skills, 
get to know other units, change their daily routine as physicians with a different 
kind of activity, and be useful to other family physicians. Payment was considered 
adequate, but not as important as the opportunity to be part of a project seen as 
innovative, important, and with potential gains for patients and physicians.
As for continuing as detailers in the future, all in the focus group showed inter-
est if it could be made alongside their regular activities as family physicians, and 
some would consider decreasing their weekly schedule as physicians to be able to 
make more visits as detailers. None wanted to stop clinical practice to become a 
full-time detailer.
In the physician survey, 99% agreed that detailers had good knowledge about 
guidelines and good communication skills, 93% agreed they had practical expe-
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rience applying guidelines to real patients, 96% agreed they were able to answer 
the questions physicians posed about the guideline being presented, and 80% 
disagreed with the statement that detailers were more committed with economic 
savings than clinical benefits. For future visits, 79% of physicians disagreed that 
they would rather be visited by more experienced physicians, 78% agreed they 
would gladly accept visits by family medicine residents, and 76% disagreed they 




Detailers classified 93.5% of visits as having an interested to the physician, 4.3% 
as indifferent, and 2.2% as skeptic. In the focus group detailers consider the vast 
majority of physicians as very receptive, with a minority described as nodding 
without really engaging.
Perception of utility
Detailers recorded that physicians committed to changing their prescribing be-
havior in 84.5% of visits. However, in the focus group detailers mentioned they 
had perceived visit effectiveness as small. They felt that physicians who showed 
most interest and engagement during the visits were the ones who most often 
claimed to be already following the guidelines. Detailers expected some changes 
to occur, especially in younger physicians. Older physicians were seen as being 
less receptive to change. Receiving a visit was seen as a passive activity, while 
changing prescription habits would require an active behavior that needs to face 
several barriers and constraints. Detailers agreed with physicians regarding that 
prescribing changes would also depend on the acceptance of patients and other 
physicians (mainly hospital specialists).
In the physician survey, 87% replied that visits led to some discussions about the 
guidelines with their colleagues in the family health unit, 91% mentioned discuss-
ing treatment changes with their patients, and 96% agreed that visits had led to 
prescribing changes in some of their patients
Continuity
In the focus group detailers noted that many physicians told them they enjoyed 
participating in the visits and wished they could continue. Being able to learn a 
guideline in a visit was valued as a solution to the lack of time physicians had to 
study the guidelines by themselves. Even physicians who had previously studied 
or discussed one or more of the guidelines found visits useful. Some physicians 
asked if they could receive visits on other guidelines.
This view was shared by the physicians in the questionnaire, 98% agreed that 
visits were useful to their practice; 95% agreed guidelines were easier to under-
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stand in a visit than by reading them; 96% would like visits to continue with other 
guidelines (mainly on cardiovascular diseases, diabetes and asthma/COPD); and 
96% would recommend participating in educational visits to other physicians. 
As for future visits, 93% considered that educational outreach should be publicly 
funded by the Ministry of Health; 79% agreed that visits should be carried out 
by organizations independent of the Ministry of Health; and 80% disagreed they 
should be limited to primary care units with specific needs.
Discussion
This process evaluation study aimed to analyze the implementation of an ed-
ucational outreach intervention to change prescribing behavior in primary care 
and gather participant views. Table 3 summarizes the main recommendations we 
would make to authors of future educational outreach trials or programs.
Reach
Data shows that recruitment of primary care units took almost 10 months, about 
twice as long as hoped by the investigators. This may be explained partially by 
the recruitment strategy. Not having the resources to directly visit more than 200 
units, we contacted health center groups and promoted the trial during unit coor-
dinators meetings, expecting them to invite physicians in their units to participate 
Table 3 - Recommendations for future trials of educational outreach
• Plan strategies to recruit less motivated physicians.
• Recruit and train a higher number of detailers than needed.
• When recruiting detailers, consider physicians appear to be less receptive 
to visits made by non-physicians.
• Emphasize persuasion and sales techniques during detailer training.
• Start the intervention as soon as possible after detailers have been trained.
• Involve practice secretaries to improve access to physicians.
• Use text-messages and email reminders to physicians to improve visit suc-
cess rate.
• Provide physicians with facilitators of patient change, such as patient hand-
outs.
• Ask physicians to indicate their preference to receive individual or small 
group visits.
• Take delays into account when scheduling visits and provide detailers with 
indications on how long to wait for physicians.
• Target visits to 15 minutes, but prepare detailers to make shorter and longer 
visits.
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(with the help of brochures prepared by the research team). A motivated unit 
coordinator was therefore needed to recruit physicians. This probably resulted 
in the recruitment being more successful among family health units (the newer 
organizational model of primary care in Portugal) than in the traditional per-
sonalized care units and among physicians who were already prescribing aligned 
with guideline recommendations (motivation to participate in the trial may have 
been associated with motivation to follow guidelines). Therefore, our sample may 
not be representative of all primary care units and family physicians in Portugal 
(where roughly 50% of physicians work in traditional units). Detailer views and 
physicians answers to the survey show most physicians mentioned they were al-
ready following guidelines. However, physicians might perceive their adherence 
to guidelines as better than it really is,11 and differences in outcomes between 
participating units and the regional average in data collected before randomiza-
tion were small and only significant for COX-2 inhibitors. Recruiting physicians 
who are more compliant with guidelines may lead to an underestimation of the 
intervention effectiveness, as physicians who have prescribing habits further away 
from guideline recommendations (i.e., with the largest room for improvement) 
may not have been included. Nonetheless, educational outreach programs still 
depend on physician’s willingness to participate. Finding ways to entice the en-
rollment of less motivated physicians is a challenge that should be addressed in 
future programs.
This trial showed a high attrition rate among invited detailers, with only half 
of those who initiated training actually completing visits. This does not hinder 
the trial’s internal validity, but should be considered when recruiting detailers for 
future interventions. To prevent attrition, we believe starting the intervention as 
soon as possible after training would be useful. Also, a higher number of detailers 
than those needed should be trained.
Dose
Visit success rate among participating physicians was high, with almost 90% of 
visits accomplished and only one physician declining further visits. The dose of 
the intervention was thus delivered according to plan. Detailers suggested chang-
es that could in the future increase the number of accomplished visits by minimiz-
ing the number of times where physicians were unavailable or absent: involving 
practice secretaries in the program to improve access to physicians and sending 
text-message or email reminders to physicians a few days prior to the visit.
Each detailer had an average of 13 physicians to visit, about two primary care 
units. This was enough to accomplish the planned visits even though detailers 
were also working as full time physicians, with only four of 360 visits being missed 
because the detailer was unavailable. It also allowed almost 90% of physicians 
to receive all three visits by the same detailer, with whom they built a working 
relationship during the trial.
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Fidelity
Fidelity of the intervention was very high. A significant effort was made to in-
sure consistency among detailers by training them and providing a common visit 
script. The full educational content was delivered in 98% of visits and all planned 
stages were performed by detailers in almost 90% of visits. Three quarters of visits 
had the planned duration, with the rest being equally divided between shorter and 
longer visits. In accordance with their training, detailers focused on guidelines 
key messages when physicians mentioned having little time, and answered ques-
tions in detail when physicians showed interest and availability for longer visits. 
Detailers were more comfortable delivering scientific information than asking 
for a prescribing change commitment from physicians and complained about not 
having received enough training to perform this particular task. Future programs 
should include greater emphasis on persuasion and sales techniques, recruiting 
people with adequate expertise in this area to train detailers.
Only a few protocol deviations were recorded during the trial, and most relat-
ing to the order of visits. Randomizing the order of visits was planned in order 
to minimize a possible effect of the physician-detailer relationship, which could 
grow stronger and make latter visits more effective. However, this complicated 
the delivery of the intervention. The research team attempted to decrease the im-
pact of these errors by regularly checking what visits had been made and acting 
promptly to minimize the gap in receiving the intervention among physicians in 
the same cluster, whilst keeping the planned order for visits.
Acceptability
Almost 90% of surveyed physicians mentioned using the National Health Di-
rectorate’s guidelines as sources of information about prescribing and detailers 
recorded physicians disagreeing with the guideline as a barrier in only 5% of vis-
its. Therefore the guidelines chosen for the trial seem acceptable to the vast ma-
jority of physicians. The most common barriers to change identified by physicians 
were related to patient resistance, 20% of physicians in the survey considered 
that patients were unwilling to change their medications. Hence, facilitators of 
patient change should be emphasized in future visits. Providing physicians with 
brochures for patients was a possible solution desired by physicians.
Physicians’ claims of already following guidelines were noted as a difficulty by 
detailers and may be considered as an acceptability issue, instead of a reach prob-
lem. Physicians may consider they follow guidelines to the extent that is possible 
to them, and that in some situations change is not possible. Hence, to be effective, 
interventions would need to focus on external factors. On the other hand, phy-
sicians may have difficulty recognizing their prescribing practice could improve, 
and so difficulty accepting the need to change.11 In this case combining education-
al outreach with audit and feedback about their actual prescribing habits would 
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probably help physicians realize they have room for improvement. Finally, some 
physicians may use their claim to already follow guidelines as a way to gain social 
and professional acceptance from the detailer or as a defensive attitude and thus 
avoid committing to change. This would mean the intervention had failed in those 
physicians.
Most physicians received detailers alone or with their residents or medical stu-
dents, but about 10% asked detailers to deliver the visit together with other phy-
sicians. Many more physicians in the survey (about one third) mentioned they 
preferred not to receive individual visits. Detailers reported some physicians to be 
more engaged when they were not alone and that having two or three physicians 
present did not seem to impair their ability to carry out the visit as planned. In 
future programs, asking physicians to indicate their preference to receive indi-
vidual or small group visits could be considered. This may decrease visit costs, as 
detailers will need to perform less visits. However, it can complicate scheduling 
as physicians might not all be available at the same time. The ability to change 
physician behavior in small groups (two or three) should also be considered. Of-
fering small group visits to physicians who prefer individual visits might decrease 
effectiveness of the intervention, while forcing physicians who prefer small group 
visits to receive detailers individually may also hamper behavior change.
Most physicians chose to receive the visits in their offices, although this made it 
more likely they would be interrupted by office staff. However, detailers consid-
ered these interruptions minor and that physicians would be more comfortable 
there. Physicians were mostly available in the afternoon which may be an import-
ant factor to consider when recruiting detailers and planning visits in the future. 
Physician delays happened in about 30% of visits, therefore, detailers should not 
schedule consecutive visits too close together, and allow for enough buffer time 
when visiting more than one primary care unit in the same day or having to re-
turn to their own jobs as physicians. Delays should also be taken into account if 
detailers are payed by the hour instead of per visit. Guidelines on how long to wait 
should be defined in advance to help detailers decide when to consider a visit un-
successful. Visit duration was deemed adequate by most physicians, but 16% con-
sidered visits had caused some disruption in their schedule. Detailers mentioned 
not having enough time in only a small proportion of visits. Hence, targeting visits 
to last 15 minutes seems appropriate, but detailers should be prepared to deliver 
only key-messages in 5 minutes or to stay and answer questions in 25 minutes.
Using brochures and physician handouts were considered adequate and useful 
by most physicians.
Detailers were pleased with their participation in the trial. Intrinsic motivational 
factors related with improving their knowledge and feeling useful to other phy-
sicians were seen by detailers as more important than payment. Detailers wished 
they could continue this activity, but not if it required them to stop practicing as 
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physicians, therefore if, as in this case, the chosen detailers are physicians then 
using part-time detailers would be more appropriate for future visits.
Physicians were largely satisfied with the detailers’ performance, considering 
they showed good knowledge about guideline and good communication skills. 
However, almost 20% of physicians considered detailers to be more concerned 
with economic savings than clinical benefits. This is concerning, as physicians 
who consider that the intervention prioritizes economic savings over patient 
gains may adhere less to prescribing recommendations.
The vast majority of physicians considered that future educational outreach pro-
grams should be publicly funded and most preferred them to be performed by 
independent organizations.
Perceived impact
Detailers classified the majority of physicians as interested and receptive. How-
ever, they perceived visit impact to be small. Overall, physicians indicated they 
were satisfied with their participation in the trial. The vast majority considered 
visits were useful, wished they would continue, would recommend them to a col-
league, and considered visits had led to some changes in their prescribing behav-
ior. Most physicians mentioned they would not find future visits as useful if made 
by other health professionals (non-physicians), but would accept family medicine 
residents. This preference should be considered only as indicative, as physicians in 
this trial did not actually experience visits by other health professionals. 
Study strengths and limitations
Using both qualitative and quantitative methods allowed us to gather a com-
prehensive view of the intervention implementation. Information gathered in the 
detailer focus group was essential to understand data entered in the visit tracker, 
and the survey allowed us to quantify physicians’ perceptions and experience 
complementing data gathered in the interviews. The perceptions of detailers 
and physicians were very consistent, strengthening our conclusions. This eval-
uation allows us to raise some hypotheses regarding the mechanisms through 
which visits work to change behavior. Some of these hypotheses include whether 
non-physicians are less effective in producing behavior change or if tailoring visits 
to be conducted individually or in small groups may be considered as a strategy to 
improve adherence and make physicians more comfortable. These could be tested 
in future trials.
However, this process evaluation also has important limitations. Detailers ob-
served themselves when they recorded visit information, as we were unable to 
have independent observers during visits. Yet, having an observer present during 
the detailer-physician interaction might have interfered with the visit by inhibit-
ing both detailer and physician, as would audio or video recording. The number 
of detailers in the focus group was small and detailers not attending might have 
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different views. Nevertheless, other detailers were asked to comment by email and 
none expressed disagreement. Finally, we did not examine the relation between 
implementation and outcomes in this study, as outcome data are still being col-
lected. This will be done when outcome data are analyzed.
Conclusions
Implementing an educational outreach program in Portuguese primary care 
was successful. If a positive change in prescribing habits is shown, then larger 
and improved educational outreach programs should be implemented. This pro-
cess evaluation showed that the intervention in the TEP trial was delivered with 
reasonable reach, high dose and very high fidelity and acceptability. Both physi-
cians and detailers perceived visits to have some impact on prescription behavior, 
however, this has to be confirmed in the assessment of outcomes. The knowledge 
gained by this evaluation will help interpret the outcomes of the trial, may guide 
the further implementation of educational outreach programs and assist other 
authors when planning similar interventions.
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Abstract
Background
Educational outreach visits are meant to improve the practice of health pro-
fessionals by promoting face-to-face visits to deliver educational contents. They 
have been shown to change prescription behavior, but long-term effects are still 
uncertain. This trial aimed to determine their effectiveness compared with passive 
guideline dissemination.
Methods
Parallel, open, superiority, cluster randomized trial. National Health Service 
primary care practices (clusters) in the Lisbon region – Portugal were recruited 
and could enter if they had at least four family physicians willing to participate 
and not planning to retire in the follow-up period. Three national guidelines were 
chosen for dissemination: acid secretion modifiers, non-steroidal anti-inflamma-
tory drugs and antiplatelets. Physicians in the intervention group received one 
15 to 20 minutes educational outreach visit at their workplace for each guideline. 
Physicians in the control group had access to guidelines through the Director-
ate-General for Health’s website (passive dissemination). Primary outcomes were 
the proportion of COX-2 inhibitors prescribed within the NSAID class and the 
proportion of omeprazole within the PPI class at 18 months after the intervention. 
A cost-benefit analysis was performed. A sample size of 38 primary care practices, 
with 220 physicians was calculated assuming the intervention would lead to a 5% 
absolute difference in compliance with guidelines. Practices were randomized by 
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minimization. Analyses were done at individual physician level using generalized 
mixed-effects models.
Results
Thirty-eight practices with 239 physicians were randomized. Of 360 planned 
visits, 322 were successfully delivered. No differences were found between the in-
tervention and control groups regarding the proportion of omeprazole prescribed 
among IBPs 18 months after the visit (46.28 vs 47.15%, 0.971) or the proportion 
of COX-2 inhibitors among NSAIDs (12.07 vs 13.08%, p=0.085). All secondary 
outcomes were also negative. There was no difference in cumulative drug costs at 
18 months (3223.50€/1000 patients in the intervention group and 3143.92€/1000 
patients in the control group, p=0.848).
Conclusions
Educational outreach visits were unsuccessful in improving compliance with 
guideline recommendations among Portuguese family physicians. No effects were 





Educational outreach, Academic detailing, Guideline adherence, Family prac-
tice, Drug utilization, Program evaluation, Cost-benefit analysis.
Background
Clinical practice guidelines have the potential to improve the quality of care 
by summarizing current medical knowledge and promoting interventions with 
proven efficacy, safety and cost-effectiveness.[1] Yet, issuing guidelines does not 
guarantee changes in clinical practice, as clinicians may not follow them for a va-
riety of reasons. Among them, not being aware of or familiar with guidelines, con-
sidering they are ambiguous or disagreeing with recommendations, perceiving 
lack of self-efficacy, organizational constraints, and patient barriers.[2,3] This may 
contribute to the problem of translating new medical knowledge to improvements 
in public health and of affordability of care.[4,5] To address this problem, several 
guideline implementation strategies have been tried, with a systematic review 
finding small to moderate effects in a majority of trials.[6]
Educational outreach visits are a type of strategy aimed at improving clinical 
practice.[7,8] They consist of face-to-face visits done by an individual (henceforth 
named a detailer), usually a healthcare professional trained in communication 
skills, to physicians or other health workers in their own setting. During the visit, 
the detailer enquires about the physician’s baseline knowledge and motivations, 
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presents content prepared by an independent organization with clear educational 
goals and using concise and graphic appealing materials, all the while stimulating 
physician interaction and providing positive reinforcement.[9] Visits are to one 
individual or a small group, in contrast with large educational meetings. A sys-
tematic review concluded that educational outreach visits have a small, but con-
sistent and potentially important, effect on prescription improvement.[8] It also 
highlighted a gap in knowledge about the performance of this type of intervention 
in the long term (beyond one year).
Portugal has a public funded National Health Service (NHS) with universal 
coverage providing the majority of primary care.[10] Primary care services are 
organized in small local practices, with 4 to 12 family physicians, plus a rough-
ly equal number of nurses and a smaller number of secretaries.[11] Patients are 
registered with a single family physician, but may visit other physicians within 
the same practice if theirs is unavailable. Physicians in a practice meet frequently 
to discuss organization of care and performance indicators (which include items 
on prescribing). The Directorate-General for Health (an agency of the Ministry 
of Health) is responsible for issuing prescribing guidelines.[12,13] Guidelines are 
made available on the agency’s website and all health professionals are supposed 
to abide by them. This makes all physicians in Portugal exposed to the guidelines 
simultaneously. However, their effectiveness in changing actual practice has not 
been studied.
In Portugal, family physicians work in group-based practices. Although educa-
tional outreach visits are directed at individual physicians, contamination among 
physicians working in the same practice is a plausible concern. In addition, a 
public health program of educational outreach visits would probably be delivered 
to all doctors in the same practice to minimize costs and loss of detailer time 
traveling. Thus, it may be more reasonable to assess educational outreach visits in 
the context of Portuguese primary care using a cluster-randomized design.
The primary objectives of the Trial to Assess the Effectiveness of Educational 
Outreach in Prescription Guidelines (TEP trial) were to determine if educational 
outreach visits, compared with passive guideline dissemination, resulted in a re-
duction of the proportion of COX-2 inhibitors prescribed among the NSAID class 
and an increase in omeprazole prescriptions among the PPI class 18 months after 
the visit (long-term). Secondary objectives were the effects on the same drugs at 
1 (short-term) and 6 months (medium-term), and the short, medium and long-
term effects in the prescription of clopidogrel. Thus, the duration or persistence 




The protocol for this trial has been published previously, along with a PaT plot, 
and a cascade diagram.[14]
Trial design
The TEP trial aimed to determine the long-term effectiveness of educational 
outreach visits and their cost-benefit relation. It was a parallel, open, superiority, 
cluster-randomized controlled trial conducted in Portuguese primary care physi-
cians. Clusters were Portuguese NHS primary care practices.
Participants
The trial recruited family physicians working in NHS practices of the Lisbon 
region, Portugal. A practice would be eligible to participate if it had at least four 
physicians. All family physicians were eligible, except those planning to retire 
or without a stable patient list. Participants were recruited through practice co-
ordinators. Family practices with at least 4 consenting family physicians served 
as the units of randomization. There was no financial incentive to participation. 
Participating physicians completed a baseline characteristics questionnaire and 
consented to schedule educational outreach visits and to the collection of their 
aggregate prescription data.
Interventions
Three guidelines were chosen for dissemination: non-steroidal anti-inflamma-
tory drugs (NSAID), acid secretion modifiers and proton pump inhibitors (PPI) 
and antiplatelets.[15-17] Physicians randomized to intervention clusters received 
three educational outreach visits during a six-month period. Key-messages 
were identified in each guideline. The NSAID guideline advocated for less use 
of COX-2 inhibitors, recommending they would only be prescribed to patients 
with increased gastrointestinal risk who did not tolerate a classical NSAID with a 
gastroprotective agent. For acid secretion modifiers, the guideline recommended 
that omeprazole should be preferred as it was as effective as other proton pump 
inhibitors and less expensive. The antiplatelets guideline recommended less use 
of clopidogrel, which should not be maintained long term after myocardial in-
farction, acute coronary syndrome, or percutaneous coronary intervention. Thus, 
we had a diverse mix of objectives aimed at improving rational prescribing where 
the objectives in one case where increasing the usage of a specific drug and in two 
other cases decrease drug usage.
Each visit was planned to focus on one guideline, last 15 to 20 minutes and have 
one family physician present (up to three were allowed if physicians preferred, but 
one-to-one visits were encouraged). The visit would begin with an introduction 
about the detailer and the purpose of the visits, confirming the physician’s avail-
ability. Then educational needs would be assessed by asking about the physician’s 
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usual practice with open questions. These would shape how the detailer would 
deliver key-messages about the guideline, addressing scientific evidence, and ben-
efits of following the guideline, barriers and facilitators of change. The physician 
would be given the opportunity to present objections, which were addressed by 
the detailer. The visit ended with a summary and encouragement for the physician 
to commit to change. A point of care summary was distributed with each visit and 
a brochure was used by the detailer as a visual aid. Copies of the brochures and 
point of care summaries are made available in appendix 1.
Whenever possible, a single detailer performed all three visits to the same physi-
cian. Visits could take place in between patient visits or at other times indicated by 
the physician. Visits could be rescheduled up to the day before they were planned, 
but if the physician was unable to attend and could not warn the detailer before-
hand that visit would be skipped. Detailers filled a short questionnaire at the end 
of each visit, included those that were not successful.
The detailers were three members of the research team (two family physicians 
and one academic pharmacologist) and nine physicians that were trained for the 
trial (six family physicians and three family medicine residents). All detailers were 
trained on the principles of educational outreach and the contents of each visit, to 
ensure consistency.
For the control group, usual guideline implementation consisted of passive dis-
semination by their publication on the Directorate-General for Health’s website. 
Outcomes
The trial had two primary outcomes, measured at the physician level: the pro-
portion of COX-2 inhibitors prescribed within the NSAID class and the propor-
tion of omeprazole within the PPI class, both measured in defined daily doses 
at 18 months after the intervention. There were seven secondary outcomes: the 
same proportions of COX-2 inhibitors and omeprazole measured at one and six 
months after the intervention, and the number of defined daily doses of clopido-
grel per 1,000 registered patients at one, six and 18 months after the intervention. 
We also conducted a cost-benefit analysis using the sum of all prescriptions 
dispensed for NSAIDs, acid suppressive therapy (PPIs, H2-receptor antagonists, 
misoprostol and reimbursed anti-acids) and clopidogrel from month one follow-
ing the intervention until month 18. Costs were considered from the perspective 
of a government supported program, with government as the payer, therefore only 
the reimbursed portion of drugs was considered. Differences in costs between 
the intervention and control group would be compared with the cost of training 
and paying detailers, preparing and printing educational materials, program co-
ordination and indirect costs of physician time (spent with a detailer rather than 
seeing a patient).
166
Only prescriptions that were dispensed were counted. Drug dispensing and cost 
data was provided by the Lisbon Regional Health Administration. In the Portu-
guese health system, prescriptions can be made for acute or chronic conditions. 
The former are valid for dispensing within 30 days and the later for six months. Of 
the studied drugs, only NSAIDs cannot be prescribed for chronic use. Physicians 
who transferred to other practices within the health region were followed and 
their prescriptions monitored. When prescription data was not available, the last 
known month’s prescription was used.
Sample size
Pilot data was obtained from three primary care practices and was used to es-
timate within unit variability and the intra-cluster correlation coefficient. Aggre-
gate data from the Regional Health Administration was used to estimate the mean 
prescription and standard deviation for primary outcomes. Our sample size was 
calculated assuming the intervention would lead to a 5% absolute difference in 
compliance with guidelines between intervention and control units for primary 
outcomes, a mean cluster size of six physicians per practice, a 1:1 allocation ratio 
of controls per intervention unit, an alpha type error of 0.025, and a dropout rate 
of about 15%. To achieve 80% power, a sample of 110 physicians in each group 
was needed. To recruit the necessary 220 physicians, 38 primary care units would 
be required. STATA 12.0 (STATA Corp, TX, USA) and its sampsi and sampclus 
commands were used to calculate sample size.
Randomization
Clusters were allocated to the intervention or control groups using minimiza-
tion, a method to achieve good balance regarding baseline characteristics that 
could influence the outcomes when the number of clusters is small.[18] We strati-
fied for number of physicians in a practice, median baseline prescription of COX-
2 inhibitors and omeprazole (above or below the regional median), proportion 
of physicians with fewer than 10 years of practice after completing vocational 
training, and type of primary care practice. The sequence of intervention visits 
for each practice was determined by simple randomization using Random.org 
sequence generator.[19]
Allocation was concealed by having the project manager assign a sequential 
number to each practice as it completed enrollment. The trial statistician received 
only anonymized data (sequential number and minimization variables), blindly 
allocated practices to each trial arm and returned allocation information to the 
trial manager.
Neither participating physicians nor detailers could be blinded. Outcomes were 
collected independently from the researchers by the Regional Health Adminis-
tration and were only provided after the intervention had ended. Unlike what 
was planned in the protocol, the lead author could not be blinded to group and 
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visit sequence allocation because the Regional Health Administration needed to 
consult with study author for data extraction. However, we were able to keep the 
trial statistician blinded.
Statistical methods
Analysis was performed using the intention to treat principle. Physicians who 
transferred to another unit in the region were followed and for those we were 
unable to retrieve prescription data we used the last working month’s prescrip-
tion. Outcomes in both groups were compared using generalized mixed-effects 
models. For model calculations, proportions of omeprazole and COX-2 inhib-
itors were logarithmically transformed [x = ln(x/(1-x)] because of non-normal 
distributions. Intra-cluster correlation coefficients were calculated for primary 
outcomes. Statistical significance was assumed for a p-value less than 0.025. STA-
TA 12.0 (STATA Corp, TX, USA) was used to conduct the analysis. No interim 
analyses were done. We conducted three post-hoc sensitivity analyses: exclud-
ing physicians with missing data on the month of the outcome, including only 
physicians with no more than two months missing data in the post-intervention 
period, and adjusting for the physician’s observed baseline prescription.
Given the intervention posed minimal risks to patients, no data monitoring 
committee was established and no stopping guidelines were defined. 
Ethical approval
The trial was approved by the ethics committees of the Lisbon Regional Health 
Administration and NOVA Medical School. Family physicians invited to partici-
pate received written information about the main aspects of the trial and partici-
pants gave consent for researchers to access their prescription data. The trial only 
collected aggregated and non-identifiable patient data.
Results
Participants
Recruitment began in March 2013 and ended in January 2014. Participant flow 
is shown in figure 1. The research team met with practice coordinators from 13 
of 15 health center groups in the Lisbon Region, representing 233 practices. Of 
these, 193 did not reply to subsequent contacts, were unwilling to participate or 
self-excluded for having less than four physicians willing to participate. Two units 
had shown interest in participating, but were excluded when other units complet-
ed enrollment first. We randomized 38 clusters with 239 participating physicians. 
Baseline characteristics for participants in the intervention and control groups 
are shown in table 1. Groups were balanced regarding the characteristics used for 
minimization. However, the number of patients per physician was higher for the 
intervention group.
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Delivery of the intervention
Of the 360 planned visits, 322 (89.4%) were successful. Another twenty-six visits 
were attempted but failed because the physician was absent (21) or unavailable 
(5). One physician declined the last two visits after the first failed, but did not 
withdraw consent to participate in the prescription analysis. Two physicians had 
Figure 1 – Participant flow diagram.
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none of the planned visits (6) as they were on extended leave. Two visits were not 
done because physicians were on short leaves. Finally, two visits failed because 
the detailer was unavailable. Only the target physician was present in 89.1% of 
successful visits. The three visits were all made by the same detailer in 88.3% of 
physicians. Detailers reported delivering the full educational content in 97.8% of 
visits.
Follow-up
Prescription data was available for both primary outcomes in 116 of 120 phy-
sicians in the intervention group and for PPIs in 112 and for NSAIDs in 108 of 
119 physicians in the control group. Secondary short-term outcomes (1 month 
after the intervention) were available for 98.3% and 99.2% of the control and in-
tervention groups, respectively; and medium term (6 months after the interven-
tion) for 96.9 and 97.6%. Overall, 29 physicians had one or more months without 
prescription data for one of the studied drugs (16 in the control group and 13 in 
the intervention group). Three physicians in the control group and two in the 
Table 1 – Baseline characteristics of participating physicians.
Intervention Control
Physicians per cluster – mean (standard deviation) 6.3 (1.4) 6.3 (1.4)
Unit type – n units (n physicians)
    Family health unit





Female – % 70.8 79.0
Age – years, median (P25-P75) 52 (41-59) 47 (38-59)
Years in practice – median (P25-P75) 13 (6.5-28) 11 (4-28)
Residency tutor–- % 55.8 52.9
Patient list size – median (P25-P75) 1874 (1812-1923) 1813 (1746-1872)
Prescription – mean (standard deviation)
    Omeprazole, %
    COX-2 inhibitors, %







NHS expenditure with NSAIDs, acid secretion 
modifiers and clopidogrel / month / 1,000 – €, 
mean (standard deviation)
189.60 (73.41) 192.72 (85.67)
COX-2 – cycloxigenase-2. NHS – National Health Service. NSAIDs – non-steroi-
dal anti-inflammatory drugs. 
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intervention group had no prescriptions of any of the studied drugs in the final six 
months of the study. For the remaining physicians, there were prescriptions after 
one or more months without data, suggesting temporary absences and not losses 
to follow-up.
Intervention effects
The results of the intervention are shown in table 2 and figure 2. There were 
no differences between the intervention and control groups regarding primary 
outcomes: proportion of omeprazole among IBPs and proportion of COX-2 in-
hibitors among NSAIDs at 18 months after the intervention. The intra-cluster 
correlation coefficient was 0.305 (95% confidence interval 0.177-0.473) for ome-
prazole prescriptions at 18 months. No significant inter-cluster correlation existed 
for COX-2 inhibitors at 18 months. There were also no significant differences in 
secondary outcomes, in total costs or class-specific costs for the period between 1 
and 18 months after the intervention.
Table 2 – Prescription and cost of the studied drugs at 1, 6 and 18 months after 
the intervention.
Intervention (n=120) Control (n=119) p
Omeprazole, % (95%CI)
    +1 month 46.86 (44.34-49.39) 47.36 (44.81-49.91) 0.744
   +6 months 48.02 (45.58-50.46) 47.90 (45.01-50.79) 0.696
   +18 months (primary) 46.28 (43.77-48.79) 47.15 (44.39-49.91) 0.971
COX-2 inhibitors, % (95%CI)
   +1 month 11.70 (9.83-13.57) 15.38 (12.87-17.90) 0.131
   +6 months 11.59 (9.28-13.89) 15.74 (13.42-18.05) 0.061
   +18 months (primary) 12.07 (9.75-14.41) 13.08 (10.75-15.41) 0.085
Clopidogrel, DDD/1000 (95%CI)
   +1 month 0.098 (0.886-0.107) 0.103 (0.094-0.112) 0.456
   +6 months 0.090 (0.082-0.098) 0.099 (0.089-0.108) 0.230
   +18 months 0.091 (0.083-0.100) 0.091 (0.082-0.100) 0.840
Cost 1-18m / 1,000, € (95%CI)
   Gastric secretion 
   modifiers
1647.79 (1541.37-1754.21) 1626.38 (1511.76-1741.01) 0.880
   NSAIDs 1099.26 (984.70-1213.81) 983.02 (873.49-1092.55) 0.515
   Clopidogrel 476.45 (428.34-524.57) 539.05 (491.22-586.87) 0.184
   Total 3223.50 (2999.55-3447.44) 3143.92 (2917.61-3370.23) 0.848
CI – confidence interval
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Figure 2 – Prescription timeline of drugs in primary and secondary outcomes 
(vertical bars) from one month before the intervention (-1) to 18 months after the 
intervention (18) in the intervention (black line) and control (grey line) groups.
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Differences between groups remained non-significant when we did three sepa-
rate sensitivity analyses excluding physicians with missing data on the month of 
the outcome, including only physicians with no more than two months missing 
data in the post-intervention period and when we adjusted for the physician’s 
observed baseline prescription.
As there were no differences in costs between groups, we did not perform a for-
mal cost-benefit analysis.
Discussion
Summary of main results
Our results showed no effect of an intervention consisting of educational out-
reach visits to modify prescribing of family physicians to align with national 
guideline recommendations. Neither short, medium nor long-term effects were 
seen and no differences in drug costs were found between the intervention and 
control groups. 
Strengths and limitations
The planned intervention was adequately implemented: educational visits were 
delivered with a very high success rate, were accepted by the clear majority of par-
ticipants and had the planned educational content. The intervention was similar 
to what would have been a government funded educational outreach program. 
Outcome data was collected independently of the researchers from and admin-
istrative database, hence we had few missing data points. We hypothesize that 
missing data points correspond to absence from work due to illness, maternity or 
paternity leave or other unforeseen causes, and that it is likely that data is missing 
completely at random and not related with being assigned to the intervention or 
control groups. We could gather long-term follow-up data for most physicians, 
which allowed the study of the intervention’s effects over time. Only five among 
239 physicians had no data points for outcomes in the last six months and may 
have been lost to follow-up (although we cannot be certain these were not tem-
porary interruptions). Costs were measured along site the effects on drug use, 
considering the whole pharmacological class and not just one drug (as costs could 
have been transferred between drugs within a class). Having the order of visits 
randomized between clusters allowed us to exclude effects of a possible build-up 
of the detailer-physician relation. Finally, results are consistent across the different 
drug classes studied.
The major limitation for the trial is that there was likely selection bias for partici-
pation. When compared with regional data, recruitment was higher among family 
health units than among personalized health care units, the observed baseline 
proportion of COX-2 inhibitors was lower than in our pilot data for the region, as 
was the baseline proportion of omeprazole.[14] Although randomization was able 
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to balance the groups regarding characteristics selected for minimization, there 
was some imbalance regarding patient list size. This certainly influenced absolute 
costs, and is why we present costs per 1,000 registered patients. It is uncertain if 
it could have influenced prescriptions, as baseline levels for the drugs of interest 
are similar (the intervention group was slightly worse in omeprazole prescriptions 
and better in COX-2 inhibitors and clopidogrel prescriptions). Another limitation 
was known from the outset and relates to prescription data. We used prescrip-
tions that had been dispensed at a community pharmacy and not all prescriptions 
issued by the participating physicians. This was because information on issued 
prescriptions is less reliable in the database and our pilot data showed a large 
percentage of prescribed drugs were never actually dispensed (due to factors like 
lack of patient adherence, mismatch between the patient’s needs and the number 
of prescribed packages, loss of prescriptions, and errors when issuing the pre-
scription).[14] Dispensing can occur up to 30 days after a prescription is issued 
for NSAIDs and up to six months for PPIs and clopidogrel. Hence, part of the 
prescriptions dispensed for PPIs and clopidogrel had not been issued in the same 
or the previous month.
Another issue to consider is the relatively large random monthly variation in 
prescription outcomes, which suggests our sample size may have been small to 
handle physicians with low prescription volume. Considering our choice of when 
to measure short, medium and long-term outcomes is somewhat arbitrary, this 
may have been an issue when measuring short and medium-term outcomes, 
where this fluctuation is more apparent for COX-2 inhibitors and clopidogrel.
Interpretation of the results
A meta-analysis of educational outreach visits showed a median adjusted risk 
difference in compliance with a desired prescribing practice of 4.8%, concluding 
educational outreach visits had an effect on prescribing.[8] Our study aimed to 
contribute one of the unanswered questions in this meta-analysis: if visit perfor-
mance deteriorates in the long-term. However, we were unable to find any short, 
medium or long-term benefits of educational outreach visits. One possible reason 
for lack of effect is that physicians more interested in improving their prescribing 
behavior self-selected for the trial and baseline prescription was already more 
compliant with guidelines than in physicians who did not volunteer to partici-
pate. It is possible that we did not target what Soumerai describes as “high-po-
tential” physicians – those with prescribing patterns more distant from guideline 
recommendations, hence, more potential to change.[9,20] Given the control group 
was also exposed to the same guidelines, it is also possible the intervention was 
not so effective when used as an add-on to existing dissemination strategies. The 
Portuguese context may have been important regarding the effects of the inter-
vention, as primary care physicians are government employed, their performance 
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is monitored through quality and spending indicators, and the National Health 
Directorate’s position on guidelines is that they are normative in nature.10
Not having shown an effect in short and medium-term outcomes limits our abili-
ty to conclude on the long-term effects of educational outreach visits. Even though 
there was no statistical significance, we could observe some separation between 
groups in NSAIDs between two and five months after the intervention and in 
clopidogrel between five and eight months, both favoring the intervention group. 
A larger delay for clopidogrel is consistent with the fact that its prescriptions are 
valid for six months. However, even these small differences seem to disappear by 
the end of the follow-up period. This suggests that, even if we had found positive 
results in the short and medium-term, effects would deteriorate over time.
Costs throughout the follow-up period were not significantly reduced in the 
intervention group, making any investment we did in producing educational ma-
terials, training detailers and conducting the visits ineffective. 
Conclusions
Educational outreach visits were unsuccessful in improving Portuguese family 
physicians’ compliance with guideline recommendations to decrease the rela-
tive use of COX-2 inhibitors in NSAID prescriptions, increase the relative use 
of omeprazole in PPI prescriptions and decrease clopidogrel use in antiplatelet 
prescriptions. No effects were observed at one, six and eighteen months after the 
intervention and there were no associated cost savings.
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Influences on family physicians to prescribe
The two studies in the Portuguese Sentinel Practice Network had similar findings 
in most respects. Portuguese physicians are treating hypertension and diabetes 
mostly in accordance with current guidelines for these conditions. They mainly 
use angiotensin converting enzyme inhibitors, thiazide and thiazide-like diuretics 
and angiotensin receptor blockers to treat hypertension, and metformin to treat 
type 2 diabetes. In both cases, family physicians make most diagnosis and are 
responsible for deciding treatment. When patients have seen other physicians first 
and already started treatment, it will rarely be changed by the family physician.
It is concerning that, although patients seem to initiate recommended treat-
ments, the observed prevalent pattern of drug use in hypertension and type 2 
diabetes in Portugal deviates from national and international recommendations. 
Sometime after the initial diagnosis and treatment decision the prescribed drugs 
will change to less cost-effective options.
There were not many differences between family physicians and hospital or 
private practice based specialists regarding the choice of the most common an-
ti-hypertensives, but there were large differences in the decision to initiate phar-
macological treatment in diabetes and which agents were chosen: specialists were 
more likely to use the newer DPP-4 inhibitors. These findings suggest that, at least 
for type 2 diabetes, specialists may have an important role adopting a newer and 
more expensive drug class and this probably influences family physicians pre-
scribing, as they rarely changed the initial treatment.
One hypothesis to explain this difference between hypertension and diabetes is 
that the novelty of drugs may be an important factor. DPP-4 inhibitors are still 
relatively new drugs and under patent protection in the Portuguese market. While 
in hypertension only aliskiren and some fixed-dose associations are still under 
patent protection, none of which are frequently used as first-line therapy. If this 
is true, then similar differences between family physicians and other specialists 
could have existed in anti-hypertensives like ACE inhibitors and angiotensin re-
ceptor blockers when they were first introduced, but then faded over time.
Impact of regulatory authorities’ recommendations
Regulatory interventions on trimetazidine and nimesulide resulted in significant 
declines in the use of these drugs. For trimetazidine, there were few concurrent 
interventions that could explain the observed changes in prescribing, and it is 
very probable that the association between regulatory intervention and decreased 
use was causal. For nimesulide there were many other factors concurring with 
regulatory interventions, making it difficult to assess the importance of each indi-
vidually. For trimetazidine, when European authorities announced a safety review 
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there was no change in use, while for nimesulide this announcement coincided 
with a sudden decrease in dispensing. It is probable that, when a drug’s adverse 
events are reported by media, doctors, patients and pharmacists become more 
aware of recommendations and change their behavior, even if no regulatory de-
cision exists. Of note, nimesulide would not have been reported in media if the 
European Medicines Agency hadn’t decided to initiate a safety review. Therefore, 
one can consider that media reports stem from actions taken by regulatory agen-
cies. Yet, not all recommendations will be picked up by general media, and effects 
on drug use should be studied with and without media reports.
In either drug, several years after safety measures were implemented, use 
tends towards stabilization at a lower level than before the intervention. Use of 
trimetazidine and nimesulide did no disappear, and two possibilities arise: either 
most physicians are using it less frequently and in patients that meet new criteria 
for use, or at least some physicians keep using the drugs despite the recommended 
restrictions.
Both studies point to the existence of differences in response to regulatory mea-
sures between family physicians, hospital clinicians and doctors in other sectors 
of the health system. Family physicians seem to be more compliant with recom-
mendations for restricted use. These differences weren’t large, but they may in-
dicate the need to address context and individual characteristics of physicians to 
improve the efficacy of safety measures.
Importantly, we could not find a decrease in clinical adverse events in the nime-
sulide study. Two explanations are plausible: that there was an increase in report-
ing associated with greater awareness of the drugs side effects, or that restrictions 
were ineffective in changing clinical outcomes.
Educational outreach visits to influence prescribing behavior
Our trial did not show a change in prescriber behavior with educational out-
reach visits. A negative result for educational outreach visits is contrary to the 
majority of literature in this field, but by no means unique. We believe that the 
study was adequately designed and the intervention was well implemented, as 
shown in our process evaluation study. Most physicians found the visits useful, 
wished the visits would continue and would recommend the program to other 
physicians, although there were no actual changes in prescribing behavior. This 
suggests that it is unlikely the negative result was a consequence of a poorly im-
plemented intervention or one that was unacceptable to physicians.
There are probably two major factors that contributed to this result: selection of 
participants and context. Physicians participating in the trial were voluntary par-
ticipants, and it is likely that those more motivated to be cost-effective prescribers 
were the ones who volunteered. This idea is supported by the low recruitment rate 
of personalized care units (the traditional primary care organization in Portugal) 
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compared with family health units (the reformed primary care), and lower use of 
COX-2 inhibitors. Also, when comparing data from the nimesulide study, physi-
cians in our sample prescribed this drug less often than the national average for 
primary care. They did, however, use less omeprazole than the regional average 
in our pilot data. But there was a significant interval between collecting pilot data 
and initiating the trial, during which omeprazole use compared to other PPIs may 
have declined (due to changes in relative costs of different PPIs or because of the 
introduction of generic esomeprazole). It is possible that physicians in the study 
were already among the best prescribers and therefore had little margin to change. 
Targeting physicians with prescribing patterns less compliant with guidelines 
could have led to different results. However, physicians cannot be forced to partic-
ipate in a randomized trial or receive educational visits. The need for physicians to 
accept the intervention is probably one of the limitations of educational outreach 
visits as a tool to change behavior.
Context factors are also important. The intervention may have failed because of 
specific factors in Portuguese primary care. The Directorate-General of Health’s 
guidelines are actually named “norms” in Portuguese, and they are viewed as nor-
mative in nature by this body and by some physicians. This may result in physicians 
highly aware of and familiar with guidelines, and motivated to comply, because 
they feel obliged to or because of other factors like performance indicators used to 
determine financial incentives for physicians. Our premise that publishing guide-
lines on the Directorate-General of Health would not lead to behavior change 
might have been untrue, making the additional dissemination with educational 
outreach visits unnecessary.
Given our negative results at short and medium term, results relative to the long-
term impact of educational outreach visits must be interpreted with caution. The 
variation observed favors deterioration and not improvement of the effect over 
time.
Our data will hopefully contribute to an update of the systematic review on 
educational outreach visits and our process evaluation will help interpret the ob-
served results.
Implications for practice
When assessing family physicians’ prescribing choices, it will be important to 
determine the extent to which other prescribers are an important influence. Pre-
scribing guideline compliance should preferably be done alongside the introduc-
tion of new drugs, and hospital and private practice based physicians should also 
be monitored. Although family physicians are responsible for most diagnosis and 
new prescriptions, efforts to improve quality should be directed at groups that 
have larger deviations from desired practice.
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Actions taken by regulatory agencies are likely to have an effect in drug use, 
although concurrent factors may also play an important role and should be con-
sidered or even taken advantage of to increase efficacy. The use of a drug under 
intervention does not disappear and adverse events may still occur. There can be 
differences in the uptake of recommendations by different groups of doctors and 
interventions may need to be customized to specific targets.
Generalized implementation of educational outreach visits in Portuguese prima-
ry care as a strategy to increase compliance with national guidelines should not be 
done. Targeting physicians least compliant with guidelines might be effective, but 
this requires further research.
Implications for future research
It will be important to clarify the extent to which family physicians are different 
from other physicians when a new drug is made available. Prescription changes 
in prevalent cases should be studied to determine how initial therapy changes as 
time from diagnosis passes, namely which drugs or classes are removed or intro-
duced, the reasons for change and who are the physicians responsible for those 
decisions. Cohort studies would be appropriate designs to monitor such changes, 
as they allow for interaction with patients and physicians over time. Studies in 
reimbursement databases are also possible and may be less expensive. However, 
researchers should first guarantee that administrative information is valid and 
complete, and confidentiality issues when extracting individual patient or physi-
cian data need to be taken under consideration.
Determining the impact of regulatory measures needs further study. It is not 
feasible to conduct a randomized controlled trial, as there is no control group 
of unexposed physicians and patients (postponing safety measures would be un-
ethical, and, for positive measures like new indications, contamination would be 
very likely to occur). This makes quasi-experimental designs like the interrupted 
time-series the best tool available. However, interrupted time-series cannot sep-
arate events that occur simultaneously or very close to one another. For these, 
evidence needs to be accumulated from several studies (using different drugs and 
in distinct settings) for a pattern to emerge on which interventions or components 
are most effective. Another subject that merits research is analyzing differences 
between physicians or groups of physicians. It seems likely that average responses 
measuring aggregate data conceal variable efficacy among different populations 
of physicians or patients. Learning if these differences are real and understanding 
why they occur could help tailor future interventions to maximize their effect. 
Finally, clinical outcomes must be a part of evaluating the impact of regulatory 
measures whenever possible, as intentions do not always translate into actual re-
sults that mater to patient safety.
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The results of our trial in educational outreach visits should be further analyzed 
to help understand why the intervention failed. This kind of post-hoc investi-
gation has many limitations, but may generate hypothesis that can be tested in 
the future. We plan to analyze subgroups of physicians, testing the interaction 
between basal compliance with guidelines, the type of practice, physician char-
acteristics and replies to our post-intervention survey and observed prescribing. 
Testing if different detailers, how visits were delivered and if the order of visits 
were important is also planned. Future studies should keep addressing the long-
term effects of educational outreach visits to confirm if they deteriorate over time.
Final remarks
Understanding doctors’ prescription behavior is not simple. Human behavior is 
complex, dependent on individual and contextual factors, with many interactions, 
changes over time and circumstances may lead to different responses. Unlike 
studying diseases and drugs, one cannot explain physician behavior with a phys-
iological mechanism. Trying to change a physician’s behavior adds complexity, as 
one can’t prescribe X milligrams of an intervention like educational outreach vis-
its or isolate the intervention from its context. Aiming to help doctors make better 
decisions for patients by choosing more effective, safer and more cost-effective 
drugs remains a worthy goal, but there is no easy or one size fits all solution that 
can be easily deployed.
A global result of this thesis is that the Family Medicine Unit at NOVA Med-
ical School now has experience in analyzing large prescription databases in the 
Portuguese National Health Service, organizing and conducting a randomized 
controlled trial and a process evaluation, as well as knowledge on some advanced 
statistical techniques (segmented regression models, hierarchical models, and 
randomization by minimization). These could benefit future research projects 
and post-graduate students.
